

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 October 2005 (13.10.2005)

PCT

(10) International Publication Number
WO 2005/095395 A2

(51) International Patent Classification⁷: **C07D 471/00**

2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).

(21) International Application Number:

PCT/JP2005/006895

(74) Agents: KAWAMIYA, Osamu et al.; AOYAMA & PARTNERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka 5400001 (JP).

(22) International Filing Date: 1 April 2005 (01.04.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2004-109551

2 April 2004 (02.04.2004) JP

(71) Applicant (for all designated States except US): TANABE SEIYAKU CO., LTD. [JP/JP]; 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): KUBOTA, Hitoshi [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). NAKAMURA, Yoshinori [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). HIGASHIJIMA, Takanori [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). YAMAMOTO, Yasuo [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). OKA, Kozo [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). IGARASHI, Shigeki [JP/JP]; c/o TANABE SEIYAKU CO., LTD.,


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDRONAPHTHYRIDINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME



(I)

(57) Abstract: A novel compound of the formula (I): wherein R¹ is alkoxy carbonyl or the like, R² is alkyl or the like; R³ is hydrogen or the like; R⁴ is alkylene or the like; R⁵ is optionally substituted heterocyclic group; R⁶, R⁷, and R⁸ are independently hydrogen; alkyl, alkoxy, or the like; R¹⁰ is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).

DESCRIPTION

TETRAHYDRONAPHTHYRIDINE DERIVATIVES
AND A PROCESS FOR PREPARING THE SAME

5

TECHNICAL FIELD

The present invention relates to a novel tetrahydronaphthyridine derivative having an inhibitory activity against cholesteryl ester transfer protein (CETP).

10

BACKGROUND ART

Hypercholesterolemia, especially high serum level of low-density lipoprotein (LDL) cholesterol, has been revealed to be a risk factor of arteriosclerotic diseases by a number of epidemiological surveys. Actually, drugs capable of decreasing LDL cholesterol level such as 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors have been used with the aim of preventing coronary artery diseases, and demonstrated to have some benefits in many large scale clinical tests. However, their preventive effect on coronary diseases is limited to some extent, and is not satisfactory enough yet.

20

Recently, low serum level of high density lipoprotein (HDL) cholesterol has been revealed to be a potent risk factor of arteriosclerotic diseases by a number of epidemiological surveys and large scale clinical tests. HDL is known to have various antiarteriosclerotic effects and attention is focused on the potentiality of drugs increasing HDL cholesterol level as a means for prevention or treatment of arteriosclerotic diseases. However, there are no drugs that can be used in a satisfactory manner for this purpose. Fibrates and HMG-CoA reductase inhibitors have only low activity of increasing HDL cholesterol; nicotinic acid derivatives can significantly increase HDL, but have serious toleration issues. Accordingly,

25
30

there has been a demand for a well-tolerated agent which can significantly elevate HDL cholesterol levels, thereby preventing or reversing the progression of atherosclerosis.

It is known that many proteins are involved in the regulation mechanism for catabolism of various lipoproteins. Among them, the role of cholesteryl ester transfer protein (CETP) became to draw attention. CETP is a protein responsible for transfer of cholesteryl ester (CE) and triglyceride between lipoproteins, and mediate the transfer of CE from HDL to LDL or to very low density lipoprotein (VLDL). Accordingly, CETP activity affects greatly the lipid composition in lipoprotein particles. For example, it is known that administration of a neutralizing monoclonal antibody to CETP to rabbit or hamster elevates HDL cholesterol levels and lower LDL cholesterol levels. Furthermore, human being having decreased or eliminated CETP activity due to gene mutation shows raised blood HDL cholesterol level and lowered blood LDL cholesterol level. On the other hand, it is known that transgenic mice and rats made to express CETP show lowered HDL cholesterol level and raised LDL cholesterol level. Thus, it is considered that CETP greatly contribute to the regulation of serum lipids, and thereby affecting the change of serum lipid profile such as decrease of HDL cholesterol level and increase of LDL cholesterol. Accordingly, it is assumed that a high value of CETP activity would induce arteriosclerosis.

In fact, CETP activity varies depending on animal species. It is known that, arteriosclerotic lesions are readily formed by cholesterol loading in animals with high CETP activity such as rabbits, whereas such lesions hardly occur in animals with low CETP activity such as rats. Furthermore, it is confirmed that continuous suppression of CETP activity by administration of antisense oligodeoxynucleotide resulted in effects such as increase of blood HDL cholesterol level and reduction in arteriosclerotic lesions in cholesterol-fed rabbits.

The above findings indicate that CETP activity is in negative correlation with HDL cholesterol, and that inhibition of CETP activity would decrease the degree of risk for arteriosclerotic diseases. It is therefore expected that compounds capable of inhibiting CETP activity can block the transfer of cholesterol from HDL to LDL, and thereby increasing HDL cholesterol that tends to prevent arteriosclerosis while lowering LDL cholesterol that tends to promote arteriosclerosis. In this way, such compounds can serve as a useful preventive or therapeutic agent for arteriosclerotic diseases, hyperlipemia or dyslipidemia and provide effective medical treatment for the first time.

Examples of compounds having CETP inhibitory activity include tetrahydronaphthyridine derivatives. See, WO00/17164, WO00/17165, WO00/17166.


However, these compounds have defects. That is, they are poorly soluble in water and cannot be absorbed enough in vivo, a sufficient blood level for taking medicinal effect can hardly be achieved even when administered as an ordinary formulation for oral administration. See, WO03/63868.

Accordingly, novel compounds in which the above-mentioned defects have been solved are highly demanded.

DISCLOSURE OF INVENTION

The present invention provides novel tetrahydronaphthyridine derivatives having an excellent CETP inhibitory activity wherein defects of existing CETP inhibitory compounds are rectified.

Thus, the present invention provides a compound of the formula (I):



wherein R¹ is a hydrogen atom, an optionally substituted alkoxy carbonyl group, an optionally substituted carbamoyl group, an optionally substituted alkyl group, an optionally substituted alkanoyl group, a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted), or a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted);

R² is a hydrogen atom or an optionally substituted alkyl group;
R³ is a hydrogen atom or an optionally substituted alkyl group;
R⁴ is an optionally substituted alkylene group;
R⁵ is a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, said heterocyclic group being optionally substituted,
R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a cyano group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkylsulfonyloxy group, an optionally substituted mono- or dialkylcarbamoyl group or an optionally substituted amino group; or
R⁶ and R⁷, or R⁷ and R⁸ may combine at the ends to form an alkylene group which alkylene group optionally contains 1 to 3 heteroatoms selected independently from nitrogen, sulfur and oxygen atoms, and may have a substituent(s); and
R¹⁰ is an aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the aromatic ring is optionally substituted), or a pharmaceutically acceptable salt thereof.

The compound (I) of the present invention encompasses a mixture of stereoisomers, respective stereoisomers in a purified or substantially

purified form. For example, the compounds of the formula (I) may have one or more asymmetric carbon atoms and therefore may occur as individual enantiomers or diastereomers, or a mixture thereof. The present compounds include respective isomers and a mixture thereof. In addition, 5 when the compound (I) has a double bond, geometric isomers may occur (cis- and trans-forms), and when the compound (I) has a group containing an unsaturated bond such as carbonyl, tautomeric forms may occur, and the present compounds include respective isomers and a mixture thereof.

Further, the pharmaceutically acceptable salts of compound (I) of 10 the present invention include an intramolecular salt, a hydrate, solvate or the like.

As used herein, the term "aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" refers to preferably a "5- to 7-membered monocyclic aromatic ring 15 optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" including specifically phenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, azepinyl, oxepinyl and thiepinyl groups, and the like.

20 The term "saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" refers to preferably a "saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen 25 atoms" including specifically the following groups. Examples of 5-membered heterocyclic group include 2H-pyrrolyl, 3H-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, oxazolinyl, oxazolidinyl, thiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, tetrazolyl, 1,2-dithiolyl, 1,3-dithiolyl, 30 3H-1,2-oxathiolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,

1,3,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, 1,2,3,4-oxatriazolyl, 1,2,3,5-oxatriazolyl, 3H-1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, 1,3,4-dioxazolyl, 5H-1,2,5-oxathiazolyl and 1,3-oxathioly groups, and the like.

5 Examples of 6-membered heterocyclic group include 2H-pyranyl, 4H-pyranyl, pyridyl, piperidinyl, 1,2-dioxinyl, 1,3-dioxinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-trithianyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 6H-1,3-oxazinyl, 6H-1,2-oxazinyl, 1,4-oxazinyl, 2H-1,2-oxazinyl, 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, 1,4-oxazinyl, o-isoxazinyl, p-isoxazinyl, 1,2,5-oxathiazinyl, 1,2,6-oxathiazinyl, 1,4,2-oxadiazinyl and 1,3,5,2-oxadiazinyl groups, and the like.

 Examples of 7-membered heterocyclic group include azepinyl, oxepinyl and thiopinyl groups, and the like.

15 Examples of 8-membered heterocyclic group include azocinyl, oxocinyl and thiocinyl groups, and the like.

 As used herein, the heterocyclic moiety of the "saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms", "saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms", and "a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" refers to the aforementioned "saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms".

 In such cases where the binding position for these aromatic ring, heterocyclic group, and the like is not specifically defined, the definition is meant to encompass all the possible binding positions. For example, the

term "pyridyl group" means 2-, 3- or 4-pyridyl group, and the term "thienyl group" means 2- or 3-thienyl group. The same is applied to other aromatic rings and heterocyclic groups.

When the saturated or unsaturated monocyclic or bicyclic heterocyclic group, heterocyclic oxy group, heterocyclic carbonyl group and heterocyclic carbonylamino group each containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms have a substituent(s), the substitution includes oxidation of heteroatom(s) in the heterocycle in the respective groups. Specifically, compounds having a heteroatom(s) in the heterocycle of said groups as N-oxide, S-oxide (SO) or S,S-dioxide (SO₂) also fall within the scope of the present invention.

The term "halogen" refers to fluorine, chlorine, bromine or iodine.

The term "alkyl group" or "alkyl" means a straight or branched saturated hydrocarbon chain having 1 to 10 carbon atoms and a cyclic saturated hydrocarbon chain having 3 to 10 carbon atoms. As a straight or branched hydrocarbon chain, those having 2 to 10 carbon atoms are preferred and those having 2 to 6 carbons are more preferred. Other preferred examples are straight chain alkyl groups having 1 to 6 carbon atoms, especially those having 1 to 4 carbon atoms. Examples of alkyl group include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, hexyl and isohexyl groups, and the like.

The term "alkoxy group" or "alkoxy" means a straight or branched alkyloxy group having 1 to 10 carbon atoms and a cyclic alkyloxy group having 3 to 10 carbon atoms. As a straight or branched hydrocarbon chain, those having 2 to 10 carbon atoms are preferred and those having 2 to 6 carbons are more preferred. Other preferred examples are straight chain alkoxy groups having 1 to 6 carbon atoms, especially those having 1 to 4 carbon atoms. Examples of alkoxy group include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy,


neopentoxy, tert-pentoxy, hexoxy and isohexoxy groups, and the like.

The term "alkylene group" or "alkylene" means a saturated hydrocarbon chain wherein a hydrogen atom is removed from each of the terminal carbons of a straight hydrocarbon chain. Preferred examples
5 include an alkylene group having 1 to 4 carbon atoms, specifically, methylene, ethylene, trimethylene and tetramethylene groups, and the like. When an alkylene group herein used contains 1 to 3 heteroatoms selected independently from nitrogen, sulfur and oxygen atoms, the term "alkylene" includes a group of the formula: $-O-(CH_2)_m-O-$, $-S-(CH_2)_m-S-$, $-NH-(CH_2)_m-$
10 $NH-$, or $-O-(CH_2)_m-NH-$ (wherein m is an integer of 1 to 4), or the like.

The term "alkanoyl group" or "alkanoyl" means a straight or branched alkylcarbonyl group having 1 to 10 carbon atoms, preferably an alkylcarbonyl group having 1 to 6 carbon atoms, more preferably an alkylcarbonyl group having 1 to 4 carbon atoms. Examples of alkanoyl
15 group include acetyl, propionyl, butyryl, valeryl and pivaloyl groups, and the like.

The term "alkenyl group" or "alkenyl" means a straight or branched hydrocarbon chain having 2 to 10 carbon atoms and containing at least one double bond, preferably an alkenyl group having 2 to 6 carbon atoms,
20 more preferably an alkenyl group having 2 to 4 carbon atoms. Examples of alkenyl group include vinyl, 1-propenyl, allyl, isopropenyl, butenyl, butadienyl and pentenyl groups, and the like.

As herein used throughout the claims and specification, when the term "mono- or di-alkyl" refers to di-alkyl, the alkyl moieties may be
25 independent from each other. In addition, a compound of the formula below means that it takes the configuration (2R*,4S*), wherein (2R*,4S*) refers to a mixture of (2R,4S) and (2S,4R).



The compounds of the present invention have CETP inhibitory activity and are effective for increasing HDL cholesterol and lowering LDL cholesterol. Accordingly, the said compounds are useful in prevention and/or treatment of diseases such as arteriosclerosis, hyperlipemia, and the like.

BEST MODE FOR CARRYING OUT THE INVENTION

Preferred compounds of the present invention are those wherein R⁵ is a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, wherein the heterocyclic group is optionally substituted by 1 to 5 substituents selected from the following group:

halogen atom, oxo group, hydroxy group, cyano group, nitro group, carboxyl group, sulfo group, optionally substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted alkenyl group, optionally substituted alkoxy group, optionally substituted cycloalkoxy group, optionally substituted alkoxycarbonyl group, carbamoyl group, optionally substituted mono- or di-alkylcarbamoyl group, optionally substituted carbamimidoyl group, optionally substituted alkylthio group, optionally substituted alkylsulfinyl group, optionally substituted alkylsulfonyl group, amino group, optionally substituted mono- or di-alkylamino group, optionally substituted alkanoylamino group, optionally substituted alkoxycarbonylamino group, optionally substituted alkylsulfonylamino group, optionally substituted mono- or di-alkylcarbamoylamino group, a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group

containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonylamino group is optionally substituted), sulfamoyl group, optionally substituted mono- or di-alkyl sulfamoyl group, optionally substituted alkanoyl group, a
5 saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted), a saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected
10 independently from oxygen, sulfur and nitrogen atoms (the heterocyclic oxy group is optionally substituted), and a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonyl group is
15 optionally substituted); and

R¹⁰ is an aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, which aromatic ring is optionally substituted by 1 to 4 substituents selected from the
20 following groups: halogen atom, carboxyl group, optionally substituted alkoxy carbonyl group, carbamoyl group, optionally substituted mono- or di-alkyl carbamoyl group, optionally substituted alkyl group, optionally substituted alkoxy group, hydroxy group, nitro group, cyano group, amino group, optionally substituted mono- or di-alkylamino group, optionally substituted alkanoyl group, optionally substituted alkylthio group, and a
25 saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted).


The substituent(s) for optionally substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted alkenyl group,
30 optionally substituted alkoxy group, optionally substituted cycloalkoxy

group, optionally substituted alkoxycarbonyl group, optionally substituted
mono- or di-alkylcarbamoyl group, optionally substituted alkylthio group,
optionally substituted alkylsulfinyl group, optionally substituted
alkylsulfonyl group, optionally substituted mono- or di-alkylamino group,
5 optionally substituted alkanoylamino group, optionally substituted
alkoxycarbonylamino group, optionally substituted alkylsulfonylamino
group, optionally substituted mono- or di-alkylcarbamoylamino group,
optionally substituted mono- or di-alkylsulfamoyl group, optionally
substituted alkanoyl group, optionally substituted alkylene group, a
10 saturated or unsaturated monocyclic or bicyclic heterocyclic
carbonylamino group containing 1 to 4 heteroatoms selected independently
from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonylamino
group is optionally substituted), a saturated or unsaturated monocyclic or
bicyclic heterocyclic group containing 1 to 4 heteroatoms selected
15 independently from oxygen, sulfur and nitrogen atoms (the heterocyclic
group is optionally substituted), a saturated or unsaturated monocyclic or
bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected
independently from oxygen, sulfur and nitrogen atoms (the heterocyclic oxy
group is optionally substituted), and a saturated or unsaturated
20 monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4
heteroatoms selected independently from oxygen, sulfur and nitrogen
atoms (the heterocyclic carbonyl group is optionally substituted) may be 1-
5 groups selected from the following groups:

halogen atom; cyano group; hydroxy group; nitro group; carboxyl
25 group; oxo group; thioxo group; sulfo group; cycloalkyl group
optionally substituted by hydroxy group, halogen atom, carboxyl group,
alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or
morpholinyl group; alkoxycarbonyl group optionally substituted by
hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group,
30 mono- or di-alkylamino group, phenyl group or morpholinyl group;

carbamoyl group; mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkanoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkoxy group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkanoyloxy group optionally substituted by halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylthio group optionally substituted by halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylsulfonyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylsulfinyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; mono- or di-alkylsulfamoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; amino group; mono- or di-alkylamino group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; mono- or di-alkylsulfamoylamino group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, mono- or di-alkylamino group, phenyl group or

morpholinyl group; mono- or di-alkylureido group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; and a group of the formula:



wherein X^1 and X^3 are independently CH_2 , NH , O , S , SO or SO_2 ; X^2 and X^5 are independently CH_2 , O , S , SO or SO_2 ; X^4 is NH , O , S , SO or SO_2 ; X^6 and X^7 are independently O or S ; X^8 is S , CO or SO ; and n , o , p , q and r are independently an integer of 1 to 4, wherein each group of the above formula is optionally substituted by 1 to 3 substituents selected from the following groups:

halogen atom, carboxyl group, hydroxy group, cyano group, oxo group, thioxo group, alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkyl group substituted by halogen, morpholinylalkyl group, phenylalkyl group, alkanoyl group, hydroxyalkanoyl group, alkoxyalkanoyl group, alkoxy group, phenylalkoxy group, alkoxycarbonyl group, benzyloxycarbonyl group, mono- or di-alkylamino group, mono- or di-alkylcarbamoyl group,

mono- or di-alkylsulfamoyl group, alkylsulfonyl group and tetrazolyl group.

Furthermore, the "aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is preferably a phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, furyl, pyrimidinyl, triazolyl or thienyl group;

The "saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is preferably a morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, hexahydroazepinyl, pyrrolinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolanyl, oxiranyl, pyrimidinyl, pyridyl, triazolyl, tetrazolyl, oxadiazolyl, dihydropyrimidinyl, pyrazinyl, thiazolyl, oxazolinyl, oxazolyl, pyridazinyl, imidazolyl, imidazolyl, pyrazinyl, thienyl, pyrrolyl, furyl or dihydrooxazinyl group.

The "saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is preferably a morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, hexahydroazepinyl, pyrrolinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolanyl, oxiranyl, pyrimidinyl, pyridyl, triazolyl, tetrazolyl, oxadiazolyl, dihydropyrimidinyl, pyrazinyl, thiazolyl, oxazolinyl, oxazolyl, pyridazinyl, imidazolyl, imidazolyl, pyrazinyl, thienyl, pyrrolyl, furyl or dihydrooxazinyl group.

The "saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is preferably a morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, hexahydroazepinyl, pyrrolinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolanyl, oxiranyl, pyrimidinyl, pyridyl, triazolyl, tetrazolyl, oxadiazolyl, dihydropyrimidinyl, pyrazinyl, thiazolyl, oxazolinyl, oxazolyl, pyridazinyl, imidazolyl, imidazolyl, pyrazinyl, thienyl, pyrrolyl, furyl or dihydrooxazinyl group.

imidazolidinylcarbonyl, oxazolidinylcarbonyl, tetrahydropyranylcabonyl, tetrahydrofuranylcabonyl, dioxolanylcabonyl, oxiranylcabonyl pyrimidinylcarbonyl, pyridylcarbonyl, triazolylcarbonyl, tetrazolylcarbonyl, oxadiazolylcarbonyl, dihydropyrimidinylcarbonyl, pyrazinylcarbonyl, 5 thiazolylcarbonyl, oxazolinylcabonyl, oxazolylcarbonyl, pyridazinylcarbonyl, imidazolinylcabonyl, imidazolylcarbonyl, pyrazinylcarbonyl, thienylcarbonyl, pyrrolylcabonyl, furylcabonyl or dihydrooxazinylcarbonyl group.

The "saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group containing 1 to 4 heteroatoms selected independently 10 from oxygen, sulfur and nitrogen atoms" is preferably a morpholinylcarbonylamino, thiomorpholinylcarbonylamino piperazinylcarbonylamino, pyrrolidinylcarbonylamino, piperidinylcarbonylamino, hexahydroazepinylcarbonylamino, pyrrolinylcarbonylamino, imidazolidinylcarbonylamino, 15 oxazolidinylcarbonylamino, tetrahydropyranylcabonylamino, tetrahydrofuranylcabonylamino, dioxolanylcabonylamino, oxiranylcabonylamino, pyrimidinylcarbonylamino, pyridylcarbonylamino, triazolylcarbonylamino, tetrazolylcarbonylamino, oxadiazolylcarbonylamino, dihydropyrimidinylcarbonylamino, pyrazinylcarbonylamino, thiazolylcarbonylamino, 20 oxazolinylcabonylamino, oxazolylcarbonylamino, pyridazinylcarbonylamino, imidazolinylcabonylamino, imidazolylcarbonylamino, pyrazinylcarbonylamino, thienylcarbonylamino, pyrrolylcabonylamino, furylcabonylamino or dihydrooxazinylcarbonylamino group.

25 In a preferred embodiment of the present invention, R¹ is a hydrogen atom; an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from 30 hydroxy group, amino group, mono- or di-alkylamino group, halogen atom,

carboxyl group, alkoxycarbonyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group and alkoxycarbonyl group), alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, hydroxy group and halogen atom), halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), morpholinyl group optionally substituted by oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), and pyrimidinyl group (said pyrimidinyl group is optionally

substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group); a carbamoyl group optionally substituted by alkoxy group; a dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; a dihydroimidazolyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; a dihydrooxazinyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; mono- or di-alkylcarbamoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group); an alkyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected

- independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group); an alkanoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group); a morpholinylcarbonyl group; a piperazinylcarbonyl group optionally substituted by alkyl group, carboxyalkyl group or alkoxycarbonylalkyl group; a pyrrolidinylcarbonyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group; or a piperidinylcarbonyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group;
- 20 R^5 is a saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms; wherein said heterocyclic group is optionally substituted by 1 to 4 substituents selected from the following groups:
- halogen atom
 - 25 oxo group;
 - hydroxy group;
 - cyano group;
 - nitro group;
 - carboxyl group;
 - 30 sulfo group;

alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy carbonyl group, carbamoyl, cycloalkyl group optionally substituted by carboxyl or alkoxy carbonyl group, phenyl group (said phenyl group is optionally substituted by alkoxy, carboxyl or alkoxy carbonyl group), sulfo group, sulfamoyl group, mono- or di-alkyl carbamoyl group, alkoxy group (said alkoxy group is optionally substituted by carboxyl, alkoxy carbonyl, hydroxy, alkoxy or phenyl group), alkanoyl group, alkanoyloxy group, alkylthio group, alkylsulfonyl group, alkylsulfinyl group, amino group, mono- or di-alkylamino group optionally substituted by alkoxy group, mono- or di-alkyl sulfamoylamino group, mono- or di-alkylureido group optionally substituted by morpholinyl group, oxiranyl group, dioxolanyl group optionally substituted by alkyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by oxo, alkoxy carbonyl or carboxyl group), piperidinyl group optionally substituted by carboxyl or alkoxy carbonyl group, piperazinyl group optionally substituted by alkyl group, hexahydroazepinyl group optionally substituted by carboxyl or alkoxy carbonyl group, morpholinyl group, and piperidinyl oxy group optionally substituted by alkyl group;

alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxy carbonyl group, benzyloxycarbonyl group and tetrazolyl group;


alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy carbonyl group, carbamoyl group, cycloalkyl group optionally substituted by carboxyl or alkoxy carbonyl group, phenyl group (said phenyl group is optionally substituted by alkoxy, carboxyl or alkoxy carbonyl group), sulfo group, sulfamoyl group, alkoxy group (said alkoxy group is optionally substituted by carboxyl, alkoxy carbonyl, hydroxy, alkoxy or

phenyl group), alkanoyl group, alkanoyloxy group, alkylthio group, alkylsulfonyl group, alkylsulfinyl group, amino group, mono- or di-alkylamino group substituted by alkoxy group, mono- or di-alkylsulfamoylamino group, mono- or di-alkylureido group optionally substituted by morpholinyl group, oxiranyl group, dioxolanyl group optionally substituted by alkyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by oxo, alkoxycarbonyl or carboxyl group), piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group, hexahydroazepinyl group optionally substituted by carboxyl or alkoxycarbonyl group, morpholinyl group, piperidinyl group optionally substituted by alkyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, pyrimidinyl group, pyridyl group and morpholinylcarbonyl group;

alkoxycarbonyl group optionally substituted by hydroxy group, carboxyl group, alkoxycarbonyl group or phenyl group; carbamoyl group; mono- or di-alkylcarbamoyl group optionally substituted by a group selected from carboxyl group, morpholinyl group, hydroxy group and alkoxy group; hydroxycarbamimidoyl group; alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group; alkylsulfinyl group;

alkylsulfonyl group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group; amino group; mono- or di-alkylamino group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group,

- alkoxy group, mono- or di-alkylamino group and morpholinyl group;
 mono- or di-alkanoylamino group optionally substituted by a group
 selected from hydroxy group, alkoxy group, carboxyl group,
 alkoxycarbonyl group and amino group;
- 5 mono- or di-alkylcarbamoylamino group optionally substituted by
 alkoxy group;
 morpholinylcarbonylamino group;
 sulfamoyl group;
 mono- or di-alkylsulfamoyl group;
- 10 alkanoyl group optionally substituted by a group selected from
 hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group,
 mono- or di-alkylamino group and morpholinyl group;
 alkoxycarbonylamino group optionally substituted by carboxyl group,
 hydroxy group, or alkoxycarbonyl group; or
- 15 a group selected from the following groups:



- wherein X^1 and X^3 are independently CH_2 , NH , O , S , SO or SO_2 ; X^2 and
 X^5 are independently CH_2 , O , S , SO or SO_2 ; X^4 is NH , O , S , SO or SO_2 ;
 20 and n , o , p , q and r are independently an integer of 1 to 4, wherein
 each group of the above formula is optionally substituted by a
 substituent(s) selected from the following groups:

- carboxyl group, halogen atom, hydroxy group, cyano group, oxo group, alkyl group, hydroxyalkyl group, alkoxyalkyl group, alkoxyalkyl group, morpholinylalkyl group, phenylalkyl group, alkanoyl group, hydroxyalkanoyl group, alkoxyalkanoyl group, alkoxy group, phenylalkoxy group, alkoxyalkyl group, benzyloxyalkyl group, mono- or di-alkylamino group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, dihydrooxadiazolyl group optionally substituted by oxo group, and tetrazolyl group;
- 10 R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a cyano group, an alkyl group, an alkoxy group, an alkoxyalkyl group, a benzyloxyalkyl group, a mono- or di-alkylcarbamoyl group or a mono- or di-alkylamino group, wherein said alkyl, alkoxy, alkoxyalkyl, benzyloxyalkyl, mono- or di-alkylcarbamoyl and mono- or di-alkylamino groups are optionally substituted by 1 to 6 substituents selected independently from halogen atom, hydroxy group, alkoxy group, alkylthio group, amino group, nitro group, cyano group, oxo group, carboxyl group, alkoxyalkyl group and mono- or di-alkylamino group; or
- 20 R⁶ and R⁷, or R⁷ and R⁸ may combine at the ends to form an alkylene group which alkylene group optionally contains 1 to 3 heteroatoms selected independently from nitrogen, sulfur and oxygen atoms;
- R¹⁰ is an aromatic monocyclic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms;
- 25 wherein the monocyclic aromatic ring is optionally substituted by 1 to 4 substituents selected independently from halogen atom, carboxyl group, alkoxyalkyl group, carbamoyl group, mono- or di-alkylcarbamoyl group, alkyl group, alkoxy group, hydroxy group, nitro group, cyano group, amino group, mono- or di-alkylamino group, alkanoyl group, alkylthio group, tetrazolyl group and dihydrooxazolyl
- 30

group, wherein the alkyl, alkoxy, mono- or di-alkylamino, mono- or di-alkylcarbamoyl, alkanoyl and alkylthio groups are optionally substituted by a substituent(s) selected independently from halogen atom, and hydroxy, alkoxy, morpholinyl, piperidinyl, pyrrolidinyl, 5 piperazinyl, alkylpiperazinyl and alkanoylpiperazinyl groups.

Furthermore, in the preferred compounds, the "aromatic monocyclic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a phenyl group, a pyridyl group, a pyrimidinyl group, a furyl group or a thienyl group; and the "saturated or 10 unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a pyrimidinyl group, a pyridyl group, a triazolyl group, a tetrazolyl group, a oxadiazolyl group, a dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an oxazolyl group, an imidazolyl group, 15 a dihydrooxazinyl group, a dihydropyrazinyl group or a pyrazolyl group.

In more preferred compounds, R¹ is a hydrogen atom; an alkoxy-carbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxy-carbonyl group, alkoxy group (said alkoxy group is optionally 20 substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxy-carbonyl group, carboxyalkoxy group and alkoxy-carbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, 25 carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group and alkoxy-carbonyl group), alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, 30 alkoxy-carbonyl group, hydroxy group and halogen atom), halogen atom,

cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), morpholinyl group optionally substituted by oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group and carboxyalkoxy group, alkoxy carbonylalkoxy group), pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), and pyrimidinyl group (said pyrimidinyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxy carbonylalkyl group and carboxyalkoxy group, alkoxy carbonylalkoxy group); dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxy carbonyl group, alkyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl group; or a mono- or di-alkylcarbamoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl

- group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group);
- 5 R^2 is an alkyl group;
- R^3 is a hydrogen atom;
- R^4 is an alkylene group;
- 10 R^5 is a heterocyclic group selected from pyrimidinyl group, pyridyl group, triazolyl group, tetrazolyl group, oxadiazolyl group, dihydropyrimidinyl group, pyrazinyl group, thiazolyl group, oxazolyl group, imidazolyl group, dihydrooxazinyl group, pyrazolyl group and dihydropyrazinyl group, wherein said heterocyclic group is substituted by 1 to 4 substituents
- 15 selected from the following groups:
- halogen atom,
 - hydroxy group;
 - oxo group;
 - cyano group;
 - 20 carboxyl group;
 - sulfo group;
 - alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy group optionally substituted by hydroxy or alkoxy group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group,
 - 25 morpholinyl group, alkanoyloxy group and alkylsulfonyl group;
 - 30

- alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, benzyloxycarbonyl group, and tetrazolyl group;
- 5 alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, alkoxy group (said alkoxy group is optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino
- 10 group optionally substituted by carboxyl or alkoxy group, morpholinyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group optionally substituted by carboxyl or alkoxy group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group,
- 15 and morpholinylcarbonyl group;
- cycloalkyl group optionally substituted by carboxyl group or alkoxycarbonyl group;
- alkoxycarbonyl group optionally substituted by phenyl group;
- carbamoyl group;
- 20 mono- or di-alkylcarbamoyl group optionally substituted by a group selected from morpholinyl group, carboxyl group, hydroxy group and alkoxy group;
- hydroxycarbamimidoyl group;
- alkylthio group optionally substituted by a group selected from
- 25 hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group;
- alkylsulfonyl group optionally substituted by a group selected from hydroxy group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group;
- amino group;
- 30 mono- or di-alkylamino group optionally substituted by a group

- selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group; alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
- 5 mono- or di-alkylureido group optionally substituted by alkoxy group; morpholinylcarbonylamino group; morpholinyl group optionally substituted by a group selected from oxo group and carboxyl group;
- 10 piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group, benzyloxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, tetrazolyl group, and dihydrooxadiazolyl group optionally substituted by oxo group;
- 15 piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group optionally substituted by phenyl group, alkoxycarbonyl group, oxo group and alkanoyl group; pyrrolidinyl group optionally substituted by a group selected from
- 20 carboxyl group, alkoxycarbonyl group, oxo group, and mono- or di-alkylamino group; pyrrolinyl group optionally substituted by oxo group; hexahydrodiazepinyl group optionally substituted by alkanoyl group; imidazolidinyl group optionally substituted by oxo group;
- 25 pyridyl group optionally substituted by carboxyl group, hydroxy group, alkanoyl group, alkyl group or hydroxyalkyl group (said pyridyl group is optionally further oxidized); tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl group;
- 30 dihydrooxadiazolyl group optionally substituted by oxo group;

- dihydroimidazolyl group;
dihydrooxazolyl group;
oxazolidinyl group optionally substituted by oxo group;
tetrahydropyridyl group optionally substituted by benzyl group;
5 pyrimidinyl group;
piperidinyloxy group optionally substituted by alkyl group or carboxyl group;
pyrrolidinyloxy group optionally substituted by a group selected from alkyl group, carboxyl group, alkoxy carbonyl group and alkanoyl group;
10 tetrahydropyranyloxy group;
tetrahydrofuranyloxy group;
optionally oxidized thianyloxy group;
morpholinyl carbonyl group;
piperazinyl carbonyl group optionally substituted by a group selected
15 from alkanoyl group and alkyl group;
pyrrolidinyl carbonyl group optionally substituted by carboxyl group or alkoxy carbonyl group; and
piperidinyl carbonyl group optionally substituted by carboxyl group or alkoxy carbonyl group;
20 R⁶ and R⁷ are independently a hydrogen atom, an alkyl group optionally substituted by halogen atom, an alkoxy group optionally substituted by halogen atom, a hydroxy group, a cyano group, or a mono- or di-alkylamino group; or
R⁶ and R⁷ may combine at the ends to form an alkylenedioxy group;
25 R⁸ is a hydrogen atom;
R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is optionally substituted by 1 to 4 substituents selected from halogen atom, alkoxy carbonyl group, alkyl group optionally substituted by halogen atom, alkoxy group optionally substituted by halogen atom, hydroxy group, cyano
30 group, amino group, mono- or di-alkylamino group and alkylthio group.

In further preferred compounds, R¹ is an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group and alkoxycarbonyl group), alkenyl group, halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), and pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group); or a dihydrooxazolyl group optionally substituted by 1 or 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; R⁵ is a pyrimidinyl group, a pyridyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an oxazolyl group, a dihydrooxazinyl group, a pyrazolyl group or a dihydropyrazinyl group, which group is substituted by 1 to 4 substituents selected from the following groups:

halogen atom;

hydroxy group;

cyano group;

carboxyl group;

alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy group optionally substituted by hydroxy or alkoxy group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group, morpholinyl group, alkanoyloxy group and alkylsulfonyl group;

alkenyl group optionally substituted by a group selected from cyano group, hydroxy group and carboxyl group;

alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, alkoxy group (said alkoxy group is optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group optionally substituted by carboxyl or alkoxy group, morpholinyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group optionally substituted by carboxyl or alkoxy group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group, and morpholinylcarbonyl group;

cycloalkyl group optionally substituted by carboxyl group or alkoxycarbonyl group;


mono- or di-alkylcarbamoyl group optionally substituted by a group selected from morpholinyl group, carboxyl group, hydroxy group and alkoxy group;

hydroxycarbamimidoyl group;

- alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group; amino group;
- 5 mono- or di-alkylamino group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, and morpholinyl group;
- alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
- 10 mono- or di-alkylureido group optionally substituted by alkoxy group; morpholinylcarbonylamino group;
- morpholinyl group optionally substituted by oxo group;
- piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group,
- 15 mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group and alkylsulfonyl group;
- piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group, alkoxycarbonyl group, oxo
- 20 group and alkanoyl group;
- pyrrolidinyl group optionally substituted by a group selected from oxo group, carboxyl group, alkoxycarbonyl group and mono- or di-alkylamino group;
- hexahydrodiazepinyl group optionally substituted by alkanoyl group;
- 25 pyridyl group optionally substituted by hydroxy group, carboxyl group, alkyl group or hydroxyalkyl group (said pyridyl group is optionally further oxidized);
- tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl group;
- 30 dihydrooxadiazolyl group optionally substituted by oxo group;

- oxazolidinyl group optionally substituted by oxo group;
 tetrahydropyridyl group optionally substituted by benzyl group;
 pyrimidinyl group;
 piperidinyloxy group optionally substituted by alkyl group or carboxyl
 5 group;
 pyrrolidinyloxy group optionally substituted by a group selected from
 alkyl group and alkanoyl group;
 tetrahydropyranyloxy group;
 tetrahydrofuranyloxy group; and
 10 optionally oxidized thianxyloxy group;
- R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is
 optionally substituted by 1 to 4 substituents selected from halogen atom,
 alkyl group optionally substituted by halogen atom, alkoxy group, hydroxy
 group, cyano group, amino group and mono- or di-alkylamino group.

- 15 In another embodiment of the present invention include compounds
 of the formula (I) wherein R⁵ is a group of the formula:




- wherein Ring A is a saturated or unsaturated 5- to 8-membered
 heterocyclic group containing 1 to 4 heteroatoms selected
 20 independently from oxygen, sulfur and nitrogen atoms, and
 R¹¹ is a group selected from the following groups:
- halogen atom;
 hydroxy group;
 oxo group;
 25 cyano group;
 carboxyl group;
 sulfo group;
 alkyl group optionally substituted by a group selected from halogen
 atom, cyano group, hydroxy group, carboxyl group, alkoxy group

optionally substituted by hydroxy or alkoxy group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, 5 piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group, morpholinyl group, alkanoyloxy group and alkylsulfonyl group; alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, 10 benzyloxycarbonyl group and tetrazolyl group; alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, alkoxy group (said alkoxy group is 15 optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group optionally substituted by carboxyl or alkoxy group, morpholinyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group 20 optionally substituted by carboxyl or alkoxy group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group and morpholinylcarbonyl group; cycloalkyl group optionally substituted by carboxyl group or alkoxycarbonyl group; 25 alkoxycarbonyl group optionally substituted by phenyl group; carbamoyl group; mono- or di-alkylcarbamoyl group optionally substituted by a group selected from morpholinyl group, carboxyl group, hydroxy group and alkoxy group; 30 hydroxycarbamimidoyl group;

alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group; alkylsulfonyl group optionally substituted by a group selected from hydroxy group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group;
5 amino group;
mono- or di-alkylamino group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;
10 alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
mono- or di-alkylureido group optionally substituted by alkoxy group; morpholinylcarbonylamino group;
morpholinyl group optionally substituted by a group selected from oxo group and carboxyl group;
15 piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group, benzyloxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, tetrazolyl group, and dihydrooxadiazolyl group optionally substituted by oxo group;
20 piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group optionally substituted by phenyl group, alkoxycarbonyl group, oxo group, and alkanoyl group;
25 pyrrolidinyl group optionally substituted by a group selected from carboxyl group, alkoxycarbonyl group, oxo group, and mono- or di-alkylamino group;
pyrrolinyl group optionally substituted by oxo group;
30 hexahydrodiazepinyl group optionally substituted by alkanoyl group;

- imidazolidinyl group optionally substituted by oxo group;
pyridyl group optionally substituted by carboxyl group, hydroxy group,
alkanoyl group, alkyl group or hydroxyalkyl group (said pyridyl group
is optionally further oxidized);
- 5 tetrazolyl group optionally substituted by a group selected from alkyl
group and hydroxyalkyl group;
dihydrooxadiazolyl group optionally substituted by oxo group;
dihydroimidazolyl group;
dihydrooxazolyl group;
- 10 oxazolidinyl group optionally substituted by oxo group;
tetrahydropyridyl group optionally substituted by benzyl group;
pyrimidinyl group;
piperidinyloxy group optionally substituted by alkyl group or carboxyl
group;
- 15 pyrrolidinyloxy group optionally substituted by a group selected from
alkyl group, carboxyl group, alkoxycarbonyl group and alkanoyl group;
tetrahydropyranyloxy group;
tetrahydrofuranyloxy group;
optionally oxidized thianyloxy group;
- 20 morpholinylcarbonyl group;
piperazinylcarbonyl group optionally substituted by a group selected
from alkanoyl group and alkyl group;
pyrrolidinylcarbonyl group optionally substituted by carboxyl group or
alkoxycarbonyl group; and
- 25 piperidinylcarbonyl group optionally substituted by carboxyl group or
alkoxycarbonyl group;

which compound is shown by the formula (I-A):



wherein each symbol has the same meaning as defined above.

More preferred embodiment includes compounds of the formula (I) wherein R¹ is a hydrogen atom; an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group and alkoxycarbonyl group), alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, hydroxy group and halogen atom), halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group,

alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), morpholinyl group optionally substituted by oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group), pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), and pyrimidinyl group (said pyrimidinyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group); dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; or a mono- or di-alkylcarbamoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group);

30 R^2 is an alkyl group;

R³ is a hydrogen atom;

R⁴ is an alkylene group;

Ring A and R¹¹ are the same groups as defined above;

5 R⁶ and R⁷ are independently a hydrogen atom, an alkyl group optionally substituted by halogen atom, an alkoxy group optionally substituted by halogen atom, a hydroxy group, a cyano group, or a mono- or d-alkylamino group; or

R⁶ and R⁷ may combine at the ends to form an alkylenedioxy group;

R⁸ is a hydrogen atom;

10 R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is optionally substituted by 1 to 4 substituents selected from halogen atom, alkoxycarbonyl group, alkyl group optionally substituted by halogen atom, alkoxy group optionally substituted by halogen atom, hydroxy group, cyano group, amino group, mono- or di-alkylamino group and alkylthio group.

15 Another preferred embodiment includes compounds of the formula (I) wherein Ring A is a saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, and R¹¹ is a group selected from the following groups:

20 halogen atom,

hydroxy group;

oxo group;

cyano group;

carboxyl group;

25 sulfo group;

alkyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxy group optionally substituted by hydroxy group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy group, pyrrolidinyl group, piperidinyl group,

30

piperazinyl group optionally substituted by alkyl group, morpholinyl group, alkanoyloxy group and alkylsulfonyl group;

alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, benzyloxycarbonyl group, and
5 tetrazolyl group;

alkoxy group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, alkoxy group optionally substituted by hydroxy group, alkylthio group,
10 alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group, morpholinyl group, pyrrolidinyl group optionally substituted by oxo group, pyrimidinyl group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group, and morpholinylcarbonyl group;

15 alkoxycarbonyl group optionally substituted by phenyl group; carbamoyl group;

mono- or di-alkylcarbamoyl group optionally substituted by a group selected from morpholinyl group and alkoxy group;

hydroxycarbamimidoyl group;

20 alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group; alkylsulfonyl group optionally substituted by a group selected from hydroxy group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group;

25 amino group;

mono- or di-alkylamino group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;

30 alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group and amino group;

- mono- or di-alkylureido group optionally substituted by alkoxy group;
morpholinylcarbonylamino group;
morpholinyl group optionally substituted by a group selected from oxo
group and carboxyl group;
- 5 piperazinyl group optionally substituted by a group selected from
cyano group, alkyl group, hydroxyalkyl group, alkoxyalkyl group,
carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group,
benzyloxyalkyl group, mono- or di-alkylcarbonyl group, mono- or
di-alkylsulfamoyl group, alkylsulfonyl group, tetrazolyl group, and
10 dihydrooxadiazolyl group optionally substituted by oxo group;
piperidinyl group optionally substituted by a group selected from
carboxyl group, hydroxy group, alkyl group optionally substituted by
hydroxy or carboxyl group, alkoxy group optionally substituted by
phenyl group, alkoxyalkyl group, oxo group, and alkanoyl group;
- 15 pyrrolidinyl group optionally substituted by a group selected from oxo
group and mono- or di-alkylamino group;
pyrrolinyl group optionally substituted by oxo group;
hexahydrodiazepinyl group optionally substituted by alkanoyl group;
imidazolidinyl group optionally substituted by oxo group;
- 20 pyridyl group optionally substituted by carboxyl group, hydroxy group,
alkyl group or hydroxyalkyl group (said pyridyl group is optionally
further oxidized);
tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl
group;
- 25 dihydrooxadiazolyl group optionally substituted by oxo group;
dihydroimidazolyl group;
dihydrooxazolyl group;
oxazolidinyl group optionally substituted by oxo group;
tetrahydropyridyl group optionally substituted by benzyl group;
- 30 pyrimidinyl group;

piperidinyl group optionally substituted by alkyl group;
 pyrrolidinyl group optionally substituted by a group selected from
 alkyl group and alkanoyl group;
 tetrahydropyranyloxy group;
 5 tetrahydrofuranyloxy group;
 optionally oxidized thianthryloxy group;
 morpholinylcarbonyl group;
 piperazinylcarbonyl group optionally substituted by a group selected
 from alkanoyl group and alkyl group; and
 10 pyrrolidinylcarbonyl group.

More preferred embodiment herein includes compounds of the
 formula (I) wherein R¹ is an alkoxy carbonyl group optionally substituted by
 a group selected from hydroxy group and alkoxy group;
 R² is an alkyl group;
 15 R³ is a hydrogen atom;
 R⁴ is an alkylene group;
 Ring A and R¹¹ are the same groups as defined above;
 R⁶ and R⁷ are independently a hydrogen atom, an alkyl group optionally
 substituted by halogen atom, an alkoxy group optionally substituted by
 20 halogen atom, a cyano group, or a mono- or di-alkylamino group; or
 R⁶ and R⁷ may combine at the ends to form an alkylenedioxy group;
 R⁸ is a hydrogen atom;
 R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is
 optionally substituted by 1 to 4 substituents selected from halogen atom,
 25 alkoxy carbonyl group, alkyl group optionally substituted by halogen atom,
 alkoxy group optionally substituted by halogen atom, hydroxy group, cyano
 group, amino group, mono- or di-alkylamino group and alkylthio group.

Examples of Ring A include a pyrimidinyl group, a pyridyl group, a
 triazolyl group, a tetrazolyl group, an oxadiazolyl group, a
 30 dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an oxazolyl

group, a dihydrooxazinyl group, a pyrazolyl group, a dihydropyrazinyl group, and the like.

More preferred compounds include those wherein Ring A is a pyrimidinyl group, a tetrazolyl group or a pyridyl group; and R¹¹ is a group
5 selected from the groups:

alkyl group optionally substituted by a group selected from carboxyl group, hydroxyalkoxy group, mono- or di-alkylamino group optionally substituted by alkoxy group, amino group, mono- or di-alkylcarbamoyl group and morpholinyl group:

10 alkenyl group optionally substituted by hydroxy group, carboxyl group or cyano group;

alkoxy group optionally substituted by a group selected from hydroxy group, carboxyl group, carbamoyl group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group,
15 hydroxyalkoxy group, carboxyalkoxy group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group, morpholinyl group, oxopyrrolidinyl group, optionally oxidized pyridyl group and morpholinylcarbonyl group;

carbamoyl group;

20 alkylthio group optionally substituted by hydroxy group or mono- or di-alkylcarbamoyl group;

mono- or di-alkylamino group optionally substituted by hydroxy group, carboxyl group or alkoxy group;

25 alkanoylamino group optionally substituted by hydroxy group or alkoxy group;

mono- or di-alkylureido group optionally substituted by alkoxy group; morpholinyl group;

30 piperazinyl group optionally substituted by a group selected from alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkanoyl group and mono- or di-alkylcarbamoyl group;

piperidinyl group optionally substituted by a group selected from carboxyl group, alkoxycarbonyl group, hydroxy group, hydroxyalkyl group, carboxyalkyl group and oxo group;

5 pyrrolidinyl group optionally substituted by a group selected from carboxyl group and mono- or di-alkylamino group;

pyridyl group that is substituted by hydroxyalkyl group or oxidized;

tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl group;

oxodihydrooxadiazolyl group;

10 pyrimidinyl group;

pyrrolidinyloxy group optionally substituted by alkanoyl group; and optionally oxidized thianyloxy group;

R⁶ is a hydrogen atom, an alkyl group optionally substituted by halogen atom, an alkoxy group, a cyano group, or a mono- or d-alkylamino group;

15 R¹⁰ is a phenyl group which is substituted by 1 to 3 substituents selected from halogen atom, alkyl group optionally substituted by halogen atom, alkoxy group and cyano group.

Still more preferred compounds include those wherein R¹ is an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected
20 independently from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group and alkoxycarbonyl group), alkenyl group, halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3
25 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl
30 group and alkoxycarbonylalkyl group), piperidinyl group (said piperidinyl

group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group), and pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group); or a dihydrooxazolyl group optionally substituted by 1 or 2 substituents selected independently from carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl group;

R¹¹ is a group selected from the groups:

- alkyl group optionally substituted by carboxyl group, alkoxy carbonyl group or hydroxy group,
- carboxyalkenyl group;
- alkoxy group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxy carbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylcarbamoyl group substituted by hydroxy group, hydroxyalkoxy group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group and oxopyrrolidinyl group;
- mono- or di-alkylamino group optionally substituted by carboxyl group;
- alkanoylamino group optionally substituted by hydroxy group or alkoxy group;
- morpholinyl group;
- piperazinyl group optionally substituted by a group selected from alkyl group, alkanoyl group and mono- or di-alkylcarbamoyl group;
- piperidinyl group optionally substituted by carboxyl group, alkoxy carbonyl group, hydroxy group, carboxyalkyl group or hydroxyalkyl group;

pyrrolidinyl group optionally substituted by mono- or di-alkylamino group;

pyridyl group that is substituted by hydroxyalkyl group or oxidized;

tetrazolyl group optionally substituted by hydroxyalkyl group;

5 pyrimidinyl group;

pyrrolidinyloxy group optionally substituted by alkyl group or alkanoyl group; and

optionally oxidized thianyloxy group; and

10 R^{10} is a phenyl group which is substituted by 1 to 3 substituents selected from alkyl group optionally substituted by halogen atom, alkoxy group and cyano group.

Still furthermore preferred compounds include those wherein R^1 is an alkoxycarbonyl group optionally substituted by 1 or 5 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, hydroxy group and cycloalkyl group; R^{11} is an alkyl group optionally substituted by carboxyl group; a carboxyalkenyl group; an alkoxy group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkylthio group and alkylsulfonyl group; an mono- or di-alkylamino group optionally substituted by carboxyl group; a 15 hydroxyalkanoylamino group; a morpholinyl group; a piperazinyl group optionally substituted by alkyl group or alkanoyl group; or a piperidinyl group optionally substituted by carboxyl group or hydroxy group;

20 R^6 is an alkyl group optionally substituted by halogen atom, an alkoxy group or a mono- or di-alkylamino group; and

25 R^7 is a hydrogen atom.

Especially preferred compounds include those wherein R^1 is an ethoxycarbonyl group, a hydroxyethoxycarbonyl group, a 2-fluoroethoxycarbonyl group, a 2,2-difluoroethoxycarbonyl group or a 2,2,2-trifluoroethoxycarbonyl group; R^2 is an ethyl group; R^{10} is a phenyl group substituted by 1 to 2 substituents selected from cyano group and 30

trifluoromethyl group; R⁶ is a methoxy group or a trifluoromethyl group. In this regard, other examples of especially preferred compounds include those wherein R¹ is a carboxy(C₂₋₁₀alkoxy)carbonyl group or an alkoxycarbonyl(C₂₋₁₀alkoxy)carbonyl group, and R², R¹⁰ and R⁶ are the same as above.

Especially more preferred compounds include those wherein R¹ is an ethoxycarbonyl group or a hydroxyethoxycarbonyl group; R² is an ethyl group; R¹⁰ is a phenyl group substituted by 1 to 2 substituents selected from cyano group and trifluoromethyl group; and R⁶ is a methoxy group.

Most preferred compounds include those listed below.

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-hydroxymethylpiperidine-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-methylpiperadin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-acetylpiperadin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(hydroxyacetylamino)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methylsulfonyl-ethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

- [1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2,3-dihydroxypropoxy)-
 pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester;
- 5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyvinyl)pyrimidin-2-
 yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
 carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)pyrimidin-2-
 yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
 10 carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-
 yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
 carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-([methyl-(2-
 15 carboxyethyl)]amino)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-
 2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-
 yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester;
- 20 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-
 yl)pyridin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethoxy)pyrimidin-2-
 yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
 25 carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-
 2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
 carboxylic acid ethyl ester;
 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxybutoxy)pyrimidin-
 30 2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

- carboxylic acid ethyl ester;
- (2R,4S)-4-[[5-(2-Carboxyethyl)pyrimidin-2-yl]-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- 5 (2R,4S)-4-[(3-Cyano-5-trifluoromethylbenzyl)-(5-[[methyl-(2-carboxyethyl)]-amino]pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[5-(4-Acetylpiperadin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-6-dimethylamino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- 10 (2R,4S)-4-[[5-(4-Acetylpiperadin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- 15 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2,2,2-trifluoroethyl ester;
- 20 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-fluoroethyl ester;
- 25 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 1-methylethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-

yl}}amino-1-((R)-4-hydroxymethyl-4,5-dihydrooxazol-2-yl)-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester; or
5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester; or
a pharmaceutically acceptable salt thereof.

10 Further examples of most preferred compounds include

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;

15 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;

20 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;

25 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

- carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
- 5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 10 carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-
- 15 2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
- 20 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 25 carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 4-carboxybutyl ester;

5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

10 carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

15 carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 4-carboxybutyl ester;

20 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

25 carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

- carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-((3-cyano-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
- 5 (2R,4S)-4-((3-cyano-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-((3-cyano-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 10 carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-((3-cyano-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyridin-2-
- 15 yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
- 20 (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 25 carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

- carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
- 5 (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 10 carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-([3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyridin-2-
- 15 yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
- 20 (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 25 carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;

- 5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

- 10 carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;

- 15 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;

- 20 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

- 25 carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

10 carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

15 carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxy-2-methylpropyl ester;

20 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-dimethylaminopyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

25 carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-dimethylaminopyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

- carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
- 5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 10 carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-
- 15 2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
- 20 (2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-
- 25 carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;

5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

10 carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-

15 carboxylic acid 4-carboxybutyl ester; or

(2R,4S)-4-[[3-cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester; or

20 a pharmaceutically acceptable salt thereof.

The present compound (I) or a pharmaceutically acceptable salt thereof can be administered either orally or parenterally, and can be formulated into pharmaceutical preparations with a conventional pharmaceutically acceptable carriers used therefor.

25 The pharmaceutically acceptable salts of the compound (I) may include, for example, alkali metal salts such as lithium, sodium or potassium salt; alkali earth metal salts such as calcium or magnesium salt; salts with zinc or aluminum; salts with organic bases such as

ammonium, choline, diethanolamine, lysine, ethylenediamine, t-butylamine, t-octylamine, tris(hydroxymethyl)aminomethane, N-methylglucosamine, triethanolamine or dehydroabiethylamine; salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid; salts with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid; or salts derived from acidic amino acids such as aspartic acid or glutamic acid.

Additionally, the pharmaceutically acceptable salts of the compound (I) may include, for example, quaternary salts formed between a compound of the formula (I) and an alkyl halide or phenylalkyl halide.

Preferred pharmaceutical preparations for oral administration of the present compound (I) or a pharmaceutically acceptable salt thereof include solid formulations such as tablets, granules, capsules or powders; and liquid formulations such as solutions, suspensions or emulsions. Preferred pharmaceutical preparations for parenteral administration include injections or infusions formulated with injectable distilled-water, physiological saline or aqueous glucose solution; suppository; or inhalation preparation.

These pharmaceutical preparations comprise a compound (I) of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier which is usually used for oral or parenteral administration. The pharmaceutically acceptable carriers for oral administration include, for example, a binder (syrup, gum acacia, gelatin, sorbit, tragacanth, polyvinylpyrrolidone, and the like), an excipient (lactose, sugar, cornstarch, potassium phosphate, sorbit, glycine, and the like), a lubricant (magnesium stearate, talc, polyethylene glycol, silica, and the like), a disintegrant (potato starch, and the like), and a wetting agent

(anhydrous sodium lauryl sulfate, and the like). The pharmaceutically acceptable carriers for parenteral administration include, for example, injectable distilled-water, physiological saline and aqueous glucose solution.

5 The dose of a compound (I) of the present invention or a pharmaceutically acceptable salt thereof varies depending on the administration route, age, body weight, disease, and condition/severity, of the patient. It however can usually be in the range of about 0.001 - 1,000 mg/kg/day, preferably in the range of about 0.01 - 100 mg/kg/day.

10 The compounds of the present invention have an inhibitory activity against CETP and show effects of increasing HDL cholesterol and lowering LDL cholesterol. Accordingly, they are useful in the prophylaxis or treatment of a subject (particularly, mammal including human) suffering from arteriosclerosis, peripheral vascular disease, dyslipidemia,
15 hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesteremia, hypertriglyceridemia, familial-hypercholesteremia, cardiovascular diseases, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, restenosis after angioplasty, hypertension, cerebral infarction, cerebral stroke, diabetes, vascular complication of diabetes,
20 thrombotic diseases, obesity, endotoxemia, or the like.

 In addition, the compounds of the present invention may be used in combination with other drugs useful for treatment of these diseases. For example, a compound of the present invention may be used in combination with an inhibitor of cholesterol synthesis such as HMG-CoA reductase
25 inhibitor, an inhibitor of cholesterol absorption such as anion exchange resin, fibrates, a triglyceride lowering agent such as niacin or other cholesterol reducer such as ACAT inhibitor.


 The compounds of the present invention have an improved bioavailability and useful as a CETP inhibitor. Above all, compounds
30 having a carboxyl group at the terminal position of respective substituents

R¹ - R¹¹, especially those having a carboxyl group at the terminal position of R¹ and/or R⁵, or R¹ and/or R¹¹ are preferred.


The compound (I) of the present invention can be prepared by the following methods.

5 PROCESS 1

The compound (I) of the present invention can be prepared by condensing a compound of the formula (II):



wherein the symbols have the same meaning as defined above with a compound of the formula (III):



wherein Z¹ is a leaving group and the other symbols have the same meaning as defined above.

The condensation can be carried out in the presence of a base in a suitable solvent.

The leaving group includes a halogen atom including chlorine atom, bromine atom, iodine atom, and a substituted sulfonyloxy group including methanesulfonyloxy group, toluenesulfonyloxy group, and trifluoromethanesulfonyloxy group.

A conventional base can be used as the base, and for example, alkaline metal hydride including sodium hydride, potassium hydride; alkaline metal hydroxide including sodium hydroxide, potassium hydroxide; alkaline earth metal hydroxide including barium hydroxide; alkaline metal alkoxide including sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide; alkaline metal carbonate including sodium carbonate, potassium carbonate, cesium carbonate;


alkaline metal bicarbonate including sodium bicarbonate, potassium bicarbonate; amines including triethylamine, diisopropylethylamine, methylpiperidine, dimethylaniline, 1,8-diazabicyclo[5.4.0]undecene, 1,4-diazabicyclo[2.2.2]octane, 1,5-diazabicyclo[4.3.0]nonene; pyridines including pyridine, dimethylaminopyridine, and the like can be preferably used.

Any solvent which does not disturb the reaction can be preferably used, and such a solvent includes, for example, hydrocarbons including pentane, hexane; aromatic hydrocarbons including benzene, toluene, nitrobenzene; halogenated hydrocarbons including dichloromethane, chloroform; ethers including diethylether, tetrahydrofuran; amides including dimethylformamide, N-methylpyrrolidone, 1,3-dimethylimidazolidin-2-one; sulfoxides including dimethylsulfoxide; alcohols including methanol, ethanol; esters including ethyl acetate, butyl acetate; ketones including acetone, methyl ethyl ketone; nitriles including acetonitrile; water, or a mixed solvent thereof.

The reaction is carried out from under cooling to under heating, preferably from -78°C to 200°C, more preferably from -30°C to 100°C.


PROCESS 2

Among the compound of the formula (I-A), a compound of the formula (I-b):




wherein the symbols have the same meaning as defined above can be prepared by

(a) cyanating a compound of the formula (II-A):




wherein the symbols have the same meaning as defined above to provide a compound of the formula (II-B):

5



wherein the symbols have the same meaning as defined above,


(b) reacting the compound (II-B) with hydroxylamine or a salt thereof to provide a compound of the formula (II-C):



10

wherein the symbols have the same meaning as defined above,

(c) alkanoylating the compound (II-C) to provide a compound of the formula (II-D):



wherein the symbols have the same meaning as defined above, and further (d) cyclizing the compound (II-D) with a base.

The cyanation in the process (a) can be carried out by reacting a
5 halogenated cyanogen in the presence of a base in a suitable solvent.

Cyanogen bromide is preferable as the halogenated cyanogen.

A conventional base can be preferably used as the base, and alkaline
metal carbonate including potassium carbonate, or alkaline metal
bicarbonate including sodium bicarbonate can be preferably used.

10 Any solvent which dose not disturb the reaction can be used and the
solvent referred to in the PROCESS 1 can be preferably used.

The reaction with hydroxylamine in the process (b) can be carried
out in the presence of a base in a suitable solvent.

15 Tertiary alkylamines including triethylamine, diisopropylethylamine,
and the like can be preferably used as the base.

Any solvent which dose not disturb the reaction can be used and the
solvent referred to in the PROCESS 1 can be preferably used.

The alkanoylation in the process (c) can be carried out with an
alkanoyl halide in the presence of a base in a suitable solvent.

20 A conventional base can be used as the base, and amines including
triethylamine or diisopropylethylamine, or pyridines including pyridine, 4-
dimethylaminopyridine can be preferably used.

Any solvent which dose not disturb the reaction can be used and the
solvent referred to in the PROCESS 1 can be preferably used.

25 In the cyclization in the process (d), a conventional base can be used

as the base, and amines including triethylamine or diisopropylethylamine; pyridines including pyridine, 4-dimethylaminopyridine; alkaline metal carbonate including potassium carbonate; or alkaline metal alkoxide including sodium methoxide can be preferably used.


- 5 Any solvent which does not disturb the reaction can be used and the solvent referred to in the PROCESS 1 can be preferably used.

Additionally, the cyclization following the alkanoylation can also be carried out in situ.


- The reaction is carried out from under cooling to under heating, preferably from -50°C to 100°C, more preferably from 0°C to 50°C.

PROCESS 3

Among the compound of the formula (I-A), a compound of the formula (I-c):



- 15 wherein the symbols have the same meaning as defined above can be prepared by reacting a compound of the formula (II-B):



wherein the symbols have the same meaning as defined above with sodium azide.

- 20 The reaction can be carried out in the presence of ammonium chloride in a suitable solvent.

Any solvent which does not disturb the reaction can be used and the

solvent referred to in the PROCESS 1 can be preferably used.

The reaction is carried out from under cooling to under heating, preferably from -50°C to 150°C, more preferably from 20°C to 100°C.

5 Additionally, a substituent(s) of compound (I) of the present invention can be converted into different one(s) within the scope of the compound (I) according to the following methods as appropriate.

In the following each process, a conventional base can be used as a base, and unless otherwise specified, the base referred to in the PROCESS 1 can be preferably used.

10 Additionally, in the following each process, a conventional acid can be used as an acid, and unless otherwise specified, a mineral acid such as hydrochloric acid, nitric acid, sulfuric acid, or an organic acid represented by sulfonic acids (e.g., methanesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid) or carboxylic acids (e.g., acetic acid, 15 trifluoroacetic acid) can be preferably used.

Further additionally, in the following each process, any solvent which does not disturb the reaction can be used, and as such, the solvent referred to in the PROCESS 1 can be preferably used.

20 The leaving group includes a halogen atom such as chlorine atom, bromine atom, iodine atom, and a substituted sulfonyloxy group such as methanesulfonyloxy group, trifluoromethanesulfonyloxy group, and toluenesulfonyloxy group.


25 In addition, in the following each process, "a saturated or unsaturated monocyclic or bicyclic heterocyclic group having one to four heteroatoms independently selected from oxygen atom, sulfur atom and nitrogen atom" in R⁵ is simply referred to as "a heterocyclic group".

(1) Among the compound (I-A), the compound wherein Ring A is a tetrazolyl group and R¹¹ is an optionally substituted alkyl group can be prepared by alkylating a compound wherein Ring A is a tetrazolyl group 30 and R¹¹ is a hydrogen atom.

The alkylation of the compound can be carried out by reacting it with a compound of the formula:



wherein R^{11A} is an optionally substituted alkyl group and Z^2 is a leaving group in a suitable solvent in the presence or absence of a base, or by reacting with a compound of the formula:




wherein the symbols have the same meaning as defined above in a suitable solvent in the presence of a phosphine and an azodicarboxylic ester.

The reaction proceeds more preferably when a catalytic amount of an alkaline metal iodide (for example, potassium iodide, and the like) is added.

Both phosphines and azodicarboxylic esters which usually employed in Mitsunobu reaction can be preferably used. Phosphines include, for example, triphenylphosphine, tributylphosphine, and the like, and azodicarboxylic esters include diethyl azodicarboxylate, diisopropyl azodiformate, and the like.


(2) Among the compound (I-A), the compound wherein Ring A is 2-oxodihydropyrimidinyl group and R^{11} is an optionally substituted alkyl group can be prepared by alkylating a compound wherein Ring A is 2-hydroxypyrimidinyl group and R^{11} is a hydrogen atom with a compound of the formula:




wherein the symbols have the same meaning as defined above.

The reaction can be carried out in the same manner as (1).

(3) The compound wherein R^5 is a heterocyclic group substituted by an optionally substituted amino group or a group of the formula:



wherein the symbols have the same meaning as defined above can be prepared by coupling a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding amine or a compound of the
 5 formula:



wherein the symbols have the same meaning as defined above.

The coupling reaction can be carried out in the presence of a palladium catalyst, and in the presence or absence of a base in a suitable
 10 solvent.


As the palladium catalyst, a conventional palladium catalyst including palladium acetate, tetrakis(triphenylphosphine)palladium, tris-(dibenzylideneacetone)dipalladium, dichlorobis(triphenylphosphine)-palladium, dichlorobis(tri-o-tolylphosphine)palladium or bis-
 15 (triphenylphosphine)palladium acetate, and the like can be used.

As the base, alkaline metal hydroxide including sodium hydroxide, potassium hydroxide; alkaline earth metal hydroxide including barium hydroxide; alkaline metal alkoxide including sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide; alkaline metal
 20 carbonate including sodium carbonate, potassium carbonate, cesium carbonate; alkaline metal bicarbonate including sodium bicarbonate, potassium bicarbonate; alkaline metal phosphate including potassium phosphate; amines including triethylamine, diisopropylethylamine, methylpiperidine, dicyclohexylmethylamine; pyridines including pyridine,
 25 4-dimethylaminopyridine, and the like can be preferably used.


Additionally, phosphines may be added in the present reaction. As the phosphines, triphenylphosphine, tributylphosphine, tri-tert-butylphosphonium tetrafluoroborate, 1,3-bis(diphenylphosphino)propane,

2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 1,1'-bis(diphenylphosphino)-ferrocene, 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl, 2-(dicyclohexylphosphino)biphenyl, and the like can be preferably used.

- 5 (4) The compound wherein R⁵ is a heterocyclic group substituted by an optionally substituted amino group or a group of the formula:



- 10 wherein the symbols have the same meaning as defined above can also be prepared by reacting a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyl group with a corresponding amine or a compound of the formula:



wherein the symbols have the same meaning as defined above.

- 15 The reaction can be carried out by optionally adding a copper catalyst in the presence or absence of a base in a suitable solvent.


Copper iodide, copper bromide, copper chloride, copper acetate, copper trifluoromethanesulfonate, and the like can be preferably used as the copper catalyst.

The same base as referred to in (3) can be preferably used.

- 20 Additionally, the reaction proceeds more preferably when N,N'-dimethylethylenediamine, 1,10-phenanthroline, ethylene glycol, phenylphenol, or the like is added.

- 25 (5) The compound wherein R⁵ is a heterocyclic group substituted by an optionally substituted amino group can be prepared by coupling a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a compound

of the formula:



wherein R^{20} is an alkyl group and $NR^{21}R^{22}$ is an optionally substituted amino group.

5 The coupling reaction can be carried out in the presence of a palladium catalyst in the presence or absence of a base in a suitable solvent.

 The same palladium catalyst, base, and phosphines as referred to in (3) can be preferably used.

10 (6) The compound wherein R^5 is a heterocyclic group substituted by a cyano group can be prepared by cyanating a compound wherein R^5 is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group.

 The cyanation can be carried out by reacting a starting compound
15 with a metal cyanide including sodium cyanide, potassium cyanide, or zinc cyanide in the presence of a palladium catalyst in a suitable solvent.

 The same palladium catalyst as that described in (3) can be preferably used.

20 (7) The compound wherein R^5 is a heterocyclic group substituted by an optionally substituted alkoxycarbonyl group can be prepared by reacting a compound wherein R^5 is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding alkylalcohol under carbon monoxide using a palladium catalyst in the presence of a base in a suitable solvent.

25 The same palladium catalyst and base as those described in (3) can be preferably used.

 Additionally, the reaction can be more preferably carried out by adding a ligand, and phosphines referred to in (3) can be preferably used as the ligand.

30 (8) The compound wherein R^5 is a heterocyclic group substituted by

an optionally substituted alkenyl group can be prepared by coupling a compound wherein R^5 is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding alkene.

5 The coupling reaction can be carried out in the presence of a palladium catalyst in the presence or absence of a base in a suitable solvent.

 The same palladium catalyst as that described in (3) can be preferably used.

10 The same base as referred to in (3) can be preferably used and silver carbonate can also be used.

 Additionally, the reaction can be more preferably carried out by adding a ligand, and phosphines referred to in (3) can be preferably used as the ligand.

15 (9) The compound wherein R^5 is a heterocyclic group substituted by an optionally substituted alkoxy group can be prepared by alkoxylation a compound wherein R^5 is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group.

 The alkoxylation can be carried out by optionally adding a copper catalyst to react a starting compound with a corresponding alcohol in a
20 suitable solvent or neat in the presence of a base.

 The same base as previously described in (3), in particular, cesium carbonate can be preferably used.

 The copper catalyst as described in (4) can be preferably used.

25 Additionally, the reaction proceeds more preferably when 1,10-phenanthroline, 2-aminopyridine, or the like is added.

 (10) The compound wherein R^5 is a heterocyclic group substituted by an optionally substituted alkoxy group can be prepared by reacting a compound wherein R^5 is a heterocyclic group substituted by an
30 alkylsulfonyl group with a corresponding alkaline metal alkoxide in a

suitable solvent. The corresponding alkaline metal alkoxide can be obtained by treating a corresponding alkylalcohol with alkaline metal hydride or alkaline metal.

5 (11) The compound wherein R⁵ is a heterocyclic group substituted by an optionally substituted alkylthio group can be prepared by reacting a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding alkylthiol.

10 The reaction can be carried out in the same manner as previously described in (9) and facilitated by adding 1,10-phenanthroline or ethylene glycol.

15 (12) The compound wherein R⁵ is a heterocyclic group substituted by an optionally substituted heterocyclic group can be prepared by coupling a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding heterocyclic boronic acid or a corresponding heterocyclic boronic ester.

The coupling can be carried out in the presence of a palladium catalyst, and in the presence or absence of a base in a suitable solvent.

20 The reaction can be carried out in the same manner as (3).

25 (13) The compound wherein R⁵ is a heterocyclic group substituted by an optionally substituted heterocyclic group can be prepared by coupling a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with a corresponding heterocyclic alkyl tin compound.

The reaction can be carried out in the same manner as (5).

30 (14) The compound wherein R⁵ is a heterocyclic group substituted by an alkoxycarbonylalkylsulfonyl group can be prepared by reacting a compound wherein R⁵ is a heterocyclic group substituted by a halogen atom or an optionally substituted alkylsulfonyloxy group with an


alkoxycarbonylalkylsulfinic acid alkaline metal salt.

The alkoxycarbonylalkylsulfinic acid alkaline metal salt can be prepared according to the method described, for example, in Baskin et al., Tetrahedron Lett., 43, 8479 (2002).


5 Additionally, the present reaction can be carried out in the presence of a copper catalyst in a suitable solvent according to the method described in the said literature.

The same copper catalyst as described in (4) can be used, and in particular, copper iodide can be preferably used.

10 (15) The compound having a group of the formula:



wherein the symbols have the same meaning as defined above as a substituent on R⁵ can be prepared by condensing a compound having a hydroxy group as a substituent on R⁵ with a compound of the formula:



15

wherein X¹¹ is O, SO, SO₂ or NR^P (R^P is a protecting group) and q is an integer from 1 to 4, and if needed, removing a protecting group for amino group.

20 As a protecting group, a conventional protecting group including benzyloxycarbonyl group, tert-butoxycarbonyl group, and the like can be used.

The reaction can be carried out in a suitable solvent in the presence of phosphines and azodicarboxylic esters. The reaction can be carried out in the same manner as (1).

25 The removal of a protecting group can be carried out in a conventional manner including catalytic reduction, acid-treatment, and the like, depending on the type of a protecting group.

(16) The compound having an aminoalkyl group as a substituent on

R⁵ can be prepared by catalytically reducing a compound having a cyano group or a cyanoalkyl group as a substituent on R⁵.


The catalytic reduction can be carried out by using a catalyst under hydrogen in a suitable solvent according to a conventional manner. The catalyst includes a palladium catalyst such as palladium-carbon, a nickel catalyst such as Raney nickel, a platinum catalyst such as platinum-carbon, and the like.

(17) The compound having an optionally substituted mono- or di-alkylsulfamoylaminoalkyl group as a substituent on R⁵ can be prepared by reacting a compound having an aminoalkyl group as a substituent on R⁵ with a corresponding halogenated mono- or di-alkylsulfamoyl.


The reaction can be carried out in a suitable solvent in the presence of a base.

(18) The compound having an optionally substituted mono-alkylcarbamoylaminoalkyl group as a substituent on R⁵ can be prepared by reacting a compound having an aminoalkyl group as a substituent on R⁵ with a corresponding alkyl isocyanate in a suitable solvent.

(19) The compound having a group of the formula:



wherein R¹² is an alkyl group and the other symbols have the same meaning as defined above as a substituent on R⁵ can be prepared by reacting a compound having a group of the formula:



wherein the symbols have the same meaning as defined above as a substituent on R⁵ with a corresponding alkyl isocyanate (R¹²NCO). The


reaction can be carried out in the same manner as (18).

(20) The compound having an optionally substituted mono- or di-alkylcarbamoylamino group as a substituent on R⁵ can be prepared by condensing a compound having an amino group as a substituent on R⁵ with an optionally substituted mono- or di-alkylamine using a carbonylating agent in a suitable solvent in the presence or absence of a base.


A conventional carbonylating agent such as carbonyldiimidazole, phosgene, triphosgene, and the like can be used.

(21) The compound having a morpholinylcarbonylamino group as a substituent on R⁵ can be prepared by condensing a compound having an amino group as a substituent on R⁵ with morpholine using a carbonylating agent in a suitable solvent. The reaction can be carried out in the same manner as (20).

(22) The compound having a group of the formula:



wherein X¹² is O or NH as a substituent on R⁵ can be prepared by treating a compound having a group of the formula:



wherein the symbols have the same meaning as defined above as a substituent on R⁵ with a carbonylating agent in a suitable solvent.

The reaction can be carried out in the same manner as (20).


(23) The compound having an optionally substituted carbamoyl group as a substituent on R⁵ can be prepared by condensing a compound having a carboxyl group as a substituent on R⁵ with a desirable amine.

The condensation can be carried out using a condensing agent in a suitable solvent. A conventional condensing agent such as


dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, carbonyldiimidazole, and the like can be preferably used.

Additionally, the condensation can be more preferably carried out by adding an activating agent including 1-hydroxybenzotriazole, 1-hydroxysuccinimide, and the like.

(24) The compound having a group of the formula:



wherein the symbols have the same meaning as defined above as a substituent on R⁵ can be prepared by condensing a compound having a carboxyl group as a substituent on R⁵ with a compound of the formula:



wherein the symbols have the same meaning as defined above.

The reaction can be carried out in the same manner as (23).

(25) The compound containing a tetrazolyl group as a substituent on R⁵ can be prepared by reacting the compound containing a cyano group as a substituent on R⁵ with an alkaline metal azide in the presence of an acid in a suitable solvent.


The alkaline metal azide includes sodium azide, lithium azide, and the like.

An ammonium salt of a halogenated hydrogen including ammonium chloride is preferable as the acid.


(26) The compound having an optionally substituted alkyl tetrazolyl group as a substituent on R⁵ can be prepared by alkylating a compound having a tetrazolyl group as a substituent on R⁵.

The alkylation can be carried out in the same manner as (1).

(27) The compound having an optionally substituted amino group or a group of the formula :




wherein the symbols have the same meaning as defined above as a substituent on R⁵ can be prepared by reacting a compound having a halogen atom or an optionally substituted alkylsulfonyloxy group as a substituent on R⁵ with a corresponding amine or a compound of the formula:




wherein the symbols have the same meaning as defined above.

The reaction can be preferably carried out in the presence or absence of a base in a suitable solvent.

(28) The compound having an optionally substituted alkylamino group or a group of the formula:



wherein R¹³ is an alkyl group optionally substituted by a hydroxy group, an alkoxy carbonyl group, a morpholinyl group or a phenyl group, and n has the same meaning as defined above as a substituent on R⁵ can be prepared by reacting a compound having an amino group or a group of the formula:




wherein the symbols have the same meaning as defined above as a substituent on R⁵ with a corresponding alkyl halide or a corresponding sulfonic alkyl ester.


The sulfonic alkyl ester including methanesulfonic ester, toluenesulfonic ester, trifluoromethanesulfonic ester, and the like can be preferably used.

The reaction can be preferably carried out in the presence or absence of a base in a suitable solvent.

(29) The compound having a group of the formula:



5 wherein X^{13} is O or NH, and the other symbols have the same meaning as defined above as a substituent on R^5 can be prepared by ring-closure of a compound having a group of the formula:



10 wherein Z^3 is a leaving group and the other symbols have the same meaning as defined above as a substituent on R^5 .

The reaction can be preferably carried out in the presence or absence of a base in a suitable solvent.

(30) The compound containing a carboxyl group as a substituent on R^5 can be prepared by hydrolyzing a compound having an alkoxy carbonyl group as a substituent on R^5 .

The hydrolysis can be carried out by treating a starting compound with a base or an acid in a suitable solvent according to a conventional manner. An alkaline metal hydroxide can be preferably used as the base.

20 (31) The compound containing a carboxyl group as a substituent on R^5 can be prepared by hydrolyzing a compound containing a cyano group as a substituent on R^5 .

The hydrolysis can be carried out by treating a starting compound with an acid in a suitable solvent.

25 (32) The compound containing a carbamoyl group as a substituent on R^5 can be prepared by hydrolyzing a compound containing a cyano group as a substituent on R^5 .

The hydrolysis can be carried out by treating a starting compound with an acid in a suitable solvent.

(33) The compound having a carboxyalkyl group as a substituent on R⁵ can also be prepared by catalytically reducing a compound having a carboxyalkenyl group, a benzyloxycarbonylalkenyl group or a benzyloxycarbonylalkyl group as a substituent on R⁵.

5 The catalytic reduction can be carried out in the same manner as (16).

(34) The compound having a hydroxy group as a substituent on R⁵ can be prepared by hydrolyzing a compound having an alkanoyloxy group as a substituent on R⁵.

10 The hydrolysis can be carried out in the same manner as (30).

(35) The compound containing sulfin (SO) or sulfoxide (SO₂) in a substituent on R⁵ can be prepared by oxidizing a compound having S in a substituent on R⁵ (for example, a compound having a thiomorpholinyl group or an alkylthio group as a substituent on R⁵).

15 The oxidation can be carried out by treating a starting compound with an oxidizing agent in a suitable solvent.

Peroxides such as hydrogen peroxide, m-chloroperbenzoic acid, acetyl hydroperoxide, and the like can be preferably used as the oxidizing agent.

20 (36) The compound containing N-oxide in a substituent on R⁵ can be prepared by oxidizing a compound having N in a substituent on R⁵ (for example, a compound having a pyridyl group as a substituent on R⁵).

The oxidation can be carried out in the same manner as (35).

25 (37) The compound having 1,2-dihydroxyalkyl group as a substituent on R⁵ can be prepared by treating a compound having an alkyl group substituted by mono- or di-alkyldioxolanyl group as a substituent on R⁵ with an acid in a suitable solvent.

A strongly acidic resin can also be preferably used as the acid, in addition to those previously described.

30 (38) The compound having an alkyl group substituted by a hydroxy

group and an optionally substituted alkoxy group as substituents on R⁵ can be prepared by reacting a compound having an oxylanylalkyl group as a substituent on R⁵ with an alkaline metal salt of corresponding alcohol in a suitable solvent.

5 The alkaline metal salt of alcohol includes a lithium salt, a sodium salt, a potassium salt, and the like.

(39) The compound having an alkyl group substituted by a hydroxy group and an amino group, or an alkyl group substituted by a hydroxy group and an optionally substituted mono- or di-alkylamino group as substituents on R⁵ can be prepared by reacting a compound having an oxylanylalkyl group as a substituent on R⁵ with ammonia or a
10 corresponding mono- or di-alkylamine in a suitable solvent.

(40) The compound having a hydroxycarbamimidoyl group as a substituent on R⁵ can be prepared by reacting a compound having a cyano group as a substituent on R⁵ with hydroxylamine or a salt thereof in a
15 suitable solvent.

The reaction can be carried out in the presence of a base in a suitable solvent.

(41) The compound having an oxodihydrooxadiazolyl group as a substituent on R⁵ can be prepared by reacting a compound having a hydroxycarbamimidoyl group as a substituent on R⁵ with a carbonylating agent in a suitable solvent in the presence or absence of a base.
20

The same carbonylating agent as that described in (20) can be used.

(42) The compound having a sulfo group as a substituent on R⁵ can be prepared by hydrolyzing a compound having an alkoxy-carbonylalkylsulfonyle group as a substituent on R⁵.
25

The hydrolysis can be carried out in the same manner as (30).

(43) The compound having a sulfamoyl group as a substituent on R⁵ can be prepared by condensing a compound having a sulfo group as a substituent on R⁵ with a desirable amine.
30

The condensation can be carried out by treating a compound having a sulfo group as a substituent on R^5 with a halogenating agent in a suitable solvent, followed by reacting the resulting compound with a desirable amine in the presence or absence of a base.

5 A conventional halogenating agent including thionyl halide, phosphorus oxyhalide, or the like can be used.

(44) The compound having a hydroxyalkyl group as a substituent on R^5 can be prepared by reducing a compound having a carboxyalkyl group as a substituent on R^5 , or by converting the carboxyl group into an acid anhydride or an ester and reducing the resulting compound.

A process for conversion into an acid anhydride can be carried out by reacting a starting compound with a halogenated alkyl formate in a suitable solvent in the presence of a base.

15 A process for conversion into an ester can be carried out by reacting a starting compound with an alcohol in the presence of a condensing agent in a suitable solvent. This process can be carried out in the same manner as (23) except that a desirable alcohol is used in place of amine.

The reduction can be carried out by treating the resulting compound with a reducing agent in a suitable solvent.

20 Boron hydrides (sodium borohydride, diborane, borane-dimethylsulfide complex, and the like), aluminum hydrides (lithium aluminum hydride, diisobutylaluminum hydride, and the like) can be preferably used as the reducing agent.

(45) The compound having a hydroxyalkyl group as a substituent on R^5 can be prepared by reducing a compound having an alkoxy-carbonylalkyl group as a substituent on R^5 .

The reduction can be carried out in the same manner as (44).

(46) The compound wherein R^{10} is an aromatic group substituted by a cyano group, optionally having one to three heteroatoms independently selected from oxygen atom, sulfur atom and nitrogen atom (hereinafter

30

referred to as "an aromatic group"), can be prepared by cyanating a compound wherein R^{10} is an aromatic group substituted by a halogen atom.

The cyanation can be carried out in the same manner as (6).

5 (47) The compound wherein R^1 is a hydrogen atom can be prepared by acid-treatment or reduction of a compound wherein R^1 is a tert-butoxycarbonyl group or a benzyloxycarbonyl group.

The acid-treatment can be carried out in the same manner as (37) and the reduction can be carried out in the same manner as (33).

10 (48) The compound wherein R^1 is an optionally substituted alkoxycarbonyl group, or an optionally substituted carbamoyl group can be prepared by reacting a compound wherein R^1 is a hydrogen atom with a carbonylating agent along with a desirable alcohol or a desirable amine in a suitable solvent.

The reaction can be carried out in the same manner as (20).

15 (49) The compound having an iodine atom as a substituent on R^5 can be prepared by iodizing the compound having a bromine atom as a substituent on R^5 .

20 The iodization can be carried out by reacting with a corresponding alkaline metal iodide in a suitable solvent while adding a copper catalyst, if desired.

The same copper catalyst as that described in (4) can be used.

Additionally, the reaction proceeds more preferably when N,N' -dimethylethylenediamine, 1,10-phenanthroline, ethylene glycol, or the like is added.

25 (50) The compound having an amino group as a substituent on R^5 can be prepared by reacting a compound having a carboxyl group as a substituent on R^5 under Curtius rearrangement reaction condition.

30 Curtius rearrangement reaction can be carried out using a conventional azidating agent (e.g., diphenylphosphorylazide) in a suitable solvent in the presence of a base.

The reaction may also be carried out by adding an alcohol to provide a compound having an optionally substituted alkoxycarbonylamino group as a substituent on R⁵, followed by removing the alkoxycarbonyl group.

5 The removal of the alkoxycarbonyl group can be carried out in a conventional manner such as acid-treatment or reduction depending on the type of alkoxycarbonyl group to be removed. The acid-treatment can be carried out in the same manner as (37) and the reduction can be carried out in the same manner as (33).

10 (51) The compound having a hydroxy group as a substituent on R⁵ can be prepared by catalytically reducing a compound having a benzyloxy group as a substituent on R⁵. The reduction can be carried out in the same manner as (33).

(52) The compound having an oxo group as a substituent on R⁵ can be prepared by oxidizing a compound having a hydroxy group as a
15 substituent on R⁵.

The oxidation can be carried out by using an oxidizing agent in a suitable solvent.

A conventional oxidizing agent can be used as the oxidizing agent, such as chromate-pyridine complex, pyridinium chlorochromate, pyridinium dichromate, Dess-Martin reagent (1,1,1-tris(acetoxy)-1,1-
20 dihydro-1,2-benziodoxol-3-(1H)-one), dimethylsulfoxide, and the like.

(53) The compound containing an optionally substituted alkoxy group as a substituent on R⁵ can be prepared by alkylating a compound containing a hydroxy group as a substituent on R⁵.

25 The alkylation can be carried out by using a corresponding compound in the same manner as (1).


(54) The compound having an optionally substituted alkanoylamino group as a substituent on R⁵ can be obtained by condensing the compound having an amino group as a substituent on R⁵ with a corresponding
30 carboxylic acid or a reactive derivative thereof.

The condensation with the corresponding carboxylic acid can be preferably carried out in a suitable solvent in the presence of a condensing agent. The reaction can be carried out in the same manner as (23).


5 Additionally, the condensation with the reactive derivative of the corresponding carboxylic acid can be carried out in a suitable solvent or neat in the presence or absence of a base.

The reactive derivative includes an acid halide, an acid anhydride, an activated ester, an activated amide, and the like.

(55) The compound having a group of the formula:



wherein R^{14} is an alkanoyl group optionally substituted by a hydroxy group or an alkoxy group, and n has the same meaning as defined above as a substituent on R^5 can be prepared by condensing a compound of a group of the formula:



wherein the symbols have the same meaning as defined above as a substituent on R^5 with a corresponding carboxylic acid or a reactive derivative thereof.

The reaction can be carried out in the same manner as (54).

20 (56) The compound having a maleimide group as a substituent on R^5 can be prepared by reacting a compound having an amino group as a substituent on R^5 with a maleic anhydride. The reaction can be carried out in a suitable solvent.

25 (57) The compound having an alkyl group substituted by a pyridyl group and a hydroxy group as substituents on R^5 can be prepared by reacting a compound having, as a substituent on R^5 , an alkyl group substituted by a pyridyl group of which nitrogen atom is oxidized with a trifluoroacetic anhydride. The reaction can be carried out in a suitable

solvent.

(58) The compound having a halogen atom as a substituent on R⁵ can be prepared by treating a compound having a hydroxy group as a substituent on R⁵ with a halogenating agent.

5 As the halogenating agent, a conventional halogenating agent including thionyl chloride, phosphorus oxychloride, as well as carbon tetrahalide (e.g., carbon tetrachloride, carbon tetrabromide, and the like) and phosphines (e.g., triphenylphosphine, tritolyphosphine, triethylphosphine, and the like) can be preferably used.

10 (59) The compound having a cyanoalkyl group as a substituent on R⁵ can be prepared by reducing a compound having a cyanoalkenyl group as a substituent on R⁵.

 The reduction can be carried out by treating a starting compound with a reducing agent or by catalytically reducing the same in a suitable
15 solvent.

 Any reducing agent can be used subject that it reduces only a double bond without affecting a cyano group. For example, sodium bis(2-methoxyethoxy)aluminum hydride in the presence of a copper bromide can be preferably used.

20 The catalytic reduction can be carried out in the same manner as (33).

(60) The compound having a hydroxyalkyl group as a substituent on R⁵ can be prepared by reducing a compound having a formyl group as a substituent on R⁵.

25 The reduction can be carried out by treating a starting compound with a reducing agent in a suitable solvent.

 The reaction can be carried out in the same manner as the process for reducing in (45).

30 (61) The compound wherein R⁶ is a hydroxy group can be prepared by demethylating a compound wherein R⁶ is a methoxy group.

The demethylation can be carried out by treating a starting compound with a demethylating agent in a suitable solvent.

As the demethylating agent, a conventional agent including trimethylsilyl iodide, hydrogen bromide/acetic acid, boron tribromide,
5 concentrated sulfuric acid, and the like can be used.

(62) The compound wherein R⁶ is an optionally substituted alkoxy group can be prepared by alkylating a compound wherein R⁶ is a hydroxy group.

The alkylation can be carried out in the same manner as (1).

10 (63) The compound wherein R⁶ is an optionally substituted alkylsulfonyloxy group can be prepared by alkylsulfonylating a compound wherein R⁶ is a hydroxy group.

The alkylsulfonylation can be carried out by reacting a corresponding alkylsulfonyl halide or a corresponding alkylsulfonic
15 anhydride in a suitable solvent in the presence or absence of a base.

(64) The compound wherein R⁶ is a cyano group can be prepared by cyanating a compound wherein R⁶ is an optionally substituted alkylsulfonyloxy group.

20 (65) The compound wherein R⁶ is an aminoalkyl group can be prepared by reducing a compound wherein R⁶ is a cyano group.

The reduction can be carried out in the same manner as (16).

(66) The compound wherein R⁶ is an alkyl group can be prepared by alkylating a compound wherein R⁶ is an optionally substituted alkylsulfonyloxy group.

25 The alkylation can be carried out by reacting alkyl aluminums in the presence of a palladium catalyst, a silver catalyst and a copper catalyst in a suitable solvent.

Tetrakis(triphenylphosphine)palladium as the palladium catalyst, silver carbonate as the silver catalyst, copper (I) chloride as the copper
30 catalyst can be preferably used.

(67) The compound having an imidazoliny group or an oxazoliny group as a substituent on R^5 can be prepared by (i) reacting a compound containing a cyano group as a substituent on R^5 with a desirable alcohol in the presence of an acid in a suitable solvent or neat to provide a compound
5 containing an alkoxy carbonimidoyl group as a substituent on R^5 , and (ii) reacting the compound containing an alkoxy carbonimidoyl group as a substituent on R^5 with 2-aminoethanol or ethylene diamine in a suitable solvent or neat.

(68) The compound having a carboxyl group as a substituent on R^1
10 can be prepared by (i) oxidizing a compound containing a hydroxyalkyl group as a substituent on R^1 in the same manner as (52) to provide a compound containing an oxo group as a substituent on R^1 , and (ii) oxidizing the compound containing an oxo group as a substituent on R^1 .

The oxidization for the second step can be carried out by using an
15 oxidizing agent in a suitable solvent. Sodium chlorite, Silver(I) oxide, Sodium periodate and the like can be preferably used as the oxidizing agent.

(69) The compound having a carboxyl group as a substituent on R^1
20 can be directly prepared by oxidizing a compound containing a hydroxyalkyl group as a substituent on R^1 .

The oxidization can be carried out by using Jones reagent, potassium permanganate, and the like as the oxidizing agent.

(70) The compound wherein R^1 is hydrogen atom can be prepared by treating a compound wherein R^1 is ethoxycarbonyl group with a silyl
25 halides or a base. Trimethylsilyl iodide can be preferably used as the silyl halides. Sodium hydroxide can be preferably used as the base.

(71) Among the compound (I-A), the compound wherein R^{11} is a hydroxyl group can be prepared by (i) reacting a compound wherein R^{11} is

a halogen atom with diboron or borane to provide a compound wherein R¹¹ is a boronic esters, and (ii) reacting the compound wherein R¹¹ is a boronic esters with peroxides.

Hydrogen peroxide solution, m-chloroperbenzoic acid or OXONE™
5 (Manufactured by DuPont) can be preferably used as the peroxides.

In each process for preparing a compound of the formula (I) described above, when protection of a functional group contained in any compound is needed, the protection can be carried out in a conventional manner as appropriate. General statement related to protecting groups
10 and their use is provided by Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, New York, 1991.

When an amino group is protected by a benzyloxycarbonyl group, the protecting group can be removed by catalytic reduction under hydrogen in a suitable solvent.


15 When a hydroxy group is protected by a benzyl group, the protecting group can also be removed by catalytic reduction in a similar manner as above.

When an amino group is protected by a t-butoxycarbonyl group, the protecting group can be removed by treatment with an acid (e.g.,
20 hydrochloric acid, trifluoroacetic acid, toluenesulfonic acid, and the like) in a suitable solvent.


When a hydroxy group is protected by a tetrahydropyranyl group, the protecting group can also be removed by treatment with an acid in a similar manner as above.

25 The reactions (1) to (71) for conversion of R¹, R⁵, R⁶ or R¹¹ can also be applied for conversion in the same manner of an other substituent of the present compound (I) as appropriate.

The starting compound (II) is a novel compound, and can be prepared by condensing a compound of the formula (V):



wherein the symbols have the same meaning as defined above with a compound of the formula (IV):




5 wherein Z^4 is a leaving group and R^5 has the same meaning as defined above.

The leaving group includes a halogen atom including chlorine atom, bromine atom, iodine atom, and a substituted sulfonyloxy group including methanesulfonyloxy group, trifluoromethanesulfonyloxy group, and toluenesulfonyloxy group.

The reaction can be carried out in a suitable solvent (for example, 1,4-dioxane, dimethylformamide, 1,3-dimethylimidazolidinone, and the like) in the presence or absence of a base (for example, diisopropylethylamine, and the like) from room temperature to under heating.

The reaction can also be carried out by adding a palladium catalyst (for example, tris(dibenzylidenacetone)dipalladium) and a phosphine [for example, triphenylphosphine, tributylphosphine, or 2-(di-tert-butylphosphino)biphenyl] at room temperature in the presence of a base (for example, sodium tert-butoxide), if desired.

The compound (V) is a novel compound and can be prepared according to the following scheme



wherein R^{15} is a protecting group for amino group and the other symbols have the same meaning as defined as above.

A conventional protecting group including a benzyloxycarbonyl group can be used as the protecting group for amino group. Additionally, an optically-active compound (V) can be prepared by protecting amino group with an optically-active protecting group for amino group (for example, an optically-active α -substituted benzyloxycarbonyl group having a chiral center at the benzyl position, such as α -methylbenzyloxycarbonyl group), resolving diastereomers in the process for preparation of compound (VI) or compound (VII), and removing the protecting group.

A compound of the formula (IX) can be prepared by reacting benzotriazole, a compound of the formula (XI) and an aldehyde of the formula (X) in a suitable solvent (for example, toluene) at room temperature.

A compound of the formula (VII) can be prepared by reacting a compound of the formula (IX) with a compound of the formula (VIII) in the presence of an acidic catalyst (for example, an organic acid including p-toluenesulfonic acid, acetic acid, methanesulfonic acid, or Lewis acid including boron trifluoride-diethylether complex, titanium tetrachloride, aluminum chloride) in a suitable solvent (for example, toluene, methylene


chloride, tetrahydrofuran, and the like) under heating or at room temperature (for example, 0°C to 150°C, preferably 25°C to 120°C).

A compound of the formula (VI) can be prepared by alkanoylation, alkoxyacylation, alkylation, and the like of a compound of the formula (VII) as appropriate.

A compound of the formula (V) can be prepared by removing a protecting group for amino group of a compound of the formula (VI). The removal of the protecting group can be carried out in a conventional manner including acid-treatment, base-treatment, reduction, and the like, depending on the type of the protecting group. When a benzyloxycarbonyl group or an α -substituted benzyloxycarbonyl group is used, they can be removed by catalytic reduction in a suitable solvent (for example, ethanol, methanol, tetrahydrofuran, acetic acid, and the like) under hydrogen. The removal of a protecting group for amino group of a compound of the formula (VII) can be carried out in the same manner as the removal of the protecting group for amino group of a compound of the formula (VI).

When an optically-active protecting group such as α -substituted benzyloxycarbonyl group is used as a protecting group for amino group, resolution of a diastereomer can be carried out in a conventional manner such as recrystallization or column chromatography.


A compound of the formula (VII) can also be prepared by reacting a compound of the formula (VIII) with a compound of the formula (XII):



This reaction can be carried out in the same manner as the reaction of a compound of the formula (VIII) with a compound of the formula (IX).

Additionally, respective substituents R^1 , R^5 , R^6 , R^7 and R^8 can be converted into a desirable substituent in accordance with any one of processes from (1) to (67).

The compound of the formula (II-A) can be prepared by condensing a compound of the formula (V) with a compound of the formula (III):



wherein the symbols have the same meaning as defined above.

5 The condensation can be carried out in the same manner as that described in WO00/17165 or PROCESS 1 above.

Many of starting materials and reagents for preparation of the aforementioned compounds are either commercially available or disclosed in literatures, or can be readily prepared by a method that is disclosed in
10 literatures or used generally in the organic synthesis.

As used herein, "3,4-dihydro-2H-naphthyridine" represents the same structure as "1,2,3,4-tetrahydronaphthyridine".

Experiment

15 The inhibitory activity of the compounds of the present invention against CETP was tested in this experiment.

Preparation of Acceptor Microemulsion

A solution of 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (3.5 mg), cholesteryl oleate (3mg) and triolein (0.7 mg) in chloroform was mixed
20 and lipid was air-dried under nitrogen gas to remove solvent. Dioxane (0.25 ml) was then added and the mixture was stirred for dissolution. The resultant lipid solution (0.2 ml) was slowly injected under the surface of Tris-saline-EDTA(TSE) buffer solution [10 mM Tris/HCl (pH 7.4), 0.15 M NaCl, 2 mM EDTA] (10 ml) with Hamilton syringe, while sonicating in ice-
25 bath. After 1-hour-sonication in ice-bath, the solution was stored at 4 °C.

Preparation of Donor Microemulsion

A solution of egg PC (phosphatidylcholine) (0.33 mg) and BODIPY-CE (0.62 mg) in chloroform was mixed. After removing solvent by air-drying lipid under nitrogen gas, TSE buffer solution (3 ml) was added and the
30 solution was sonicated in ice-bath. This solution was filtered to sterilize

through 0.22 μ m filter and stored at 4 °C.

Inhibitory Activity against CETP in vitro

A test solution was prepared using dimethyl sulfoxide as a solvent. Plasma from a healthy volunteer was diluted to 0.64 % with TSE buffer, and to the resultant plasma solution (187 μ l) was added a test solution (3 μ l) or the solvent alone followed by incubation at 37 °C for 24 hours. After addition of TSE buffer solution (10 μ l) containing 5 % donor microemulsion and 5 % acceptor microemulsion, the mixture was incubated at 37 °C for 3 hours. Before and after the incubation, the fluorescence intensity was measured at Ex.550nm/Em.600nm. CETP activity was defined as the difference between the measurements obtained before incubation and after incubation. The decreasing rate of the difference in the sample was defined as the inhibition rate of CETP activity. IC₅₀ for each sample was calculated from the inhibition rate of CETP activity.


Results

Example No.	IC ₅₀ (nM)
22	0.39
116	0.11
269	1.9
337	0.4
356	0.98
383	4.6
409	0.83

EXAMPLES

The present invention is illustrated in more detail by Examples, but the present invention should not be construed to be limited thereto.

In Examples, the compounds having a structure of the formula:



indicate that the Configuration thereof is (2R*,4S*). Besides, Me means a

methyl group.

EXAMPLE 1

- (1) A solution of 5-amino-2-methoxypyridine (10 g) in toluene (20 ml) is added dropwise to a suspension of benzotriazole (9.6 g) in toluene (150 ml).
5 Then, a solution of propionaldehyde (6.35 ml) in toluene (20 ml) is added thereto dropwise at 30°C or below, and the mixture is stirred at room temperature overnight. The suspension is filtered and the resulting crystals are washed with ether to give (1-benzotriazol-1-yl-propyl)-(6-methoxypyridin-3-yl)amine (19.7 g). mp.: 109.3-110.3°C.
- 10 (2) (1-Benzotriazol-1-yl-propyl)-(6-methoxypyridin-3-yl)amine (15 g) and N-vinyl-carbamic acid benzyl ester (9.4 g) are dissolved in toluene (200 ml), then thereto is added p-toluenesulfonic acid monohydrate (100 mg), and the mixture is stirred at 80°C for 4 hours under nitrogen flow. After allowing to cooled to room temperature, the reaction solution is added to a
15 mixture of a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with a saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 8:1 → 4:1) to give (2R*, 4S*)-(2-ethyl-6-methoxy-
20 1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl) carbamic acid benzyl ester (14.31 g). MS (m/z): 342 [M+H]⁺
- (3) (2R*,4S*)-(2-Ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl) carbamic acid benzyl ester (5.1 g) and pyridine (18 ml) are dissolved in methylene chloride (150 ml), then thereto is added ethyl chloroformate
25 (14.3 ml) dropwise under ice-cooling, and the mixture is stirred at the same temperature for 30 minutes. An aqueous citric acid solution is added to the reaction solution. The organic layer is washed with a saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column
30 chromatography (silica gel; hexane:ethyl acetate = 4:1 → 2:1) to give

(2R*,4S*)-4-benzyloxycarbonylamino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.58 g). MS (m/z): 414 [M+H]⁺

(4) (2R*,4S*)-4-Benzyloxycarbonylamino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.5 g) and ammonium formate (2.09 g) are dissolved in methanol (50 ml), thereto is added 10 % palladium/carbon (550 mg) under nitrogen flow, and the mixture is stirred at 40°C for 30 minutes. The catalyst is removed by filtration and then the filtrate is concentrated under reduce pressure. A saturated aqueous sodium hydrogen carbonate solution and methylene chloride are added to the residue. The organic layer is washed with a saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol=90:1 → 20:1) to give (2R*,4S*)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5] naphthyridine-1-carboxylic acid ethyl ester (3.88 g). MS (m/z): 280 [M+H]⁺

(5) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2 g) and 5-bromo-2-chloropyrimidine (3.46 g) are dissolved in N,N-dimethylformamide (20 ml), and the mixture is heated to 150°C and stirred for 5 hours. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 19:1→7:3) to give (2R*,4S*)-4-(5-bromopyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.08 g). MS (m/z): 436/438 [M+H]⁺

(6) (2R*,4S*)-4-(5-Bromopyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is

dissolved in N,N-dimethylformamide (2 ml), then thereto is added sodium hydride (17 mg, 62.7 %) at room temperature, and the mixture is stirred for 10 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (158 mg), the mixture is stirred at room temperature for 10 minutes. Water and ethyl acetate are added to the reaction mixture. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduce pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 49:1 → 3:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (190 mg). MS (m/z): 662/664 [M+H]⁺

EXAMPLE 2

(1) (S)-1-Phenylethylalchol (16.1 g) and pyridine (10.7 ml) are dissolved in chloroform (100 ml), and thereto is added a solution (100 ml) of p-nitrophenyl chloroformate (26.6 g) in chloroform. The reaction solution is stirred at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 85:15 → 70:30) to give p-nitrophenyl (S)-1-phenylethyl carbonate (35.6 g).

(2) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (34.3 g), p-nitrophenyl (S)-1-phenylethyl carbonate (35.3 g) and triethylamine (17.1 ml) are dissolved in acetonitrile (250 ml) and the mixture is heated under reflux for 3 hours. The reaction solution is partitioned by adding ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:hexane:ethyl acetate = 10:10:1) to give (2R*,4S*)-2-ethyl-6-methoxy-4-[(S)-1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (44.0 g). MS

(m/z): 428 [M+H]⁺

(3) (2R*,4S*)-2-Ethyl-6-methoxy-4-[(S)-1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (44.0 g) is recrystallized from hexane (100 ml) to give (2R,4S)-2-ethyl-6-methoxy-4-[(S)-1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (13.83 g). MS (m/z): 428 [M+H]⁺

(4) Ten % palladium/carbon (2.0 g) is added to a solution (85 ml) of (2R,4S)-2-ethyl-6-methoxy-4-[(S)-1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.49 g) in ethanol and stirred under hydrogen for 4 hours. Palladium/carbon is removed by filtration, and the filtrate is concentrated under reduced pressure to give (2R,4S)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.56 g). MS (m/z): 280 [M+H]⁺

(5) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.49 g) and 5-bromo-2-chloropyrimidin (9.5 g) are dissolved in 1,4-dioxane (100 ml), then thereto is added N,N-diisopropylethylamine (8.55 ml), and the mixture is heated under reflux for 5 hours. The reaction solution is concentrated under reduced pressure, and the residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 95:5→80:20) to give (2R,4S)-2-ethyl-6-methoxy-4-(5-bromopyrimidin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.29 g). MS (m/z): 436/438 [M+H]⁺

(6) (2R,4S)-2-Ethyl-6-methoxy-4-(5-bromopyrimidin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.20 g) is dissolved in N,N-dimethylformamide (75 ml), then thereto is added sodium hydride (62.7 %, 942 mg) under ice-cooling, and the mixture is stirred for 30 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (8.7 g), the mixture is stirred for 30 minutes. Water and ethyl acetate are added to

the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 95:5→80:20) to give (2R,4S)-4- $\{[3,5$ -
5 bis(trifluoromethyl)benzyl]- $\{5$ -bromopyrimidin-2-yl $\}$ amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.01 g). MS (m/z): 662/664 [M+H]⁺

EXAMPLE 3

(1) (2S,4R)-(2-Ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-
10 yl)carbamic acid (S)-1-phenylethyl ester (840 mg) and pyridine (0.956 ml) are dissolved in methylene chloride (5 ml). After adding dropwise a solution (5 ml) of ethyl chloroformate (1.13 ml) in methylene chloride under ice-cooling, the mixture is stirred at room temperature for one hour. The reaction solution is washed with 1N aqueous sodium hydroxide solution,
15 1N hydrochloric acid and a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 90:10→60:40) to give (2S,4R)-2-ethyl-6-methoxy-4- $\{[(S)$ -1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-
20 carboxylic acid ethyl ester (1.00 g). MS (m/z): 428 [M+H]⁺

(2) Ten % palladium/carbon (100 mg) is added to a solution (10 ml) of (2S,4R)-2-ethyl-6-methoxy-4- $\{[(S)$ -1-phenylethoxycarbonylamino]-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.00 g) in ethanol, and the mixture is stirred for 3 hours under hydrogen.
25 Palladium/carbon is removed by filtration, and the filtrate is concentrated under reduced pressure to give (2S,4R)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (619 mg). MS (m/z): 280 [M+H]⁺

(3) (2S,4R)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
30 [1,5]naphthyridine-1-carboxylic acid ethyl ester (610 mg) and 5-bromo-2-

chloropyrimidine (1.06 g) are dissolved in 1,4-dioxane (5 ml), then thereto is added N,N-diisopropylethylamine (0.951 ml), and the mixture is heated under reflux overnight. The reaction solution is concentrated under reduced pressure, and the residue is purified by column chromatography (silica gel; hexane:ethyl acetate= 95:5→80:20) to give (2S,4R)-2-ethyl-6-methoxy-4-(5-bromopyrimidin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (853 mg). MS (m/z): 436/438 [M+H]⁺.


(4) (2S,4R)-2-Ethyl-6-methoxy-4-(5-bromopyrimidin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (735 mg) is dissolved in N,N-dimethylformamide (5 ml), sodium hydride (62.7 %, 84 mg) is added thereto under ice-cooling, and the mixture is stirred for 30 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (0.463 ml), the mixture is stirred at room temperature for 30 minutes. Water and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 95:5→75:25) to give (2S,4R)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (950 mg). MS (m/z): 662/664 [M+H]⁺.

EXAMPLE 4

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.38 g) is dissolved in 1,4-dioxane (36 ml), then thereto are added sodium iodide (11.4 g), copper iodide (360 mg) and N,N'-dimethylethylenediamine (420 μ l), and the mixture is stirred at 105°C for 24 hours under nitrogen flow. After allowing to cool to room temperature, water is added to the reaction mixture, followed by extraction with ethyl acetate twice. The organic layer is washed with a saturated brine, dried

over magnesium sulfate, then thereto is added a small amount of NH-silica gel, and filtered. The filtrate is concentrated under reduced pressure. Isopropyl ether and ethyl acetate are added to the resulting residue and the precipitated solid is collected by filtration to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (7.23 g). MS (m/z): 710 [M+H]⁺

EXAMPLE 5



The corresponding starting compounds are treated in a similar manner to Example 4 to give the above compound. MS (m/z): 710 [M+H]⁺.

EXAMPLE 6

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (6 g) is dissolved in N,N-dimethylformamide (20 ml), and thereto are added palladium acetate (200 mg), 1,1'-bis(diphenylphosphino)ferrocene (1 g), benzyl alcohol (18.6 ml) and triethylamine (12.6 ml). The mixture is bubbled with carbon monoxide at room temperature for 5 minutes, heated to 90°C and stirred under carbon monoxide overnight. The reaction solution is cooled to room temperature, then thereto is added a saturated aqueous sodium hydrogen carbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 8:1, followed by

NH-silica gel; hexane: ethyl acetate=10:1) to give (2R*,4S*)-4-((5-benzyloxy-carbonylpyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.64 g). MS (m/z): 718 [M+H]⁺

5 EXAMPLE 7

(2R*,4S*)-4-((5-Benzyloxycarbonylpyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (752 mg) is dissolved in a mixed solution of tetrahydrofuran (18 ml) and methanol (6 ml), then
10 thereto is added 10 % palladium/carbon (300 mg), and the mixture is stirred at room temperature for 4 hours and 30 minutes under hydrogen. The reaction solution is filtered, and concentrated under reduced pressure to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
15 carboxylic acid ethyl ester (564 mg). MS (m/z): 628 [M+H]⁺

EXAMPLE 8

(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide
20 (4 ml) and thereto are added morpholine (0.03 ml) and 1-hydroxybenzotriazole (50 mg) at room temperature. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride (70 mg) is added to the mixture under ice-cooling, triethylamine (0.04 ml) is added thereto dropwise, and the mixture is stirred at room temperature overnight.
25 A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate =
30 4:1→1:1) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-(5-(morpholin-

4-carbonyl) pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (142 mg). MS (m/z): 697 [M+H]⁺

EXAMPLES 9-13

- 5 The corresponding starting compounds are treated in a similar manner to Example 8 to give the compounds as listed in Table 1.





Table 1

Example No.	R	Physical properties , etc.
9		MS (m/z): 681 [M+H] ⁺
10		MS (m/z): 710 [M+H] ⁺
11		MS (m/z): 738 [M+H] ⁺
12		MS (m/z): 685 [M+H] ⁺

13		MS (m/z): 740 [M+H] ⁺
----	-----------------------------------------------------------------------------------	----------------------------------

EXAMPLE 14

- (1) (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3 g) is dissolved in toluene (100 ml), then thereto are added triethylamine (2 ml), diphenylphosphoryl azide (1.5 ml) and benzyl alcohol (0.5 ml) at room temperature, and the mixture is heated to 90°C and stirred for 4 hours. The reaction solution is cooled to room temperature, then thereto is added a saturated aqueous sodium hydrogen carbonate solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 17:3→7:3) to give (2R*,4S*)-4-[(5-benzyloxycarbonylamino-2-yl)-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.27 g). MS (m/z): 733 [M+H]⁺
- (2) (2R*,4S*)-4-[(5-Benzyloxycarbonylamino-2-yl)-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.27 g) is dissolved in a mixed solution of tetrahydrofuran (60 ml). After adding methanol (40 ml), 10 % palladium/carbon (400 mg), the mixture is stirred at room temperature under hydrogen for 3 hours. The reaction solution is filtered, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→3:2) to give (2R*,4S*)-4-[(5-aminopyrimidin-2-yl)-[3,5-

bis(trifluoromethyl)benzyl}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.46 g). MS (m/z): 599 [M+H]⁺

EXAMPLE 15

5 (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in toluene (2 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (6.9 mg), sodium
10 tert-butoxide (54.8 mg), 2-(di-tert-butylphosphino)biphenyl (9.0 mg) and pyrrolidine (47 μ l). The mixture is stirred at room temperature for 45 minutes under nitrogen flow, then heated to 80°C, and stirred for 18 hours. After cooling to room temperature, ether is added to the reaction solution. The mixture is filtered, and the filtrate is concentrated under reduced
15 pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1 \rightarrow 7:3) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(pyrrolidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (158.5 mg). MS (m/z): 653 [M+H]⁺.

EXAMPLES 16-30

20 The corresponding starting compounds are treated in a similar manner to Example 15 to give the compounds as listed in Table 2.












Table 2-1

Example No.	Configuration	R [*] RN-	Physical properties, etc.
16	(2R [*] ,4S [*])		MS (m/z): 696 [M+H] ⁺
17	(2R,4S)		MS (m/z): 696 [M+H] ⁺
18	(2R [*] ,4S [*])		MS (m/z): 657 [M+H] ⁺
19	(2R [*] ,4S [*])		MS (m/z): 671 [M+H] ⁺
20	(2R [*] ,4S [*])		MS (m/z): 715 [M+H] ⁺
21	(2R [*] ,4S [*])		MS (m/z): 669 [M+H] ⁺
22	(2R,4S)		MS (m/z): 669 [M+H] ⁺
23	(2R,4S)		MS (m/z): 712 [M+H] ⁺




Table 2-2

Example No.	Configuration	R'RN-	Physical properties, etc.
24	(2R,4S)		MS (m/z): 627 [M+H] ⁺
25	(2S,4R)		MS (m/z): 669 [M+H] ⁺
26	(2R*,4S*)		MS (m/z): 739 [M+H] ⁺
27	(2R*,4S*)		MS (m/z): 739 [M+H] ⁺
28	(2R*,4S*)		MS (m/z): 773 [M+H] ⁺
29	(2R,4S)		MS (m/z): 773 [M+H] ⁺
30	(2R*,4S*)		MS (m/z): 667 [M+H] ⁺

EXAMPLE 31

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (120 mg) is dissolved in ethyl acetate (1 ml) and thereto is added 4N-HCl/ethyl acetate (0.09 m). The solvent is concentrated under reduced pressure, ether and hexane are added thereto and the precipitated powder is filtered to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester hydrochloride (112 mg). MS (m/z): 669 [M+H]⁺.

EXAMPLE 32

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-iodopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in isopropanol (1 ml), then thereto are added copper iodide (2.7 mg), ethylene glycol (31 μ l), potassium phosphate (119 mg) and 2-methylaminoethanol (20 μ l), and the mixture is heated to 80°C under nitrogen flow, and stirred for 20 hours. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→3:7) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[methyl-(2-hydroxyethyl)]aminopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (58.2 mg). MS (m/z): 657 [M+H]⁺.

EXAMPLES 33 and 34

The corresponding starting compounds are treated in a similar manner to Example 32 to give the compounds as listed in Table 3.




Table 3

Example No.	R'RN-	Physical properties, etc.
33		MS (m/z): 643 [M+H] ⁺
34		MS (m/z): 687 [M+H] ⁺

EXAMPLE 35

5 (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromo-pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in toluene (2 ml), and thereto are added copper iodide (7.2 mg), 2-phenylphenol (25.5 mg), potassium phosphate (318.4 mg) and (±)-piperidin-3-yl-methanol (172.8


10 mg). The mixture is heated to 80°C under nitrogen flow and stirred for 5 days. After addition of distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate

15 = 9:1→4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-hydroxymethylpiperidin-1-yl) pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (22.8 mg). MS (m/z): 697 [M+H]⁺.

EXAMPLE 36

To a solution of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (245 mg) in ethanol (2 ml) is added aqueous 2N-potassium hydroxide solution (0.332 ml) and the mixture is heated under reflux at 50°C for 1 hour. The reaction solution is diluted with ethyl acetate and acidified with 1N-hydrochloric acid. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform to chloroform: methanol = 90:10) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (210 mg). MS (m/z): 711 [M+H]⁺.

EXAMPLE 37



The corresponding starting compounds are treated in a similar manner to Example 36 to give the above compound. MS (m/z): 711 [M+H]⁺.

EXAMPLE 38


To a solution (1.5 ml) of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (120 mg) in tetrahydrofuran is added diisobutylaluminum hydride (1M solution in toluene, 0.486 ml) under ice-cooling, and the mixture is stirred for 1 hour. A saturated aqueous ammonium chloride solution is added to

the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 80:20→70:30) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-hydroxymethylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (110 mg). MS (m/z): 697 [M+H]⁺.

EXAMPLE 39

To a solution of (2R*,4S*)-4-[[5-(4-benzyloxypiperidin-1-yl) pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (700 mg) in ethanol (10 ml) is added 10 % palladium/carbon (100 mg), and the mixture is stirred under hydrogen overnight. Palladium/carbon is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 80:20→50:50) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-hydroxypiperidin-1-yl) pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (313 mg). MS (m/z): 683 [M+H]⁺.

EXAMPLE 40



The corresponding starting compounds are treated in a similar manner to Example 39 to give the above compound. MS (m/z): 683(M+H)⁺

EXAMPLE 41

To a solution (1 ml) of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-hydroxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is added 1,1,1-tris(acetoxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (74 mg),
5 and the mixture is stirred at room temperature for 3 hours. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 90:10→60:40) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-oxopiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
10 [1,5]naphthyridine-1-carboxylic acid ethyl ester (51 mg). MS (m/z): 681 [M+H]⁺

EXAMPLE 42

To a solution (2 ml) of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-hydroxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (140 mg) in
15 N,N-dimethylformamide is added sodium hydride (62.7 %, 9.4 mg), and the mixture is stirred at room temperature for 10 minutes. Methyl iodide (0.019 ml) is added thereto, and the mixture is stirred at room temperature for 2 hours. Water and ethyl acetate are added thereto, the organic layer is
20 washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 90:10→60:40) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-methoxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
25 [1,5]naphthyridine-1-carboxylic acid ethyl ester (71 mg). MS (m/z): 697 [M+H]⁺

EXAMPLES 43-47

The corresponding starting compounds are treated in a similar manner to Example 15 to give the compounds as listed in Table 4.




Table 4


Example No.	Configuration	R-	Physical properties, etc.
43	(2R*,4S*)		MS (m/z): 802 [M+H] ⁺
44	(2R,4S)		MS (m/z): 802 [M+H] ⁺
45	(2R*,4S*)		MS (m/z): 740 [M+H] ⁺
46	(2R*,4S*)	Me—	MS (m/z): 682 [M+H] ⁺
47	(2R,4S)	Me—	MS (m/z): 682 [M+H] ⁺

EXAMPLE 48

- 5 (2R*,4S*)-4-{{5-(4-Benzoyloxycarbonylpiperazin-1-yl)pyrimidin-2-yl}-
 [3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester (938 mg) is dissolved in a
 mixture solvent of tetrahydrofuran:methanol (1:1) (6 mL), then thereto is
 added 10 % palladium/carbon (300 mg), and the mixture is stirred at room
 10 temperature under hydrogen flow for 13 hours. The catalyst is removed by
 filtration, and the filtrate is concentrated. The resulting residue is purified

by column chromatography (silica gel; chloroform: methanol = 10:0→9:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(piperazin-1-yl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (786 mg). MS (m/z): 668 [M+H]⁺

EXAMPLE 49



The corresponding starting compounds are treated in a similar manner to Example 48 to give the above compound. MS (m/z): 668 [M+H]⁺

EXAMPLE 50

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(piperazin-1-yl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (110 mg) is dissolved in methylene chloride (1 ml), then thereto are added triethylamine (0.1 ml) and acetyl chloride (19 μ l), and the mixture is stirred at room temperature under nitrogen flow for 2 hours. After adding distilled water, the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform: methanol = 9:1) to give (2R*,4S*)-4-[[5-(4-acetyl piperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (103.6 mg). MS (m/z): 710 [M+H]⁺

EXAMPLES 51-55

The corresponding starting compounds are treated in a similar manner to Example 50 to give the compounds as listed in Table 5.




Table 5

Example No.	Configuration	R-	Physical properties, etc.
51	(2R,4S)		MS (m/z): 710 [M+H] ⁺
52	(2R*,4S*)		MS (m/z): 740 [M+H] ⁺
53	(2R,4S)		MS (m/z): 740 [M+H] ⁺
54	(2R*,4S*)		MS (m/z): 746 [M+H] ⁺
55	(2R*,4S*)		MS (m/z): 775 [M+H] ⁺

(2R*,4S*)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(piperazin-1-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (1 ml), then thereto are added 2-iodoethanol (26 μ l) and excess potassium carbonate, and the mixture is heated to 50°C under nitrogen flow and stirred for 5 hours. After adding distilled water, the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 19:1→9:1) to give (2R*,4S*)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-[4-(2-hydroxyethyl)piperazin-1-yl]pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (128 mg). MS (m/z): 712 [M+H]⁺

EXAMPLES 57 and 58

The corresponding starting compounds are treated in a similar manner to Example 56 to give the compounds as listed in Table 6.





Table 6

Example No.	R-	Physical properties, etc.
57		MS (m/z): 754 [M+H] ⁺

58		MS (m/z): 768 [M+H] ⁺
----	-----------------------------------------------------------------------------------	----------------------------------

EXAMPLES 59 and 60

The corresponding starting compounds are treated in a similar manner to Example 36 to give the compounds as listed in Table 7.






Table 7

Example No.	R-	Physical properties, etc.
59		MS (m/z): 726 [M+H] ⁺
60		MS (m/z): 740 [M+H] ⁺

EXAMPLE 61

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(piperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (110 mg) is dissolved in methylene chloride (1 ml), triethylamine (0.1 ml) and ethyl isocyanate (20 μ l) are added thereto and stirred at room temperature under nitrogen flow for 2 hours. A distilled water is added to the mixture and extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried

over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→1:1) to give (2R*,4S*)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(4-ethylcarbamoylpiperazin-1-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (104.4 mg). MS (m/z): 739 [M+H]⁺

EXAMPLE 62

(2R*,4S*)-4-{{5-Aminopyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (4 ml), then thereto are added acetyl chloride (0.03 ml) and triethylamine (0.1 ml), and the mixture is stirred at room temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→1:1) to give (2R*,4S*)-4-{{5-acetylamino-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (132 mg). MS (m/z): 641 [M+H]⁺

EXAMPLES 63-65

The corresponding starting compounds are treated in a similar manner to Example 62 to give the compounds as listed in Table 8.




Table 8

Example No.	R-	MS (m/z)
63		MS (m/z): 671 [M+H] ⁺
64		MS (m/z): 703/705 [M+H] ⁺
65		MS (m/z): 705/707 [M+H] ⁺

EXAMPLE 66

- 5 (2R*,4S*)-4-((5-Aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in N,N-dimethylformamide (4 ml), carbobenzyloxyglycine (210 mg) and 1-hydroxybenzotriazole (170 mg) are added thereto at room temperature, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (240 mg) is added under ice-cooling, triethylamine (0.15 ml) is added dropwise and then stirred at room temperature overnight. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column
- 10
- 15

chromatography (silica gel; hexane: ethyl acetate = 4:1→1:1) to give
 (2R*,4S*)-4-({5-[(2-benzyloxycarbonylamino)acetylamino]pyrimidin-2-yl}-
 [3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester (631 mg). MS (m/z): 790
 5 [M+H]⁺

EXAMPLES 67 and 68

The corresponding starting compounds are treated in a similar
 manner to Example 66 to give the compounds as listed in Table 9.




Table 9


Example No.	R-	Physical properties, etc.
67		MS (m/z): 657 [M+H] ⁺
68		MS (m/z): 791 [M+H] ⁺

EXAMPLE 69

(2R*,4S*)-4-({5-[2-(Benzyloxycarbonylamino)acetylamino]pyrimidin-2-
 15 yl}-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-
 2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (631 mg) is dissolved in
 methanol (10 ml), 10 % palladium/carbon (100 mg) is added thereto and
 then the mixture is stirred at room temperature under hydrogen for 30

minutes. The reaction solution is filtered, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform: methanol= 1:0→9:1) to give (2R*,4S*)-4-{{5-(2-aminoacetyl-amino)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (463 mg). MS (m/z): 626 [M+H]⁺

EXAMPLE 70



The corresponding starting compounds are treated in a similar manner to Example 39 to give the above compound. MS (m/z): 701 [M+H]⁺


EXAMPLE 71

(2R*,4S*)-4-{{5-Aminopyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in methylene chloride (4 ml), then thereto are added carbodiimidazole (60 mg) and triethylamine (0.1 ml), and the mixture is stirred at room temperature for 1 hour. Morpholine (0.05 ml) is added to the reaction solution, and the mixture is stirred at room temperature for 2 hours and 30 minutes. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 7:3→1:1→0:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-

{{(morpholin-4-yl)carbonyl}amino}pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (154 mg).

MS (m/z): 712 [M+H]⁺

EXAMPLE 72



5


The corresponding starting compounds are treated in a similar manner to Example 71 to give the above compound. MS (m/z): 700 [M+H]⁺

EXAMPLE 73

(2R*,4S*)-4-{{5-(2-Aminoacetyl)amino}pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (4 ml), then thereto are added carbodiimidazole (40 mg) and triethylamine (0.08 ml), and the mixture is stirred at room temperature for 3 hours and 30 minutes. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:2→3:7) to give (2R*,4S*)-4-{{3,5-bis(trifluoromethyl)benzyl]-[5-(2,5-dioxoimidazolidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (126 mg). MS (m/z): 682 [M+H]⁺

20


EXAMPLE 74



The corresponding starting compounds are treated in a similar manner to Example 73 to give the above compound. MS (m/z): 683 [M+H]⁺
EXAMPLE 75

5 (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-chlorobutylamino)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (283 mg) is dissolved in N,N-dimethylformamide (4 ml), then thereto is added sodium hydride (18 mg) under ice-cooling, and the mixture is stirred at room temperature
10 overnight. Water is added to the reaction solution and the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 7:3→1:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-oxopyrrolidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl
15 ester (132 mg). MS (m/z): 667 [M+H]⁺

EXAMPLE 76



The corresponding starting compounds are treated in a similar manner to Example 75 to give the above compound. MS (m/z): 669 [M+H]⁺

EXAMPLE 77

- 5 (1) (2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-[2-(2-hydroxyethoxy)acetylamino]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (90 mg) is dissolved in chloroform (4 ml), then thereto are added mesyl chloride (0.1 ml) and triethylamine (0.2 ml) under ice-cooling, and the mixture is stirred
- 10 at room temperature for 2 hours. Water is added to the reaction solution and the mixture is extracted with chloroform. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-(2-methanesulfonyloxyethoxy)acetylamino]pyrimidin-2-yl})amino-2-
- 15 ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (143 mg).
- (2) (2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-[2-(2-methanesulfonyloxyethoxy)acetylamino] pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester
- 20 (143 mg) is dissolved in tetrahydrofuran (4 ml), sodium tert-butoxide (48 mg) is added thereto and then the mixture is stirred at room temperature for 4 hours and 30 minutes. A saturated aqueous ammonium chloride solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried

over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1 → 1:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-oxomorpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (51 mg). MS (m/z): 683 [M+H]⁺

EXAMPLE 78

(2R*,4S*)-4-[[5-Aminopyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in toluene (10 ml), then thereto is added maleic anhydride (150 mg), and the mixture is heated under reflux for 1 hour and 30 minutes. After cooling to room temperature, a saturated aqueous ammonium chloride solution is added to the reaction solution, followed by extraction with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1 → 3:2) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2,5-dioxo-2,5-dihydropyrrol-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (77 mg). MS (m/z): 679 [M+H]⁺

EXAMPLE 79

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-iodopyrimidin-2-yl]]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.50 g) is dissolved in toluene (10 ml), then thereto are added benzyl alcohol (1.02 ml), copper iodide (94 mg), 1,10-phenanthroline (178 mg) and cesium carbonate (1.61 g), and the mixture is stirred at 100°C under nitrogen flow for 6 hours. The mixture is allowed to cool to room temperature, then thereto are added benzyl alcohol (0.51 ml), copper iodide (94 mg), 1,10-phenanthroline (178 mg), cesium carbonate (0.80 g)

and toluene (2 ml), and the mixture is stirred at 100°C under nitrogen flow overnight. The reaction mixture is allowed to cool to room temperature, then thereto are added benzyl alcohol (0.51 ml), copper iodide (94 mg), 1,10-phenanthroline (178 mg) and cesium carbonate (0.80 g), and the mixture is stirred at 100°C under nitrogen flow for 5 hours. After allowing to cool to room temperature, water and ethyl acetate are added to the reaction solution, and the insoluble materials are removed by filtration on Celite™. The organic layer of filtrate is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. Copper iodide (94 mg), 1,10-phenanthroline (178 mg), cesium carbonate (1.61 g) and toluene (5 ml) are added to the resultant residue and stirred at 100°C under nitrogen flow overnight. After allowing to cool to room temperature, water and ethyl acetate are added to the reaction solution, and the insoluble materials are removed by filtration on Celite™. The organic layer of filtrate is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 10:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-benzyloxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.25 g). MS (m/z): 690 [M+H]⁺

EXAMPLES 80 and 81

The corresponding starting compounds are treated in a similar manner to Example 79 to give the compounds as listed in Table 10.







Table 10

Example No.	Configuration	R-	Physical properties, etc.
80	(2R,4S)		MS (m/z): 690 [M+H] ⁺
81	(2R*,4S*)		MS (m/z): 713 [M+H] ⁺

EXAMPLE 82

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-benzyloxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.52 g) is dissolved in methanol (270 ml), then thereto is added 10 % palladium/carbon, and the mixture is stirred at room temperature under hydrogen for 30 minutes. The reaction mixture is filtered, and the filtrate is concentrated under reduced pressure to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.33 g). MS (m/z): 600 [M+H]⁺

EXAMPLE 83



The corresponding starting compounds are treated in a similar manner to Example 82 to give the above compound. MS (m/z): 600 [M+H]⁺

EXAMPLE 84

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-

yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (1 ml), then thereto is added sodium hydride (63 %, 11 mg) under ice-cooling, and the mixture is stirred at 0°C for 30 minutes. Methyl iodide (23 μ l) is added thereto, and the mixture is stirred for 2 hours under ice-cooling. To the reaction mixture is added 10 % aqueous citric acid solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-methoxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (120 mg). MS (m/z): 614 [M+H]⁺

EXAMPLES 85-88

The corresponding starting compounds are treated in a similar manner to Example 84 to give the compounds as listed in Table 11.






Table 11

Example No.	R-	Physical properties, etc.
85		MS (m/z): 686 [M+H] ⁺
86		MS (m/z): 657 [M+H] ⁺

87		MS (m/z): 672 [M+H] ⁺
88		MS (m/z): 658 [M+H] ⁺

EXAMPLE 89

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (1 ml), then thereto are added potassium carbonate (200 mg) and 2-bromoethanol (162 μ l), and the mixture is stirred at 60°C overnight. To the reaction mixture is added 10 % aqueous citric acid solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 2:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-(2-hydroxyethoxy)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (95 mg). MS (m/z): 644 [M+H]⁺

EXAMPLES 90-92

The corresponding starting compounds are treated in a similar manner to Example 89 to give the compounds as listed in Table 12.







Table 12

Example No.	Configuration	R-	Physical properties, etc.
90	(2R,4S)		MS (m/z): 644 [M+H] ⁺
91	(2R*,4S*)		MS (m/z): 658 [M+H] ⁺
92	(2R*,4S*)		MS (m/z): 688 [M+H] ⁺

EXAMPLE 93

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in tetrahydrofuran (1 ml), then thereto are added pyrimidin-2-ylmethanol (41 mg) and triphenylphosphine (98 mg). After adding dropwise 40 % diethyl azodicarboxylate-toluene solution (163 μ l) under ice-cooling, the mixture is stirred at room temperature for 1 hour and 30 minutes. Water is added to the reaction mixture and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 2:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(pyrimidin-2-ylmethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (118 mg). MS (m/z): 692 [M+H]⁺

EXAMPLES 94-107

The corresponding starting compounds are treated in a similar manner to Example 93 to give the compounds as listed in Table 13.




Table 13-1

Example No.	Configuration	R-	Physical properties, etc.
94	(2R*,4S*)		MS (m/z): 705 [M+H] ⁺
95	(2R,4S)		MS (m/z): 705 [M+H] ⁺
96	(2R*,4S*)		MS (m/z): 684 [M+H] ⁺
97	(2R,4S)		MS (m/z): 670 [M+H] ⁺
98	(2R*,4S*)		MS (m/z): 697 [M+H] ⁺
99	(2R*,4S*)		MS (m/z): 697 [M+H] ⁺
100	(2R,4S)		MS (m/z): 683 [M+H] ⁺
101	(2R*,4S*)		MS (m/z): 759 [M+H] ⁺




Table 13-2


Example No.	Configuration	R-	Physical properties, etc.
102	(2R*,4S*)		MS (m/z): 711 [M+H] ⁺
103	(2R,4S)		MS (m/z): 714 [M+H] ⁺
104	(2R*,4S*)		MS (m/z): 671 [M+H] ⁺
105	(2R,4S)		MS (m/z): 671 [M+H] ⁺
106	(2R*,4S*)		MS (m/z): 674 [M+H] ⁺
107	(2R*,4S*)		MS (m/z): 714 [M+H] ⁺

EXAMPLE 108

- 5 (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-ethoxycarbonyl-methoxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (128 mg) is dissolved in methanol (3 ml), then thereto is added 1M aqueous sodium hydroxide solution (2 ml), and the mixture is stirred at room temperature for 2 hours.

To the reaction mixture is added 10 % aqueous citric acid solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform: methanol = 19:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-carboxymethoxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg). MS (m/z): 658 [M+H]⁺

EXAMPLE 109



The corresponding starting compounds are treated in a similar manner to Example 108 to give the above compound. MS (m/z): 686 [M+H]⁺

EXAMPLE 110

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxymethoxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (1 ml), then thereto is added morpholine (30 μ l). After addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride (66 mg) and 1-hydroxybenzotriazole hydrate (46 mg) under ice-cooling, the mixture is stirred at room temperature for 4 hours. Water is added to the reaction mixture and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The

resulting residue is purified by column chromatography (silica gel; chloroform: methanol = 19:1) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-(morpholin-4-yl)-2-oxoethoxy]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (138 mg). MS (m/z): 727 [M+H]⁺

EXAMPLES 111-113

The corresponding starting compounds are treated in a similar manner to Example 110 to give the compounds as listed in Table 14.




Table 14

Example No.	R-	Physical properties, etc.
111		MS (m/z): 671 [M+H] ⁺
112		MS (m/z): 685 [M+H] ⁺
113		MS (m/z): 701 [M+H] ⁺

EXAMPLE 114

(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methylsulfonyl-ethoxy)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in


chloroform (1 ml), then thereto is added m-chloroperbenzoic acid (60 mg) is added thereto, and the mixture is stirred at room temperature for 2 hours. After addition of a saturated aqueous sodium hydrogen carbonate solution, the reaction mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform: methanol = 19: 1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methylsulfinylethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (125 mg). MS (m/z): 690 [M+H]⁺

EXAMPLE 115

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methylsulfanyl-ethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (226 mg) is dissolved in chloroform (1.5 ml), then thereto is added m-chloroperbenzoic acid (248 mg), and the mixture is stirred at room temperature for 40 minutes. A saturated aqueous sodium hydrogen carbonate solution is added thereto, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated aqueous sodium hydrogen carbonate solution followed by a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform: methanol = 19: 1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methanesulfonylethoxy)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (182 mg). MS (m/z): 706 [M+H]⁺

EXAMPLE 116



The corresponding starting compounds are treated in a similar manner to Example 115 to give the above compound. MS (m/z): 706 [M+H]⁺

5 EXAMPLE 117

To a solution (10 ml) of (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-[2-(pyridin-2-yl)ethoxy]pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) in chloroform is added m-chloroperbenzoic acid (79 mg), and the mixture is stirred at room temperature for 2 hours. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 75: 25→ 0:100) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-[2-(1-oxypyridin-2-yl)ethoxy]pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (173 mg). MS (m/z): 721 [M+H]⁺

EXAMPLE 118


A mixture of (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-[2-(1-oxypyridin-2-yl)ethoxy]pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (115 mg), trifluoroacetic anhydride (0.226 ml) and N,N-dimethylformamide (5 ml) is stirred at room temperature overnight. The reaction solution is partitioned by adding ethyl acetate and an aqueous saturated sodium bicarbonate solution. The organic layer is washed with a saturated brine, dried over

magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by tin layer silica gel chromatography (hexane: ethyl acetate = 1:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-hydroxy-2-(pyridin-2-yl)ethoxy]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (24 mg).
 5 MS (m/z): 721 [M+H]⁺

EXAMPLE 119

(2R*,4S*)-4-({5-[(S)-1-Benzylpyrrolidin-3-yl]oxy}pyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 10 [1,5]naphthyridine-1-carboxylic acid ethyl ester (280 mg) is dissolved in methanol (5 ml), then thereto is added 10 % palladium/carbon (50 mg), and the mixture is stirred at room temperature under hydrogen overnight. The reaction solution is filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column
 15 chromatography (NH-silica gel; hexane: ethyl acetate = 4:1→3:2→0:1) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[(S)-pyrrolidin-3-yl]oxy}pyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (168 mg). MS (m/z): 669 [M+H]⁺

20 EXAMPLE 120



The corresponding starting compounds are treated in a similar manner to Example 50 to give the above compound. MS (m/z): 711 [M+H]⁺
 EXAMPLE 121

(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (147 mg) is dissolved in tetrahydrofuran (2 ml), then thereto is added 1N-hydrochloric acid (2 ml), and the mixture is stirred overnight. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:2→3:7) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2,3-dihydroxypropoxy)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (72 mg). MS (m/z): 674 [M+H]⁺

EXAMPLE 122

(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl))-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in 2-methoxyethanol (1.0 ml), then thereto are added copper iodide (21 mg), 1,10-phenanthroline (41 mg) and cesium carbonate (368 mg), and the mixture is stirred at 110°C under nitrogen flow over 15 hours. After cooling to room temperature, water is added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer is washed with a saturated brine twice, dried over magnesium sulfate, a small amount of NH-silica gel is added thereto, the mixture is filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:1) to give ethyl (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-methoxyethyl ester (38 mg). MS (m/z): 688 [M+H]⁺

EXAMPLE 123


(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl))-
amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
acid ethyl ester (400 mg) is dissolved in isopropyl alcohol (2 ml), then
5 thereto are added 2-mercaptoethanol (96 μ l), copper iodide (20 mg),
ethylene glycol (62 μ l) and potassium carbonate (156 mg), and the mixture
is stirred at 80°C under nitrogen flow overnight. After cooling to room
temperature, water is added to the reaction mixture, followed by extraction
with ethyl acetate. The organic layer is washed with a saturated brine
10 twice, dried over magnesium sulfate, and concentrated under reduced
pressure. The resulting residue is purified by column chromatography
(silica gel; hexane: ethyl acetate = 2:1 \rightarrow 1:1) to give (2R,4S)-4-[[3,5-
bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethylsulfanyl)pyrimidin-2-yl))-
amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
15 acid ethyl ester (110 mg). MS (m/z): 660 [M+H]⁺

EXAMPLE 124

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-
yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
carboxylic acid ethyl ester (400 mg) is dissolved in isopropyl alcohol (2 ml),
20 then thereto are added thioglycolic acid methyl ester (120 μ l), copper iodide
(20 mg), ethylene glycol (62 μ l) and potassium carbonate (156 mg), and the
mixture is stirred at 80°C under nitrogen flow overnight. After allowing to
cool to room temperature, water is added to the reaction mixture, followed
by extraction with ethyl acetate. The organic layer is washed with a
25 saturated brine twice, dried over magnesium sulfate, and concentrated
under reduced pressure. The resulting residue is dissolved in methanol (6
ml), then thereto are added 1M-aqueous sodium hydroxide solution (3 ml)
and tetrahydrofuran (6 ml), and the mixture is stirred at room temperature
for 10 minutes. Ten % aqueous citric acid solution is added to the reaction
30 mixture and the mixture is extracted with ethyl acetate. The organic layer

is washed with a saturated brine twice, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 2:1→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-carboxymethylsulfanylpyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (153 mg). MS (m/z): 674 [M+H]⁺

EXAMPLE 125



The corresponding starting compounds are treated in a similar manner to Example 110 to give the above compound. MS (m/z): 687 [M+H]⁺

EXAMPLES 126 and 127

The corresponding starting compounds are treated in a similar manner to Example 115 to give the compounds as listed in Table 15.






Table 15

Example No.	R	Physical properties, etc.
126		MS (m/z): 692 [M+H] ⁺
127		MS (m/z): 719 [M+H] ⁺

Example 128


(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is dissolved in tetrahydrofuran (2 ml), then thereto are added ethyl chloroformate (0.02 ml) and triethylamine (0.04 ml) under ice-cooling, and the mixture is stirred for 30 minutes. The reaction solution is filtered, sodium borohydride (18 mg) is added to the filtrate, and the mixture is stirred for 1 hour and 40 minutes. To the reaction solution is added 1N-hydrochloric acid and the mixture is extracted with ethyl acetate. The organic layer is washed successively with water, a saturated aqueous sodium hydrogen carbonate solution and a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→3:2) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(hydroxymethyl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (80 mg). MS (m/z): 614 [M+H]⁺

EXAMPLE 129

(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxymethylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in

tetrahydrofuran (4 ml), then thereto are added sodium hydride (12 mg) and methyl iodide (0.02 ml) under ice-cooling, and the mixture is stirred at room temperature for 3 hours and 30 minutes. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→3:2) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-methoxymethylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (92 mg). MS (m/z): 628 [M+H]⁺

EXAMPLE 130



The corresponding starting compounds are treated in a similar manner to Example 129 to give the above compound. MS (m/z): 656 [M+H]⁺

EXAMPLE 131

(1) (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-(hydroxymethyl)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in N,N-dimethylformamide (4 ml), then thereto is added sodium hydride (28 mg) under ice-cooling, and the mixture is stirred for 30 minutes. 2-(2-Bromoethoxy)tetrahydropyran (0.15 ml) is added to the reaction solution, and the mixture is stirred at room temperature for 2 hours and 30 minutes.

After addition of sodium hydride (28 mg) and 2-(2-bromoethoxy)-tetrahydropyran (0.15 ml), the mixture is stirred at 50°C for 2 hours and 30 minutes. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution, followed by extraction with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→3:2) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-{2-[(tetrahydropyran-2-yl)oxy]ethoxymethyl}pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (201 mg). MS (m/z): 742 [M+H]⁺

(2) (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-{2-[(tetrahydropyran-2-yl)oxy]ethoxymethyl}pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in methanol (5 ml), then thereto is added 1N-hydrochloric acid (1 ml), and the mixture is stirred for 1 hour and 30 minutes. After adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→1:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-5-[(2-hydroxy)ethoxymethyl]pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (124 mg). MS (m/z): 658 [M+H]⁺

EXAMPLE 132

(1) (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(hydroxymethyl)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1 g) is dissolved in

methylen chloride (20 ml), then thereto are added triphenylphosphine (855 mg) and carbon tetrabromide (1.35 g), and the mixture is stirred for 3 hours. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction solution and the mixture is extracted with ethyl acetate.

5 The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1 → 4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(bromomethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

10 [1,5]naphthyridine-1-carboxylic acid ethyl ester (690 mg). MS (m/z): 676/678 [M+H]⁺

(2) Morpholine (0.02 ml) is dissolved in N,N-dimethylformamide (2 ml), then thereto is added sodium hydride (9 mg) under ice-cooling, and the mixture is stirred for 30 minutes. (2R*,4S*)-4-[[3,5-

15 Bis(trifluoromethyl)benzyl]-[5-(bromomethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (112 mg) is added to the reaction solution under ice-cooling, and the mixture is stirred at room temperature for 1 hour and 30 minutes. A saturated aqueous sodium hydrogen carbonate solution is added to the

20 reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:1→1:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[(morpholin-

25 4-yl)methyl]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (33 mg). MS (m/z): 683 [M+H]⁺

EXAMPLES 133-136

The corresponding starting compounds are treated in a similar

30 manner to Example 132 to give the compounds as listed in Table 16.




Table 16

Example No.	R	Physical properties, etc.
133		MS (m/z): 667 [M+H] ⁺
134		MS (m/z): 696 [M+H] ⁺
135		MS (m/z): 671 [M+H] ⁺
136		MS (m/z): 681 [M+H] ⁺

EXAMPLE 137

- 5 (2R*,4S*)-4-{{3,5-Bis(trifluoromethyl)benzyl}-(5-bromopyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (367 mg), acrylic acid benzyl ester (180 mg), tris (dibenzylideneacetone)dipalladium (61 mg), dicyclohexylmethylamine (162 mg) and tri-*t*-butyl phosphonium tetrafluoroborate (39 mg) are dissolved in
- 10 1,4-dioxane (4 ml), and the mixture is stirred at room temperature under nitrogen flow for 3 days. An aqueous citric acid solution and ethyl acetate are added to the reaction solution and the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column
- 15 chromatography (silica gel; hexane: ethyl acetate = 23:2→3:2) to give

(2R*,4S*)-4-[[5-(2-benzyloxycarbonylvinyl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (372 mg). MS (m/z): 744 [M+H]⁺

5 EXAMPLES 138-139

The corresponding starting compounds are treated in a similar manner to Example 137 to give the compounds as listed in Table 17.




Table 17

Example No.	Configuration	R-	Physical properties, etc.
138	(2R,4S)		MS (m/z): 744 [M+H] ⁺
139	(2R*,4S*)		MS (m/z): 635 [M+H] ⁺

10

EXAMPLE 140

(2R,4S)-4-[[5-(2-Benzyloxycarbonylvinyl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.02 g) is dissolved in a mixture of tetrahydrofuran (50 ml) and methanol (9 ml). After addition of 10 % palladium/carbon (600 mg), the mixture is stirred at room temperature under hydrogen for 2 hours and 30 minutes. The reaction solution is filtered, and concentrated under reduced pressure. The


15

resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:2→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-carboxyvinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.7 g). MS (m/z): 654 [M+H]⁺

EXAMPLE 141

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyvinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in a mixed solution of tetrahydrofuran (15 ml) and methanol (5 ml), then thereto is added 10 % palladium/carbon (160 mg), and the mixture is stirred at room temperature under hydrogen for 3 hours and 30 minutes. The reaction solution is filtered, and concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (498 mg). MS (m/z): 656 [M+H]⁺

EXAMPLE 142




The corresponding starting compounds are treated in a similar manner to Example 141 to give the above compound. MS (m/z): 656 [M+H]⁺

EXAMPLE 143

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyvinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-


[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in tetrahydrofuran (4 ml), then thereto are added ethyl chloroformate (0.04 ml) and triethylamine (0.06 ml) under ice-cooling, and the mixture is stirred for 30 minutes. The reaction solution is filtered, then thereto is added sodium borohydride (58 mg), and the mixture is stirred for 1 hour and 30 minutes under ice-cooling. 1N-Hydrochloric acid is added to the reaction solution and the mixture is extracted with ethyl acetate. The organic layer is washed with water, a saturated aqueous sodium hydrogen carbonate solution and a saturated brine successively, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-hydroxypropenyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (155 mg). MS (m/z): 640 [M+H]⁺

EXAMPLE 144



The corresponding starting compounds are treated in a similar manner to Example 143 to give the above compound. MS (m/z): 642 [M+H]⁺

EXAMPLE 145



The corresponding starting compounds are treated in a similar manner to Example 110 to give the above compound. MS (m/z): 669 [M+H]⁺

5 EXAMPLE 146

To a suspension (1 ml) of copper bromide (227 mg) in tetrahydrofuran is added dropwise 65 % solution (982 mg) of bis(2-methoxyethoxy)aluminum sodium hydride in toluene under ice-cooling, and the mixture is stirred at the same temperature for 30 minutes. The reaction solution is cooled to -78°C, and thereto is added 2-butanol (0.29 ml). Subsequently, a solution (0.5 ml) of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-cyanovinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) in tetrahydrofuran is added thereto dropwise, and the mixture is stirred at the same temperature for 2 hours. After allowing to warm to room temperature, the mixture is stirred for additional 2 hours. To the reaction solution is added a saturated aqueous ammonium chloride solution, and the mixture is partitioned by adding ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by thin layer silica gel chromatography (hexane: ethyl acetate = 2:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-cyanoethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (74 mg). MS (m/z): 637

[M+H]⁺

EXAMPLE 147

A mixture of (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-cyanovinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (385 mg), sodium azide (99 mg), ammonium chloride (81 mg) and N,N-dimethylformamide (5 ml) is stirred at 100°C overnight. The mixture is partitioned by adding ethyl acetate and a saturated brine. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform to chloroform:methanol =5:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[2-(tetrazole-5-yl)vinyl]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (155 mg). MS (m/z): 678 [M+H]⁺

EXAMPLE 148

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-iodopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in N,N-dimethylformamide (2 ml), then thereto are added pyridine-4-boronic acid (87 mg), tetrakis(triphenylphosphine)palladium (81 mg) and potassium carbonate (117 mg), and the mixture is stirred at 100°C under nitrogen flow for 2 hours. After allowing to cool to room temperature, water is added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(pyridin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (131 mg). MS (m/z): 661 [M+H]⁺

EXAMPLES 149 and 150

The corresponding starting compounds are treated in a similar manner to Example 148 to give the compounds as listed in Table 18.




Table 18

Example No.	Configuration	R-	Physical properties, etc.
149	(2R*,4S*)		MS (m/z): 661 [M+H] ⁺
150	(2R,4S)		MS (m/z): 662 [M+H] ⁺

EXAMPLE 151

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in toluene (2 ml), then thereto are added 2-tributylstannylpyridine (105 μ l) and tetrakis(triphenylphosphine)palladium (16 mg), and the mixture is stirred at 100°C under nitrogen flow overnight. After allowing to cool to room temperature, 10 % aqueous potassium fluoride solution is added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer is washed with a 10 % aqueous potassium fluoride solution and a saturated brine successively, dried over magnesium sulfate, and

concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(pyridin-2-yl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (138 mg). MS (m/z): 661 [M+H]⁺

EXAMPLE 152

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in N,N-dimethylformamide (2 ml), then thereto are added 5-formylpyridin-3-boronic acid pinacol ester (164 mg), tetrakis(triphenylphosphine) palladium (81 mg) and sodium carbonate (90 mg), and the mixture is stirred at 100°C overnight under nitrogen flow. After allowing to cool to room temperature, a saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-formylpyridin-3-yl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (119 mg). MS (m/z): 689 [M+H]⁺

EXAMPLE 153

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-formylpyridin-3-yl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (118 mg) is dissolved in tetrahydrofuran (1.5 ml), then thereto is added 1M-diisobutylaluminum hydride-tetrahydrofuran solution (0.33 ml) dropwise under ice-cooling and the mixture is stirred for 1 hours under nitrogen flow under ice-cooling. A aqueous saturated ammonium chloride solution is added to the reaction

mixture and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 1:1) to give
5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-hydroxymethylpyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (84 mg). MS (m/z): 691 [M+H]⁺

EXAMPLE 154

10 (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (350 mg) is dissolved in 1,4-dioxane (1 ml), then thereto are added pyrrolidin-2-one (100 mg), tris(dibenzylideneacetone)-dipalladium (23 mg), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (21
15 mg) and cesium carbonate (241 mg) and the mixture is stirred at 100°C under nitrogen flow overnight. After allowing to cool to room temperature, water is added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, then thereto is added a small amount of NH-silica gel,
20 the mixture is filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (105 mg). MS
25 (m/z): 584 [M+H]⁺

EXAMPLE 155

(1) A mixture of (2R*,4S*)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg), 2-chloro-4,6-dimethoxypyrimidin (468 mg), N,N-diisopropylethylamine (0.467 ml) and
30 1,4-dioxane (5 ml) is heated under reflux for 2 days. The reaction solution

is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 80:20→60:40) to give (2R*,4S*)-4-(4,6-dimethoxypyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (280 g). MS (m/z): 418 [M+H]⁺

(2) (2R*,4S*)-4-(4,6-Dimethoxypyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (260 mg) is dissolved in N,N-dimethylformamide (1 ml), then thereto is added sodium hydride (62.7 %, 31 mg) under ice-cooling, and the mixture is stirred for 15 minutes. Then, 3,5-bis(trifluoromethyl)benzyl bromide (0.171 ml) is added thereto, and the mixture is stirred at room temperature for 2 hours. Water and ethyl acetate are added to the reaction solution, the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 90:10→60:40) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-(4,6-dimethoxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (285 mg). MS (m/z): 644 [M+H]⁺

EXAMPLE 156


(1) (2R*,4S*)-4-(5-Bromopyridin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in N,N-dimethylformamide (3 ml), then thereto is added sodium hydride (28 mg) under ice-cooling, and the mixture is stirred for 30 minutes. 1-Bromomethyl-3,5-dimethylbenzene (171 mg) is added to the reaction solution and the mixture is stirred at room temperature for one day. Water is added to the reaction solution and the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:

ethyl acetate = 9:1→4:1) to give (2R*,4S*)-4-[(5-bromopyrimidin-2-yl)-(3,5-dimethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (268 mg). MS (m/z): 554/556 [M+H]⁺

- 5 (2) (2R*,4S*)-4-[(5-Bromopyrimidin-2-yl)-(3,5-dimethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (268 mg) is dissolved in toluene (10 ml), then thereto are added tris(dibenzylideneacetone)dipalladium (44 mg), sodium tert-butoxide (70 mg), 2-(di-tert-butylphosphino)biphenyl (57 mg) and morpholine (0.06 ml),
 10 and the mixture is stirred at room temperature under nitrogen for 1 hour. The reaction solution is heated to 50°C and stirred for 1 hour. NH-Silica gel is added to the reaction solution and the mixture is filtered. A saturated aqueous sodium hydrogen carbonate solution is added to the filtrate and the mixture is extracted with ether. The organic layer is
 15 washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 3:1→1:1) to give (2R*,4S*)-4-[(3,5-dimethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid
 20 ethyl ester (168 mg). MS (m/z): 561 [M+H]⁺


EXAMPLE 157



The corresponding starting compounds are treated in a similar manner to Example 156-(1) to give the above compound. MS (m/z):


- 25 551/553 [M+H]⁺

EXAMPLE 158




The corresponding starting compounds are treated in a similar manner to Example 156-(2) to give the above compound. MS (m/z): 558 [M+H]⁺

EXAMPLE 159



The corresponding starting compounds are treated in a similar manner to Example 137 to give the above compound. MS (m/z): 633 [M+H]⁺

EXAMPLE 160




The corresponding starting compounds are treated in a similar

manner to Example 141 to give the above compound. MS (m/z): 545 [M+H].

EXAMPLES 161-176


The corresponding starting compounds are treated in a similar manner to Example 156 to give the compounds as listed in Table 19.



5

Table 19-1

Example No.	R	Physical properties, etc.
161		MS (m/z): 593 [M+H] ⁺
162		MS (m/z): 563 [M+H] ⁺
163		MS (m/z): 567/569 [M+H] ⁺
164		MS (m/z): 601 [M+H] ⁺
165		MS (m/z): 551 [M+H] ⁺
166		MS (m/z): 599 [M+H] ⁺

167		MS (m/z): 617 [M+H] ⁺
-----	-----------------------------------------------------------------------------------	-------------------------------------










Table 19-2

Example No.	R	Physical properties, etc.
168		MS (m/z): 591 [M+H] ⁺
169		MS (m/z): 547 [M+H] ⁺
170		MS (m/z): 569 [M+H] ⁺
171		MS (m/z): 585/587 [M+H] ⁺
172		MS (m/z): 619 [M+H] ⁺
173		MS (m/z): 587 [M+H] ⁺




Table 19-3

Example No.	R	Physical properties, etc.
174		MS (m/z): 601/603 [M+H] ⁺
175		MS (m/z): 615 [M+H] ⁺
176		MS (m/z): 656 [M+H] ⁺

EXAMPLE 177

- 5 (1) (2R*,4S*)-4-(5-Bromopyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1 g), tris(dibenzylideneacetone)dipalladium (210 mg), sodium tert-butoxide (661 mg), 2-(di-tert-butylphosphino)biphenyl (137 mg) and morpholine (400 μ l) are dissolved in toluene (10 ml), and the mixture is stirred at 40°C under
- 10 nitrogen flow for 19 hours. After cooling to room temperature, a saturated brine and ethyl acetate are added to the reaction solution. The organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography

(NH-silica gel; hexane: ethyl acetate = 9:1→2:1) to give (2R*,4S*)-2-ethyl-6-methoxy-4-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (560 mg). MS (m/z): 443 [M+H]⁺

- 5 (2) (2R*,4S*)-2-Ethyl-6-methoxy-4-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (118 mg) is dissolved in N,N-dimethylformamide (2 ml), then thereto is added sodium hydride (62.7 %, 13 mg) under nitrogen flow under ice-cooling, and the mixture is stirred at room temperature for 30 minutes.
- 10 After addition of 4-fluorobenzyl bromide (86 μ l) under ice-cooling, the mixture is stirred at room temperature overnight. Water and ethyl acetate are added to the mixture, the mixture is washed with a saturated brine, the organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column
- 15 chromatography (silica gel; hexane: ethyl acetate = 2:1→1:1) to give (2R*,4S*)-2-ethyl-4-[(4-fluorobenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (93 mg). MS (m/z): 551 [M+H]⁺

EXAMPLES 178-183

- 20 The corresponding starting compounds are treated in a similar manner to Example 177-(2) to give the compounds as listed in Table 20.










Table 20

Example No.	R	Physical properties, etc.
178		MS (m/z): 569 [M+H] ⁺
179		MS (m/z): 619 [M+H] ⁺
180		MS (m/z): 611/613 [M+H] ⁺
181		MS (m/z): 601/603 [M+H] ⁺
182		MS (m/z): 565 [M+H] ⁺
183		MS (m/z): 633 [M+H] ⁺

EXAMPLE 184

Trimethylsilyl chloride (4.6 ml) is added dropwise to a suspension of
 5 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.4 g), sodium iodide (5.4 g) and acetonitrile (50 ml) at 80°C. After addition, the reaction solution is cooled to room temperature, and a saturated aqueous sodium thiosulfate solution and
 10 ethyl acetate are added thereto. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 2:1→0:1) to give

(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (988 mg). MS (m/z): 655 [M+H]⁺

EXAMPLE 185

5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (207 mg) is dissolved in N,N-dimethylformamide (3 ml), then thereto is added sodium hydride (62.7 %, 15 mg) under ice-cooling, and the mixture is stirred at room
10 temperature for 30 minutes. After addition of ethyl iodide (50 μ l) under ice-cooling, the mixture is stirred at room temperature for 2 hours. Water and ethyl acetate are added to the mixture, the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column
15 chromatography (silica gel; hexane: ethyl acetate = 9:1 \rightarrow 7:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-6-ethoxy-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (141 mg). MS (m/z): 683 [M+H]⁺

EXAMPLE 186

20 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg), cesium carbonate (55 mg) and 2-chloro-2,2-difluoroacetic acid methyl ester (44 mg) are dissolved in N,N-dimethylformamide (1 ml) and stirred at 75°C for
25 17 hours. The reaction solution is cooled to room temperature, and thereto are added an aqueous citric acid solution and ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate =
30 9:1 \rightarrow 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-

yl)pyrimidin-2-yl]]amino-6-difluoromethoxy-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (101 mg). MS (m/z): 705 [M+H]⁺

EXAMPLE 187

5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (775 mg) and pyridine (287 μ l) are dissolved in methylene chloride (5 ml), then thereto is added trifluoromethanesulfonic anhydride (240 μ l) dropwise under ice-cooling
10 and the mixture is stirred at the same temperature for 4 hours. An aqueous citric acid solution is added to the reaction solution, the organic layer is washed with a saturated aqueous sodium hydrogen carbonate solution, followed by a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by
15 column chromatography (silica gel; hexane: ethyl acetate = 6:1→2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (567 mg). MS (m/z): 787 [M+H]⁺

20 EXAMPLE 188

A mixture of (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (732 mg), tetrakis(triphenylphosphine)palladium
25 (catalytic amount), zinc cyanide (142 mg) and N,N-dimethylformamide (10 ml) is stirred at 95°C under nitrogen flow for 8 hours. After cooling to room temperature, water and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The
30 resulting residue is purified by column chromatography (silica gel; hexane:

ethyl acetate = 4:1→2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-6-cyano-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (572 mg). MS (m/z): 664 [M+H]⁺

5 EXAMPLE 189

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-6-cyano-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (458 mg) is dissolved in ethanol (5 ml), then thereto is added a catalytic amount of Raney nickel, and the mixture is stirred at room temperature under hydrogen for 5 hours. The catalyst is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 1:2→0:1) to give (2R,4S)-6-aminomethyl-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (211 mg). MS (m/z): 668 [M+H]⁺

EXAMPLE 190

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in 1,4-dioxane (3 ml), and thereto are added a catalytic amount of tetrakis(triphenylphosphine)palladium, a catalytic amount of silver carbonate and a catalytic amount of copper (I) chloride under nitrogen flow. After adding dropwise trimethylaluminum-hexane solution (1M, 480 μ l), the mixture is stirred at 60°C for 30 minutes. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 9:1→4:1) to

give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (153 mg). MS (m/z): 653 [M+H]⁺

5 EXAMPLE 191

(1) 5-Amino-2-methoxypyridine (5.0 g) is dissolved in methylene chloride (100 ml) and thereto is added sodium sulfate (3.5 g). The reaction solution is cooled to -25°C, then thereto is added acetaldehyde (2.26 ml), and the mixture is stirred at the same temperature for 2 hours and 30
10 minutes. Sodium sulfate is removed by filtration, and the filtrate is cooled to -25°C. After adding N-vinyl-carbamic acid benzyl ester (7.12 g) and boron trifluoride-diethylether complex (0.51 ml), the mixture is stirred at the same temperature for 1 hour, and then at room temperature overnight. The reaction solution is concentrated under reduced pressure, and the
15 resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→3:1) to give (2R*,4S*)-(6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)carbamic acid benzyl ester (8.56 g). MS (m/z): 328 [M+H]⁺

(2) (2R*,4S*)-(6-Methoxy-2-methyl-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)carbamic acid benzyl ester (8.55 g) and pyridine (10.6 ml) are dissolved
20 in methylene chloride (75 ml), then thereto is added ethyl chloroformate (12.5 ml) dropwise under ice-cooling, and the mixture is stirred at the same temperature for 2 hours. An aqueous citric acid solution is added to the reaction solution, the organic layer is washed with a saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The
25 resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→3:1) to give (2R*,4S*)-4-benzyloxycarbonylamino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (6.18 g). MS (m/z): 400 [M+H]⁺

30 (3) (2R*,4S*)-4-Benzyloxycarbonylamino-6-methoxy-2-methyl-3,4-

dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.83 g) is dissolved in a mixture solvent of ethanol (60 ml) and tetrahydrofuran (60 ml), then thereto is added 10 % palladium/carbon (500 mg), and the mixture is stirred at room temperature under hydrogen for 7 hours. The catalyst is removed by filtration, the filtrate is concentrated under reduced pressure to give (2R*,4S*)-4-amino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.85 g). MS (m/z): 266 [M+H]⁺

(4) (2R*,4S*)-4-Amino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.80 g), 5-bromo-2-chloropyrimidin (6.92 g) and N,N-diisopropylethylamine (6.23 ml) are dissolved in 1,4-dioxane (50 ml) and the mixture is heated under reflux for 4 hours. After cooling to room temperature, the reaction solution is partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→6:4) to give (2R*,4S*)-4-(5-bromopyrimidin-2-yl)amino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.92 g). MS (m/z): 422/424 [M+H]⁺

(5) (2R*,4S*)-4-(5-Bromopyrimidin-2-yl)amino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.9 g) is dissolved in N,N-dimethylformamide (60 ml), then thereto is added sodium hydride (62.7 %, 697 mg) at room temperature, and the mixture is stirred for 10 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (3.85 ml), the mixture is stirred at room temperature for 2 hours. Water and ethyl acetate is added to the reaction solution, the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is crystallized from

diisopropyl ether and hexane to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]amino-6-methoxy-2-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (6.1 g). MS (m/z): 648/650 [M+H]⁺

5 EXAMPLES 192-195

The corresponding starting compounds are treated in a similar manner to Example 15 to give the compounds as listed in Table 21.




Table 21

Example No.	R	Physical properties, etc.
192		MS (m/z): 655 [M+H] ⁺
193		MS (m/z): 668 [M+H] ⁺
194		MS (m/z): 696 [M+H] ⁺
195		MS (m/z): 710 [M+H] ⁺

10

EXAMPLE 196


(1) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3 g), 2,5-dibromopyridine (5.09 g), tris(dibenzylideneacetone)dipalladium (196 mg), sodium tert-butoxide (2.1 g), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (169 mg) are dissolved in toluene (30 ml), and the mixture is stirred at

15

room temperature under nitrogen flow overnight. A saturated brine and ethyl acetate are added to the reaction solution and the organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→8:1) to give (2R*,4S*)-4-(5-bromopyridin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (306 mg). MS (m/z): 435/437 [M+H]⁺

(2) The resulting product is treated in a similar manner to Example 1-(6) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (207 mg). MS (m/z): 661/663 [M+H]⁺

EXAMPLE 197



The corresponding starting compounds are treated in a similar manner to Example 196 to give the above compound. MS (m/z): 661/663 [M+H]⁺

EXAMPLES 198 and 199

The corresponding starting compounds are treated in a similar manner to Example 15 to give the compounds as listed in Table 22.





Table 22

Example No.	Configuration	Physical properties, etc.
198	(2R*,4S*)	MS (m/z): 668 [M+H] ⁺
199	(2R,4S)	MS (m/z): 668 [M+H] ⁺

Example 200

- (1) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.3 g), 6-chloronicotinonitrile (4.9 g) and N,N-diisopropylethylamine (4.1 ml) are dissolved in 1,4-dioxane (25 ml), and the mixture is stirred under reflux for 24 hours. A saturated brine and ethyl acetate are added to the reaction solution, the organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 4:1) to give (2R*,4S*)-4-(5-cyanopyridin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.13 g). MS (m/z): 382 [M+H]⁺
- (2) The resulting product is treated in a similar manner to Example 1-(6) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-cyanopyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.53 g). MS (m/z): 608 [M+H]⁺

EXAMPLE 201



The corresponding starting compounds are treated in a similar manner to Example 147 to give the above compound. MS (m/z): 651 [M+H]⁺

5 EXAMPLE 202

(2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-(tetrazol-5-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (120 mg), potassium carbonate (51 mg) and excess of 2-bromoethanol are dissolved in N,N-dimethylformamide (3 ml), and the mixture is stirred at 50°C for 2 hours. Water and ethyl acetate are added to the reaction solution and the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 2:1→1:1) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-[2-(2-hydroxyethyl)-2H-tetrazole-5-yl]pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (119 mg). MS (m/z): 695 [M+H]⁺

EXAMPLE 203

20 A suspension of (2R*,4S*)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-cyanopyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (127 mg) and conc. hydrochloric acid (2 ml) is stirred under reflux for 2 hours. Water and ethyl acetate are added to the reaction solution, the organic layer is

washed with a saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol =19:1→9:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-carboxypyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (48 mg). MS (m/z): 627 [M+H]⁺

EXAMPLE 204


(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-cyanopyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.5 g) is dissolved in ethanol (30 ml) and thereto is added acetyl chloride (14 ml) at 0°C dropwise. After addition dropwise, the mixture is stirred at room temperature overnight. A saturated aqueous sodium hydrogen carbonate solution and ethyl acetate are added to the reaction solution, the organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→1:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-ethoxycarbonimidoylpyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (221 mg), [MS (m/z): 654 [M+H]⁺], (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-carbamoylpyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (404 mg)[MS (m/z): 626 [M+H]⁺] and (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-ethoxycarbonylpyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (596 mg)[MS (m/z): 655 [M+H]⁺].

EXAMPLE 205

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-ethoxycarbonimidoylpyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) and

ethylenediamine (150 μ l) are dissolved in ethanol (3 ml), and the mixture is stirred under reflux for 4 hours. After cooling to room temperature, a saturated brine and ethyl acetate are added to the reaction solution. The organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 1:1 \rightarrow 1:2) to give (2R*,4S*)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(4,5-dihydro-1H-imidazol-2-yl)pyridin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (96 mg). MS (m/z): 651 [M+H]⁺

EXAMPLE 206



The corresponding starting compounds are treated in a similar manner to Example 205 to give the above compound. MS (m/z): 652 [M+H]⁺

EXAMPLE 207


(1) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.13 g) is dissolved in 1,4-dioxane (40 ml), then thereto are added diisopropylethylamine (4 ml) and 5-chloropyrazine-2-carboxylic acid benzyl ester (1.9 g), and the mixture is heated to 110°C under nitrogen flow and stirred for 20 hours. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by

column chromatography (silica gel; hexane: ethyl acetate = 4:1→1:1) to give (2R*,4S*)-4-(5-benzyloxycarbonylpyrazin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.24 g). MS (m/z): 492 [M+H]⁺

- 5 (2) (2R*,4S*)-4-(5-Benzyloxycarbonylpyrazin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.2 g) is dissolved in N,N-dimethylformamide (20 ml), then thereto is added sodium hydride (62.7 %, 223 mg) under ice-cooling, and the mixture is stirred for 10 minutes. After adding 3,5-bis(trifluorobenzyl) bromide (1
10 ml), the mixture is stirred at room temperature for 20 hours. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→4:1) to give
15 (2R*,4S*)-4-((5-benzyloxycarbonylpyrazin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.39 g). MS (m/z): 718 [M+H]⁺

EXAMPLE 208



20

The corresponding starting compounds are treated in a similar manner to Example 7 to give the above compound. MS (m/z): 628 [M+H]⁺

EXAMPLE 209

- 25 (2R*,4S*)-4-((3,5-Bis(trifluoromethyl)benzyl)-[5-carboxypyrazin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid ethyl ester (1 g) is dissolved in toluene (8 mL), then thereto are added triethylamine (0.67 mL) and diphenylphosphoryl azide (0.52 mL), and the mixture is stirred at room temperature under nitrogen flow for 1 hour. After adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is stirred at room temperature for 2 hours. The mixture is extracted with ether, the organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is dissolved in toluene (8 mL) and stirred at 80°C for 5 days. After adding water, the mixture is extracted with ether. The organic layer is dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 4:1→1:1) to give (2R*,4S*)-4-((5-aminopyrazin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (540 mg). MS (m/z): 599 [M+H]⁺

EXAMPLE 210

(1) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5 g) is dissolved in toluene (50 ml), then thereto are added tris(dibenzylideneacetone)dipalladium (293 mg), sodium tert-butoxide (3.8 g), 2-(di-tert-butylphosphino)biphenyl (376 g) and 2,6-dichloropyrazine (4.7 g), and the mixture is stirred at room temperature under nitrogen flow for 23 hours. After adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 6:1→3:1) to give (2R*,4S*)-4-(6-chloropyrazin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.3 g). MS (m/z): 392 [M+H]⁺

(2) (2R*,4S*)-4-(6-Chloropyrazin-2-yl)amino-2-ethyl-6-methoxy-3,4-

5 dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.1 g) is dissolved in N,N-dimethylformamide (15 ml), then thereto is added sodium hydride (62.7 %, 139.7 mg) under ice-cooling, and the mixture is stirred for 15 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (0.94 ml), the mixture is stirred at room temperature for 20 hours. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1→7:3) to give
10 (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(6-chloropyrazin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (900 mg). MS (m/z): 618/620 [M+H]⁺

EXAMPLE 211

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(6-chloropyrazin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in 1,3-dimethylimidazolidinone (2 ml), then thereto are added diisopropylethylamine (0.13 ml) and morpholine (0.6 ml), and the mixture is heated to 100°C and stirred for 3 days. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 9:1→7:3) to give
20 (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(6-(morpholin-4-yl)pyrazin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (223.2 mg). MS (m/z): 669 [M+H]⁺
25

EXAMPLES 212 and 213

The corresponding starting compounds are treated in a similar manner to Example 211 to give the compounds as listed in Table 23.




Table 23

Example No.	R	Physical properties, etc.
212		MS (m/z): 657 [M+H] ⁺
213		MS (m/z): 671 [M+H] ⁺

Example 214

(1) (2R*,4S*)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

5 [1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in isopropanol (5 ml), then thereto are added copper iodide (10.3 mg), ethylene glycol (0.12 ml), potassium phosphate (454 mg) and 4-(5-iodopyrimidin-2-yl)morpholine (311.5 mg), and the mixture is heated to 80°C and stirred under nitrogen flow for 20 hours. After adding distilled

10 water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 17:3→3:1) to give (2R*,4S*)-2-ethyl-6-methoxy-4-[2-(morpholin-4-yl)pyrimidin-5-yl]amino-3,4-

15 dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (122.2 mg). MS (m/z): 443 [M+H]⁺

(2) (2R*,4S*)-2-Ethyl-6-methoxy-4-[2-(morpholin-4-yl)pyrimidin-5-yl]amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (50 mg) is dissolved in acetonitrile (0.5 ml), then thereto is added sodium

20 hydride (62.7 %, 5.4 mg) at room temperature, and the mixture is stirred

for 10 minutes. After adding 3,5-bis(trifluoromethyl)benzyl bromide (27 μ l), the mixture is stirred for 22 hours. After adding distilled water, the mixture is extracted with ether. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane: ethyl acetate = 9:1 \rightarrow 4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[2-(morpholin-4-yl)pyrimidin-5-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (24.8 mg). MS (m/z): 669 [M+H]⁺


10 EXAMPLE 215

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in 1,4-dioxane (3 ml), and thereto are added a catalytic amount of tetrakis(triphenylphosphine)palladium, a catalytic amount of silver carbonate and a catalytic amount of copper (I) chloride under nitrogen flow. After adding dropwise a triethylaluminum-hexane solution (1M, 480 μ l), the mixture is stirred at 60°C for 30 minutes. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate = 9:1 \rightarrow 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2,6-diethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (83 mg); MS (m/z): 667 [M+H]⁺ and (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (77mg). MS (m/z): 639 [M+H]⁺.

30 EXAMPLE 216

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (18 g) is dissolved in N,N-dimethylformamide (60 ml), and thereto are added palladium acetate (611 mg), 1,1'-bis(diphenylphosphino)-ferrocene (3.02 g), ethanol (31.7 ml) and triethylamine (37.9 ml). The mixture is purged by carbon monoxide at room temperature for 10 minutes, then is heated at 90°C and stirred overnight under carbon monoxide. The reaction solution is cooled to room temperature, and thereto is added saturated brine and extracted with ethyl acetate. The organic layer is washed with saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 8:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-ethoxycarbonylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (12.4 g). MS (m/z): 656 [M+H]⁺.

EXAMPLE 217




A corresponding starting compound is treated in a similar manner to Example 36 to give the compound of Example 217. MS (m/z): 628 [M+H]⁺

EXAMPLE 218

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in N,N-dimethylformaldehyde (2 ml), and thereto are added triethylamine (53 μ l), 3-

methylaminopropionic acid tert-butyl ester hydrochloride (101.14 mg), 1-hydroxybenzotriazole hydrate (65 mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (92 mg) under ice-cooling. The mixture is stirred at room temperature for 21 hours. The reaction solution is concentrated under reduced pressure, then the residue is partitioned by adding a saturated aqueous sodium bicarbonate solution and ethyl acetate, and the organic layer is concentrated under reduced pressure. The resulting residue is dissolved in a solution (2 ml) of 4N hydrochloric acid in 1,4-dioxane and stirred at room temperature for 1 hour. To the reaction solution is added excessive saturated aqueous sodium bicarbonate solution, and the mixture is neutralized with 1N HCl, then extracted with ethyl acetate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give (2R,4S)-4-([3,5-bis-(trifluoromethyl)benzyl]-[5-[(2-carboxyethyl)methylcarbamoyl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (223 mg). MS (m/z): 713 [M+H]⁺.

EXAMPLE 219



A corresponding starting compound is treated in a similar manner to Example 218 to give the compound of Example 219. MS (m/z): 725 [M+H]⁺

EXAMPLE 220

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-carboxypyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid ethyl ester (200 mg) is dissolved in N,N-dimethyl-formaldehyde (2 ml), and thereto are added triethylamine (53 μ l), 3-amino-propionic acid methyl ester hydrochloride (67 mg), 1-hydroxybenzotriazole hydrate (65 mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (92 mg) under ice-cooling. The mixture is stirred for 21 hours. The reaction solution is concentrated under reduced pressure, then the residue is partitioned by adding a saturated aqueous sodium bicarbonate solution and ethyl acetate, and the organic layer is concentrated under reduced pressure. The resulting residue is dissolved in methanol (2 ml), and thereto is added 5N aqueous NaOH solution (1 ml), and the mixture is stirred at room temperature for 2 hours. To the reaction solution is added 6N HCl (0.85 ml), and then the mixture is extracted with ethyl acetate and the organic layer is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 19:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[(2-carboxyethyl)-carbamoyl]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (190 mg). MS (m/z): 699 [M+H]⁺.

20 EXAMPLES 221-222

Corresponding starting compounds are treated in a similar manner to Example 220 to give the compounds listed in Table 24.






Table 24

Example No.	R	Physical properties, etc.
221		MS (m/z): 685 [M+H] ⁺
222		MS (m/z): 699 [M+H] ⁺

EXAMPLE 223

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in N,N-dimethylformaldehyde (2 ml), and thereto are added triethylamine (67 μ l), O-(tert-butyldimethylsilyl)-serine methyl ester (112.02 mg), 1-hydroxybenzotriazole hydrate (64.86 mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (92.02 mg). The mixture is stirred at room temperature for 2.5 hours. The reaction solution is concentrated under reduced pressure, then the residue is partitioned by adding a saturated aqueous sodium bicarbonate solution and ethyl acetate, and the organic layer is concentrated under reduced pressure. The resulting residue is dissolved in tetrahydrofuran (2 ml), and thereto is added 1M tetrabutylammonium fluoride-tetrahydrofuran solution (0.55 ml) and the mixture is stirred at room temperature for 10 minutes. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxy-1-methoxycarbonyl-ethylcarbamoyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (229.5 mg). MS (m/z): 729 [M+H]⁺.


(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxy-1-methoxycarbonyl-ethylcarbamoyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (220 mg) is dissolved in methanol (3 ml), and thereto is added 2N aqueous NaOH solution (3 ml), and the mixture is stirred at room temperature for 23 hours. The reaction solution is partitioned by adding 6N HCl (1 ml) and chloroform, and the organic layer is dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 49:1→19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(1-carboxy-2-hydroxy-ethylcarbamoyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (133.5 mg). MS (m/z): 713 [M-H].

EXAMPLE 224

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-bromopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in toluene (5 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (41 mg), sodium tert-butoxide (65 mg), 2-(di-tert-butylphosphino)biphenyl (54 mg) and 3-methylaminopropionic acid tert-butyl ester (108 mg). The mixture is stirred overnight under nitrogen at room temperature. The reaction solution is cooled to room temperature, then partitioned by adding ethyl acetate and saturated brine. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[[methyl-(2-tert-butoxycarbonyl-ethyl)]amino]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (106 mg). MS (m/z): 741 [M+H].

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-[[methyl-(2-tert-butoxycarbonylethyl)]amino]pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is dissolved in 4N HCl/ethyl acetate solution (1 ml), and stirred at room temperature for 30 minutes. The reaction solution is partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine, dried over magnesium sulfate, then concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-[[methyl-(2-carboxyethyl)]amino]pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (55 mg). MS (m/z): 685 [M+H]⁺.

EXAMPLE 225



15

A corresponding starting compound is treated in a similar manner to Example 224 to give the compound of Example 225. MS (m/z): 729 [M+H]⁺

EXAMPLE 226

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1 g) is dissolved in toluene (25 ml), and thereto are added triethylamine (0.66 ml), diphenylphosphoryl azide (0.52 ml) and benzyl alcohol (0.2 ml). The mixture is heated at 90°C and stirred

20

overnight. The reaction solution is cooled to room temperature, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-((5-benzyloxycarbonylaminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.1 g). MS (m/z): 733 [M+H]⁺.


(2) (2R,4S)-4-((5-Benzyloxycarbonylaminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.1 g) is dissolved in N,N-dimethylformamide (15 ml), and thereto is added 63% sodium hydride (69 mg) under ice-cooling. The reaction mixture is stirred for 30 minutes, and thereto is added ethyl 4-bromobutyrate (0.33 ml) under ice-cooling, and the mixture is stirred at room temperature for 2.5 hours. The mixture is partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-((5-[benzyloxycarbonyl-(3-ethoxycarbonylpropyl)]aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (898 mg). MS (m/z): 847 [M+H]⁺.

(3) (2R,4S)-4-((5-[Benzyloxycarbonyl-(3-ethoxycarbonylpropyl)]aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in methanol (12 ml), and thereto is added 1N aqueous NaOH solution (2 ml). The mixture is stirred at room temperature for 1 day.

To the mixture is added 1N HCl, and the reaction solution is concentrated under reduced pressure. The residue is partitioned by adding ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-({5-[benzyloxycarbonyl-(3-carboxypropyl)]aminopyrimidin-2-yl}-[3,5-bis(trifluoromethyl)-benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (219 mg). MS (m/z): 819 [M+H]⁺.

- (4) (2R,4S)-4-({5-[Benzyloxycarbonyl-(3-carboxypropyl)]aminopyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (154 mg) is dissolved in methanol (5 ml), and thereto is added 10% palladium-carbon (25 mg). The mixture is stirred for 1.5 hours under hydrogen. The reaction solution is filtered, and then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→7:3) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)-benzyl}-[5-(3-carboxypropyl)aminopyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (98 mg). MS (m/z): 685 [M+H]⁺.


EXAMPLE 227



A corresponding starting compound is treated in a similar manner to Example 226 (4) to give the compound of Example 227. MS (m/z): 599

[M+H]⁺

EXAMPLE 228



A corresponding starting compound is treated in a similar manner to
 5 Example 14 to give the compound of Example 228. MS (m/z): 657 [M+H]⁺

EXAMPLE 229

(2R,4S)-4-((5-Aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])-
 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
 acid ethyl ester (500 mg) is dissolved in acetonitrile (10 ml), and thereto is
 10 added oxetan-2-one (0.08 ml). The mixture is heated to reflux for 3 days.
 The reaction solution is cooled to room temperature, and concentrated
 under reduced pressure. The resulting residue is purified by column
 chromatography (silica gel; chloroform:methanol = 1:0→4:1) to give
 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)amino-
 15 pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester (199 mg). MS (m/z): 671
 [M+H]⁺.

EXAMPLE 230

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)-
 20 aminopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in a
 mixture of tetrahydrofuran (5 ml) and methanol (1 ml), and thereto is
 added a 2.0M solution of trimethylsilyl diazomethane in hexane (0.5 ml).
 The mixture is stirred at room temperature for 30 minutes. The reaction
 25 solution is concentrated under reduced pressure, and the resulting residue

is purified by column chromatography (silica gel; hexane:ethyl acetate = 7:3→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonyl)aminopyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (232 mg). MS (m/z):
5 685 [M+H]⁺.

EXAMPLE 231

(1) (2R,4S)-4-[[5-Benzyloxycarbonylamino]pyrimidin-2-yl]-[3,5-bis-(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in
10 tetrahydrofuran (5 ml), and thereto is added 63% sodium hydride (20 mg) under ice-cooling. The mixture is stirred for 30 minutes, and thereto is added methyl iodide (30 μ l) under ice-cooling. The resulting mixture is stirred overnight at room temperature, and then partitioned by adding
15 water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-[[methyl-(benzyloxycarbonyl)]amino]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
20 [1,5]naphthyridine-1-carboxylic acid ethyl ester (275 mg). MS (m/z): 747 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-[[methyl-(benzyloxycarbonyl)]amino]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.34 g) is
25 dissolved in methanol (20 ml), and thereto is added 10% palladium-carbon (250 mg). The mixture is stirred for 3 hours under hydrogen. The reaction solution is filtered, and then the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 17:3→7:3) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-methylaminopyrimidin-2-yl]]amino-2-ethyl-6-
30

methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (698 mg). MS (m/z): 613 [M+H]⁺.

EXAMPLE 232

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-methylaminopyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in N,N-dimethylformamide (5 ml), and thereto are added ethyl 4-bromobutyrate (13 μ l) and potassium carbonate (50 mg). The mixture is heated at 50°C and stirred for 2 hours. The reaction solution is cooled to room temperature, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:2) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-5-[(3-ethoxycarbonylpropyl)-methyl]aminopyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (85 mg). MS (m/z): 727 [M+H]⁺.

EXAMPLE 233

(1) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in toluene (4 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (42 mg), sodium tert-butoxide (65 mg), 2-(di-tert-butylphosphino)biphenyl (54 mg) and piperidin-4-yl-ethyl acetate (116 mg). The mixture is stirred overnight at room temperature under nitrogen flow, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate

= 9:1→7:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-ethoxycarbonylmethylpiperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (125 mg). MS (m/z): 753 [M+H]⁺.

5 (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-ethoxycarbonylmethylpiperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (106 mg) is dissolved in methanol (8 ml), and thereto is added 1N aqueous NaOH solution (3 ml). The mixture is stirred at room temperature for 3.5 hours, and partitioned
10 by adding 1N HCl and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-carboxymethylpiperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
15 [1,5]naphthyridine-1-carboxylic acid ethyl ester (70 mg). MS (m/z): 725 [M+H]⁺.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxymethylpiperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
20 [1,5]naphthyridine-1-carboxylic acid ethyl ester (62 mg) is dissolved in ethanol (3 ml), and thereto is added 1N aqueous NaOH solution (84 µl). The mixture is stirred at room temperature for 5 minutes. The reaction solution is concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-carboxymethylpiperazin-1-yl)pyrimidin-2-yl]]-
25 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester sodium salt (56 mg). MS (m/z): 723 [M-Na]⁻.

EXAMPLES 234-235

Corresponding starting compounds are treated in a similar manner to Example 233 (1)-(2) to give the compounds listed in Table 25.





Table 25

Example No.	R'RN-	Physical properties, etc.
234		MS (m/z): 711 [M+H] ⁺
235		MS (m/z): 713 [M+H] ⁺

EXAMPLE 236



5

A corresponding starting compound is treated in a similar manner to Example 233 (2)-(3) to give the compound of Example 236. MS (m/z): 697 [M-Na]⁻

EXAMPLES 237-238

10

Corresponding starting compounds are treated in a similar manner to Example 233 (3) to give the compounds listed in Table 26.




Table 26

Example No.	R'RN-	Physical properties, etc.
237		MS (m/z): 711 [M+H] ⁺
238		MS (m/z): 669 [M-Na] ⁻

EXAMPLE 239

5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(piperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in ethanol (3 ml), and thereto are added sodium bicarbonate (76.4 mg) and cyanogen bromide (35 mg). The mixture is stirred at room temperature for


10 13 hours, and partitioned by adding water and diethyl ether to the reaction solution. The resulting mixture is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(4-cyanopiperazin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-

15 3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (183 mg). MS (m/z): 693 [M+H]⁺.

EXAMPLE 240

- (1) Hydroxylamine hydrochloride (45.2 mg) is dissolved in dimethylsulfoxide (1.5 ml), and thereto is added triethylamine (90.6 μ l). To the reaction solution is added tetrahydrofuran, and the insoluble materials are removed by filtration and the filtrate is evaporated to remove tetrahydrofuran under reduced pressure. To the resulting solution is added (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(4-cyanopiperazin-1-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (80 mg), and the mixture is heated at 75°C and stirred for 15 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with water and saturated brine, dried over magnesium sulfate, then concentrated under reduced pressure to give the crude material of (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-[4-(N-hydroxycarbamimidoyl)piperazin-1-yl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester. MS (m/z): 726 [M+H]⁺.
- (2) The crude material of (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-[4-(N-hydroxycarbamimidoyl)piperazin-1-yl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in acetonitrile (1 ml), and thereto is added carbodiimidazole (29 mg). The mixture is heated at 60°C and stirred for 17 hours. The reaction solution is cooled to room temperature, and partitioned by adding 1N HCl and ethyl acetate. The resulting solution is washed with water and saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-[4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)piperazin-1-yl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (42 mg). MS (m/z): 752 [M+H]⁺.

EXAMPLE 241



A corresponding starting compound is treated in a similar manner to Example 147 to give the compound of Example 241. MS (m/z): 736 [M+H]⁺

5 EXAMPLE 242

(1) (2R,4S)-4-((5-Aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]-naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in N,N-dimethylformamide (4 ml), and thereto are added 4-tert-butyl (S)-2-tert-butoxycarbonylamino succinate
10 (123 mg) and 1-hydroxybenzotriazole (68 mg), then added under ice-cooling 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride (96 mg) and triethylamine (0.06 ml). The mixture is stirred at room temperature for 2 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is
15 washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-((S)-3-tert-butoxycarbonyl-2-tert-butoxycarbonylamino propionylamino)pyrimidin-2-yl])amino-2-ethyl-6-
20 methoxy-3,4-dihydro-2H-[1,5]-naphthyridine-1-carboxylic acid ethyl ester (242 mg). MS (m/z): 870 [M+H]⁺.

(2) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-((S)-3-tert-butoxycarbonyl-2-tert-butoxycarbonylamino propionylamino)pyrimidin-2-yl])-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]-naphthyridine-1-carboxylic

acid ethyl ester (235 mg) is dissolved in dichloromethane (10 ml), and thereto is added trifluoroacetic acid (1 ml). The mixture is stirred at room temperature for 2 hours, and then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→0:1) to give (2R,4S)-4-{{5-((S)-2-amino-3-carboxypropionylamino)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (103 mg). MS (m/z): 712 [M-H].

EXAMPLE 243

(1) (2R,4S)-4-{{5-Aminopyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (273 mg) is dissolved in N,N-dimethylformamide (5 ml), and thereto are added methyl 3-chlorocarbonylpropionate (67 μ l) and triethylamine (0.19 ml) under ice-cooling. The mixture is stirred at room temperature for 1 hour, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→1:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(3-methoxycarbonylpropionylamino)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (138 mg) as a crude product. MS (m/z): 713 [M+H].

(2) The crude product (130 mg) of (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(3-methoxycarbonylpropionylamino)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is treated in a similar manner to Example 233 (2) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(3-carboxypropionylamino)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (121 mg). MS (m/z): 699 [M+H].

EXAMPLE 244

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in toluene (10 ml), and thereto are added triethylamine (0.66 ml), diphenylphosphoryl azide (0.52 ml) and methanol (1 ml). The mixture is heated at 60°C and stirred for 2 days. The reaction solution is cooled to room temperature, a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-methoxycarbonylamino)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (25 mg). MS (m/z): 657 [M+H]⁺.

EXAMPLE 245

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-aminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (400 mg) is dissolved in dichloromethane (5 ml), and thereto are added N,N'-carbonyldiimidazole (162 mg) and triethylamine (0.28 ml). The mixture is stirred at room temperature for 1.5 hours, then thereto is added ethane-1,2-diol (75 µl). The mixture is stirred for 3 days, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-(2-hydroxyethoxycarbonylamino)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (222 mg). MS (m/z): 687 [M+H]⁺.

EXAMPLES 246-248

Corresponding starting compounds are treated in a similar manner to Example 245 to give the compounds listed in Table 27.




Table 27

Example No.	R-	Physical properties, etc.
246		MS (m/z): 701 [M+H] ⁺
247		MS (m/z): 715 [M+H] ⁺
248		MS (m/z): 757 [M+H] ⁺

5

EXAMPLE 249


(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-hydroxyethoxy-carbonylamino)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (192 mg) is dissolved in acetone (5 ml), and thereto is added 2.67M chromium (VI) oxide in dilute sulfuric acid solution (320 μ l) under ice-cooling. The mixture is stirred for 4.5 hours, and partitioned by adding sodium bisulfite, water and ethyl acetate. The organic layer is washed with saturated brine and dried over

10

- magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→7:3) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)-benzyl}-(5-carboxymethoxycarbonylaminopyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (78 mg). MS (m/z): 701 [M+H]⁺.
5. methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester

EXAMPLES 250-251

Corresponding starting compounds are treated in a similar manner to Example 249 to give the compounds listed in Table 28.




10

Table 28


Example No.	R-	Physical properties, etc.
250		MS (m/z): 715 [M+H] ⁺
251		MS (m/z): 729 [M+H] ⁺

EXAMPLE 252



A corresponding starting compound is treated in a similar manner to Example 121 to give the compound of Example 252. MS (m/z): 717 [M+H]⁺


EXAMPLE 253



5

A corresponding starting compound is treated in a similar manner to Example 243 (1) to give the compound of Example 253. MS (m/z): 727 [M+H]⁺

EXAMPLE 254




10


A corresponding starting compound is treated in a similar manner to Example 233 (2) to give the compound of Example 254. MS (m/z): 713

[M+H]⁺

EXAMPLE 255



A corresponding starting compound is treated in a similar manner to
 5 Example 62 to give the compound of Example 255. MS (m/z): 727 [M+H]⁺
 EXAMPLE 256



A corresponding starting compound is treated in a similar manner to
 Example 233 (2)-(3) to give the compound of Example 256. MS (m/z): 711
 10 [M-Na]⁻


EXAMPLE 257

(1) (2R,4S)-4-((5-Aminopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])-
 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
 acid ethyl ester (300 mg) is dissolved in N,N-dimethylformamide (4 ml), and
 15 thereto are added methyl chlorocarbonate (116 μ l) and triethylamine (280
 μ l). The mixture is stirred at room temperature for 4 hours, and
 partitioned by adding a saturated aqueous sodium hydrogen carbonate
 solution and ethyl acetate. The organic layer is washed with saturated

brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-methoxycarbonylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (247 mg). MS (m/z): 657 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-methoxycarbonylaminopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (238 mg) is treated in a similar manner to Example 226 (2) and (3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-[[[3-carboxypropyl]-(methoxycarbonyl)]-amino]pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (187 mg). MS (m/z): 743 [M+H]⁺.

EXAMPLE 258



A corresponding starting compound is treated in a similar manner to Example 233 (3) to give the compound of Example 258. MS (m/z): 741 [M-Na]⁻.

EXAMPLE 259

(1) (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in tetrahydrofuran (2 ml),

and thereto are added methyl lactate (174 mg) and triphenylphosphine (438 mg), then added dropwise a solution (0.73 ml) of 40% diethyl azodicarboxylate in toluene under water-cooling. The mixture is stirred at room temperature for 3 hours, and thereto is added water. The resulting solution is extracted with ethyl acetate, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. To the resulting residue are added methylene chloride, isopropyl ether and hexane, and the precipitated insoluble materials are removed by filtration and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 6:1) to give (2R*,4S*)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(1-methoxycarbonylethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (157 mg). MS (m/z): 686 [M+H]⁺.

(2) (2R*,4S*)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(1-methoxycarbonylethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (154 mg) is dissolved in tetrahydrofuran (2 ml), and thereto is added dropwise a solution (1.12 ml) of 1M diisobutylaluminum hydride in toluene under ice-cooling and the mixture is stirred at 0°C for 3 hours. To the reaction mixture is added a 10% aqueous citric acid solution, and the resulting mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1) to give (2R*,4S*)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(2-hydroxy-1-methylethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (88 mg). MS (m/z): 658 [M+H]⁺.

EXAMPLES 260-264

Corresponding starting compounds are treated in a similar manner

to Example 259 (1) to give the compounds listed in Table 29.





Table 29

Example No.	R-	Physical properties, etc.
260		MS (m/z): 688 [M+H] ⁺
261		MS (m/z): 700 [M+H] ⁺
262		MS (m/z): 714 [M+H] ⁺
263		MS (m/z): 714 [M+H] ⁺
264		MS (m/z): 754 [M+H] ⁺



A corresponding starting compound is treated in a similar manner to Example 114 to give the compound of Example 265. MS (m/z): 716 [M+H]⁺
EXAMPLES 266-267

- 5 Corresponding starting compounds are treated in a similar manner to Example 121 to give the compounds listed in Table 30.




Table 30

Example No.	R-	Physical properties, etc.
266		MS (m/z): 674 [M+H] ⁺
267		MS (m/z): 674 [M+H] ⁺

10 EXAMPLE 268

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (170 mg) is dissolved in methylene chloride (3

ml), and thereto are added 4-methoxycarbonylphenylboronic acid (51 mg), copper (II) acetate (52 mg), triethylamine (79 μ l) and molecular sieves 4A (170 mg). The mixture is stirred overnight at room temperature. The insoluble materials are removed by filtration and the filtrate is partitioned by adding ethyl acetate and saturated brine. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1 \rightarrow 3:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(4-methoxycarbonylphenoxy)-pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (132 mg). MS (m/z): 734 [M+H]⁺.

EXAMPLE 269

(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-(5-hydroxypyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in tetrahydrofuran (3 ml), and thereto are added at room temperature potassium tert-butoxide (28 mg) and β -propiolactone (16 μ l). The reaction solution is stirred overnight at room temperature, and then partitioned by adding ethyl acetate and 1N HCl. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 9:1) and LC/MS (CAPCEL PAK MGII (SHISEIDO), water:methanol = 60:40 \rightarrow 0:100, 40 ml/min) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(2-carboxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (12 mg). MS (m/z): 672 [M+H]⁺.


EXAMPLE 270

(1) (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-(5-hydroxypyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid ethyl ester (3.5 g) and ethyl 4-bromobutyrate (928 μ l) is dissolved in N,N-dimethylformamide (20 ml), and thereto is added potassium carbonate (969 mg). The mixture is stirred overnight at 50°C. The reaction solution is cooled to room temperature, and partitioned by adding ethyl acetate and water. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.77 g). MS (m/z): 714 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.71 g) is dissolved in ethanol (35 ml), and thereto is added 2N aqueous NaOH solution (7.8 ml). The mixture is stirred overnight at room temperature. The reaction solution is concentrated under reduced pressure, and the residue is partitioned by adding ethyl acetate and 1N HCl. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.55 g). MS (m/z): 686 [M+H]⁺.

EXAMPLE 271



A corresponding starting compound is treated in a similar manner to Example 270 to give the compound of Example 271. MS (m/z): 700 [M+H]⁺
EXAMPLES 272-275

- 5 Corresponding starting compounds are treated in a similar manner to Example 270 (1) to give the compounds listed in Table 31.





Table 31

Example No.	R-	Physical properties, etc.
272		MS (m/z): 728 [M+H] ⁺
273		MS (m/z): 742 [M+H] ⁺
274		MS (m/z): 756 [M+H] ⁺

275		MS (m/z): 684 [M+H] ⁺
-----	-----------------------------------------------------------------------------------	----------------------------------

EXAMPLES 276-280

Corresponding starting compounds are treated in a similar manner to Example 270 (2) to give the compounds listed in Table 32.









Table 32

Example No.	R-	Physical properties, etc.
276		MS (m/z): 726 [M+H] ⁺
277		MS (m/z): 720 [M+H] ⁺
278		MS (m/z): 700 [M+H] ⁺
279		MS (m/z): 714 [M+H] ⁺

280		MS (m/z): 728 [M+H] ⁺
-----	-----------------------------------------------------------------------------------	----------------------------------

EXAMPLE 281

(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-oxotetrahydrofuran-3-yloxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

5 [1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg) is dissolved in ethanol (1 ml), and thereto is added 2N aqueous NaOH solution (1 ml). The mixture is stirred at room temperature for 3 hours, and partitioned by adding 1N HCl (2 ml) and ethyl acetate to the reaction solution. The organic layer is concentrated under reduced pressure. The resulting

10 residue is purified by column chromatography (silica gel; chloroform:methanol = 19:1→9:1). The resulting residue is dissolved in ethanol (1 ml), and thereto is added 2N aqueous NaOH solution (81 μ l), then concentrated under reduced pressure to give (2R,4S)-4-{{3,5-bis-(trifluoromethyl)benzyl}-[5-(1-carboxy-3-hydroxypropoxy)pyrimidin-2-yl]}-

15 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester sodium salt (114 mg). MS (m/z): 700 [M-Na]⁻.

EXAMPLE 282

(1) (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-ethoxycarbonyl-pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

20 [1,5]naphthyridine-1-carboxylic acid ethyl ester (1.0 g) is dissolved in tetrahydrofuran (7 ml), and thereto is added 1M-diisobutylaluminum hydride-tetrahydrofuran solution (3.36 ml) under ice-cooling. The mixture is stirred at room temperature for 2 hours. To the reaction solution is added a saturated aqueous ammonium chloride solution, and the mixture


25 is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced

pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→2:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-hydroxymethylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (760 mg). MS (m/z): 614 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxymethylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (735 mg) is dissolved in chloroform (5 ml), and thereto is added manganese dioxide (2 g). The mixture is stirred overnight at room temperature. The manganese dioxide is removed by filtration and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-formylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (450 mg). MS (m/z): 612 [M+H]⁺.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-formylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (185 mg), L-proline tert-butyl ester (62 mg), acetic acid (35 μ l) are dissolved in 1,2-dichloroethane (3 ml), and thereto is added sodium triacetoxyborohydride (128 mg). The mixture is stirred at room temperature for 2 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate to the reaction solution. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-(2-(S)-tert-butoxycarbonylpyrrolidin-1-ylmethyl)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg). MS (m/z): 767 [M+H]⁺.

EXAMPLE 283



A corresponding starting compound is treated in a similar manner to Example 224 (2) to give the compound of Example 283. MS (m/z): 711 [M+H]⁺

EXAMPLE 284

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-carboxypyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (335 mg) is dissolved in methylene chloride (2 ml), and thereto are added oxalyl chloride (70 μ l) and drops of N,N-dimethylformamide. The mixture is stirred at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the residue is dissolved in tetrahydrofuran (1 ml) and acetonitrile (1 ml), and thereto are added triethylamine (93 μ l) and 2M trimethylsilyl diazomethane-hexane solution (587 μ l). The mixture is stirred overnight at room temperature. The reaction solution is concentrated under reduced pressure, and to the residue are added 2,6-lutidine (500 μ l) and benzyl alcohol (500 μ l). The mixture is stirred at 150°C for 15 minutes. The reaction solution is cooled to room temperature, and extracted by adding ethyl acetate and 1N HCl. The organic layer is washed with a saturated sodium bicarbonate water and saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:1) to give (2R,4S)-4-[[5-benzyloxycarbonylmethylpyrimidin-2-yl]-

[3,5-bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (60 mg). MS (m/z): 732 [M+H]⁺.

(2) (2R,4S)-4-((5-Benzyloxycarbonylmethylpyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (53 mg) is dissolved in ethanol (0.5 ml), and thereto is added 10% palladium-carbon (10 mg). The mixture is stirred under hydrogen at room temperature for 3 hours. The palladium-carbon is filtered, and then the filtrate is concentrated under reduced pressure to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-(5-carboxymethylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (44 mg). MS (m/z): 642 [M+H]⁺.

EXAMPLE 285

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxymethylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (130 mg) is dissolved in acetone (2.5 ml), and thereto are added potassium carbonate (108 mg) and ethyl bromoacetate (0.129 ml). The mixture is stirred at room temperature for 6 days. The reaction solution is concentrated under reduced pressure, and thereto is added water. The mixture is stirred for 40 hours, and partitioned by adding chloroform to the reaction solution. The organic layer is dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-(5-carboxymethoxymethylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (33.8 mg). MS (m/z): 672 [M+H]⁺.


EXAMPLE 286

(1) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxymethylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (170 mg) is dissolved in dimethylsulfoxide (45 μ l), and thereto are added 5N aqueous NaOH solution (5 μ l) and acrylic acid tert-butyl ester (0.14 ml). The mixture is stirred at room temperature for 1 hour, and partitioned by adding water and diethyl ether to the reaction solution. The organic layer is dried over magnesium sulfate, and then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1 \rightarrow 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-tert-butoxycarbonylethoxymethyl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (161 mg). MS (m/z): 742 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-tert-butoxycarbonylethoxymethyl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (155 mg) is dissolved in a solution (3 mL) of 4N HCl in 1,4-dioxane, and the mixture is stirred at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-carboxyethoxymethyl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (145 mg). MS (m/z): 686 [M+H]⁺.

EXAMPLE 287




A corresponding starting compound is treated in a similar manner to Example 233 (3) to give the compound of Example 287. MS (m/z): 656 [M+H]⁺

EXAMPLE 288

- 5 (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-hydroxymethyl-pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (526 mg) is dissolved in chloroform (3 ml), and thereto is added manganese dioxide (1.5 g). The mixture is stirred at room temperature for 19 hours. The reaction solution
10 is filtered through Celite™, and the filtrate is concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-formylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg). MS (m/z): 612 [M+H]⁺.
- 15 (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-formylpyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in toluene (3 ml), and thereto are added benzyloxycarbonylamino(dimethoxyphosphoryl)acetic acid methyl ester (238 mg) and 1,8-diazabicyclo[5,4,0]undec-7-ene (98 µl). The mixture
20 is stirred at room temperature for 18 hours, and partitioned by adding 1N HCl and ethyl acetate to the reaction solution. The organic layer is washed with water and saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→1:1) to give
25 (2R,4S)-4-[[5-((Z)-2-benzyloxycarbonylamino-2-methoxycarbonylvinyl)-pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (209 mg). MS (m/z): 817 [M+H]⁺.
- (3) (2R,4S)-4-[[5-((Z)-2-Benzyloxycarbonylamino-2-methoxycarbonyl-
30 vinyl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-

methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in methanol (4 ml), and thereto is added 10% palladium-carbon (140 mg). The mixture is stirred under hydrogen at room temperature for 22 hours. The reaction solution is filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give (2R,4S)-4-[[5-(2-amino-2-methoxycarboxyethyl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (118 mg). MS (m/z): 685 [M+H]⁺.

EXAMPLE 289



A corresponding starting compound is treated in a similar manner to Example 233 (2) to give the compound of Example 289. MS (m/z): 671 [M+H]⁺.

EXAMPLE 290

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-hydroxypropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (940 mg) is dissolved in dichloromethane (20 ml), and thereto are added triphenylphosphine (850 mg) and carbon tetrabromide (1.0 g). The mixture is stirred at room temperature for 1 hour, and partitioned by adding water and chloroform. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The

resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-bromopropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (576 mg) as a crude product. MS (m/z): 704/706 [M+H]⁺.

(2) The crude product (150 mg) of (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-bromopropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in N,N-dimethylformamide (4 ml), and thereto is added morpholine (60 µl).

The mixture is stirred at room temperature for 2 days, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[3-(morpholin-4-yl)propyl]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (114 mg). MS (m/z): 711 [M+H]⁺.

EXAMPLE 291


(1) The crude product (230 mg) of (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-bromopropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in tetrahydrofuran (4 ml), and thereto is added 15% sodium methanethiolate solution (0.3 ml). The mixture is stirred at room temperature for 4.5 hours, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-methylsulfanylpropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (216 mg) as a crude product. MS (m/z): 672 [M+H]⁺.

(2) The crude product (210 mg) of (2R,4S)-4-[[3,5-bis(trifluoromethyl)-benzyl]-[5-(3-methylsulfonylpropyl)pyrimidin-2-yl]]amino-2-ethyl-6-

5 methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in chloroform (4 ml), and thereto is added m-chloroperbenzoic acid (160 mg). The mixture is stirred at room temperature for 2 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated
10 brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 7:3→2:3) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-(3-methanesulfonylpropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid
15 ethyl ester (63 mg). MS (m/z): 704 [M+H]⁺.

EXAMPLE 292




A corresponding starting compound is treated in a similar manner to Example 137 to give the compound of Example 292. MS (m/z): 635 [M+H]⁺

20 EXAMPLE 293

Copper (I) bromide (746 mg) is suspended in tetrahydrofuran (5 ml), and thereto is added dropwise a 65% toluene solution (3.23 g) of sodium bis(2-methoxyethoxy)aluminum hydride under ice-cooling under nitrogen and the mixture is stirred for 30 minutes. The reaction solution is cooled
25 to -78°C, and thereto are added 2-butanol (954 µl) and (2R,4S)-4-[[3,5-bis-

(trifluoromethyl)benzyl]-[5-(2-cyanovinyl)pyrimidin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (330 mg). The mixture is stirred at the same temperature for 2 hours, and then stirred at room temperature for 2 hours. To the reaction solution is added a saturated aqueous ammonium chloride solution, and the insoluble materials are removed by filtration through Celite™ and the resulting filtrate is partitioned by adding ethyl acetate and water. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-cyanoethyl)pyrimidin-2-yl]]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester 254 (mg). MS (m/z): 637 [M+H]⁺.

EXAMPLE 294



A corresponding starting compound is treated in a similar manner to Example 147 to give the compound of Example 294. MS (m/z): 680 [M+H]⁺

EXAMPLE 295

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-hydroxypropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1 g) and triphenylphosphine (491 mg) are dissolved in dichloromethane (10 ml), and thereto is added carbon tetrabromide (775 mg). The mixture is stirred overnight at room temperature. The reaction solution is concentrated

under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(3-bromopropyl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (955 mg). MS (m/z): 704/706 [M+H]⁺.

(2) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-(3-bromopropyl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (946 mg) and sodium 3-methoxy-3-oxopropan-1-sulfinate (281 mg) are dissolved in dimethylsulfoxide (8 ml), and the mixture is stirred overnight under nitrogen flow at room temperature. To the reaction solution are added water and ethyl acetate, and the organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1→1:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-[3-(2-methoxycarbonylethanesulfonyl)propyl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (801 mg). MS (m/z): 776 [M+H]⁺.

(3) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-[3-(2-methoxycarbonylethanesulfonyl)propyl]pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) and 2N aqueous NaOH solution (516 μ l) are dissolved in ethanol (3 ml), and the mixture is stirred at room temperature for 30 minutes. To the reaction solution is added 2N aqueous HCl solution (520 μ l), and the mixture is stirred overnight. To the reaction mixture is added ethyl acetate, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→4:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)-

benzyl]-[5-(3-sulfopropyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (96 mg). MS (m/z): 704 [M-H]⁺.

EXAMPLE 296

5 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-sulfopropyl)-pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (125 mg) is dissolved in thionyl chloride (3 ml) and stirred at 80°C for 2 hours. The reaction solution is cooled to room temperature, and then concentrated under
10 reduced pressure. To the resulting residue is added chloroform (3 ml), then added a solution (2 ml) of 7N ammonia in methanol under ice-cooling. The mixture is stirred at room temperature for 3 hours. To the reaction solution are added water and ethyl acetate, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated
15 under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→1:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(3-methoxysulfonylpropyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (29 mg) MS (m/z): 720 [M+H]⁺, and (2R,4S)-4-
20 {{3,5-bis(trifluoromethyl)benzyl}-[5-(3-sulfamoylpropyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (10 mg) MS (m/z): 705 [M+H]⁺.

EXAMPLE 297

(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-cyanoethyl)-
25 pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in ethanol (5 ml), and thereto are added sodium carbonate (292 mg) and hydroxylamine hydrochloride (192 mg). The mixture is heated at 80°C and stirred for 31.5 hours. The reaction solution is cooled to room temperature,
30 and partitioned by adding water and ethyl acetate. The organic layer is

washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give

(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-(N-hydroxycarbamimidoyl)ethyl]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (297 mg) MS (m/z): 670 [M+H]⁺, and (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-carbamoyl-ethyl]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (140 mg) MS (m/z): 655 [M+H]⁺.

EXAMPLE 298


(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-[2-(N-hydroxycarbamimidoyl)ethyl]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (140 mg) is dissolved in acetonitrile (1 ml), and thereto is added carbodiimidazole (51 mg). The mixture is heated at 60°C and stirred for 25.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[2-(5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl)ethyl]pyrimidin-2-yl})amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (84 mg). MS (m/z): 696 [M+H]⁺.

EXAMPLE 299


(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-bromopyrimidin-2-yl})-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.0 g), zinc cyanide (352 mg) and tetrakis(triphenylphosphine)palladium (347 mg) are dissolved in N,N-

dimethylformamide (10 ml), and stirred under nitrogen at 100°C for 4 hours. The reaction solution is partitioned by adding ethyl acetate and water. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-benzyl]-(5-cyanopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.69 g). MS (m/z): 609 [M+H]⁺.

EXAMPLE 300




A corresponding starting compound is treated in a similar manner to Example 147 to give the compound of Example 300. MS (m/z): 652 [M+H]⁺
EXAMPLE 301



A corresponding starting compound is treated in a similar manner to Example 202 to give the compound of Example 301. MS (m/z): 696 [M+H]⁺
EXAMPLE 302

Hydroxylamine hydrochloride (285 mg) is dissolved in dimethylsulfoxide (4 ml), and thereto is added triethylamine (0.57 ml). To the reaction solution is added tetrahydrofuran, and the insoluble materials are removed by filtration and the filtrate is evaporated to remove tetrahydrofuran under reduced pressure. To the resulting solution is added (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-(5-cyanopyrimidin-2-yl)}-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg), and the mixture is heated at 75°C and stirred for 1 hour. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-(5-(N-hydroxycarbamimidoyl)pyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (510 mg). MS (m/z): 642 [M+H]⁺.

EXAMPLE 303



A corresponding starting compound is treated in a similar manner to Example 298 to give the compound of Example 303. MS (m/z): 668 [M+H]⁺.

EXAMPLE 304

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)}-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in N,N-dimethylformamide (2 ml), and thereto are added tetrakis(triphenylphosphine)palladium (81 mg), pyridine-

3-boronic acid (87 mg) and potassium carbonate (117 mg). The mixture is stirred under nitrogen flow at 100°C for 2 hours. After allowing to cool to room temperature, to the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated
5 brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 4:1) to give (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(pyridin-3-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester
10 (96 mg). MS (m/z): 661 [M+H]⁺.

EXAMPLE 305

(1) (2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(pyridin-3-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (812 mg) and benzyl bromide (292 μ l) are
15 dissolved in acetonitrile (8 ml), and stirred at 50°C for 6 hours. The reaction solution is concentrated under reduced pressure, and the residue is crystallized and washed with isopropyl ether to give 1-benzyl-3-(2-{[3,5-bis(trifluoromethyl)benzyl]-((2R,4S)-1-ethoxycarbonyl-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)}aminopyrimidin-5-yl)pyridinium
20 bromide (1.01 g). MS (m/z): 661 [M+H-PhCH₂Br]⁺.

(2) 1-Benzyl-3-(2-{[3,5-bis(trifluoromethyl)benzyl]-((2R,4S)-1-ethoxycarbonyl-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)}aminopyrimidin-5-yl)pyridinium bromide (117 mg) is dissolved in methanol
25 (2 ml), and thereto is added sodium tetrahydroborate (11 mg). The mixture is stirred under nitrogen flow at room temperature for 10 minutes. To the reaction solution are added a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate, and the organic layer is washed with saturated brine, and then dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column
30 chromatography (silica gel; hexane:ethyl acetate = 4:1→2:1) to give (2R,4S)-

4-[[5-(1-benzyl-1,2,5,6-tetrahydropyridin-3-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (65 mg). MS (m/z): 755 [M+H]⁺.

5 EXAMPLE 306

(2R,4S)-4-[[5-(1-Benzyl-1,2,5,6-tetrahydropyridin-3-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (432 mg) is dissolved in methanol (10 ml), and thereto is added a catalytic amount of 10% palladium-carbon and the mixture is stirred overnight under hydrogen at room temperature. The catalyst (10% palladium-carbon) is removed by filtration, and then the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 1:2→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-benzyl]-[5-(piperidin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (177 mg). MS (m/z): 667 [M+H]⁺.

EXAMPLE 307

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(piperidin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (143 mg) and triethylamine (45 μ l) are dissolved in dichloromethane (2 ml), and thereto is added acetyl chloride (23 μ l) at 0°C and the mixture is stirred at room temperature for 1 hour. To the reaction solution are added a saturated aqueous citric acid solution and dichloromethane. The organic layer is washed with saturated brine and dried over sodium sulfate, and then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:2→0:1) to give (2R,4S)-4-[[5-(1-acetyl-piperidin-3-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid

ethyl ester (134 mg). MS (m/z): 709 [M+H]⁺.

EXAMPLE 308

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(pyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (402 mg) is dissolved in dichloromethane (5 ml), and thereto is added m-chloroperbenzoic acid (210 mg) under ice-cooling and the mixture is stirred at room temperature for 1 hour. To the reaction solution is added a saturated aqueous sodium hydrogen carbonate solution. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→49:1) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-(1-oxy-pyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (361 mg). MS (m/z): 677 [M+H]⁺.

EXAMPLE 309

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(1-oxy-pyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (272 mg) is dissolved in acetic anhydride (3 ml), and stirred under reflux for 3 days. The reaction solution is cooled to room temperature, and thereto and concentrated under reduced pressure. The resulting residue is dissolved in methanol, and thereto is added concentrated aqueous ammonia solution and the mixture is stirred at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:2→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-hydroxypyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (150 mg). MS (m/z): 677 [M+H]⁺.

EXAMPLE 310

- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in N,N-dimethylformamide (2.5 ml), and thereto are added tetrakis(triphenylphosphine)palladium (98 mg), 5-formylpyridine-3-boronic acid pinacol ester (197 mg) and sodium carbonate (108 mg). The mixture is stirred overnight under nitrogen flow at 100°C. After allowing to cool to room temperature, to the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-formylpyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (69 mg). MS (m/z): 689 [M+H]⁺.
- (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(5-formylpyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (65 mg) is dissolved in tert-butyl alcohol (0.67 ml), and thereto are added water (0.18 ml), 2-methyl-2-butene (44 μ l) and monosodium phosphate dihydrate (15 mg), and slowly added sodium chlorite (36 mg) under water-cooling. The mixture is stirred at room temperature for 1 hour. To the reaction mixture is added a 10% aqueous citric acid solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 19:1→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-carboxypyridin-3-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (54 mg). MS (m/z): 705 [M+H]⁺.

EXAMPLE 311

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is dissolved in chloroform (1.5 ml), and thereto is added m-chloroperbenzoic acid (48 mg) and the mixture is stirred at room temperature for 30 minutes. To the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate. The acidic impurities are removed using a small amount of NH-silica gel, and the organic layer is concentrated under reduced pressure. To the resulting residue are added diethyl ether and isopropyl ether, and the precipitated crystals are removed by filtration to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-(4-oxymorpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (89 mg). MS (m/z): 685 [M+H]⁺.

EXAMPLE 312

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-hydroxypropenyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (750 mg) is dissolved in chloroform (15 ml), and thereto is added m-chloroperbenzoic acid (303 mg) under ice-cooling. The mixture is stirred at room temperature for 2 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 7:3→2:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-[1-(3-chlorobenzoyloxy)-2,3-dihydroxypropyl]pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-

[1,5]naphthyridine-1-carboxylic acid ethyl ester (677 mg) as a crude product. MS (m/z): 812/814 [M+H]⁺.

(2) The crude product (360 mg) of (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-{5-[1-(3-chlorobenzoyloxy)-2,3-dihydroxypropyl]pyrimidin-2-yl})-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in methanol (10 ml), and thereto is added 1N aqueous NaOH solution (5 ml) and the mixture is stirred at room temperature for 30 minutes. The reaction solution is concentrated under reduced pressure, and partitioned by adding ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(1,2,3-trihydroxy)propylpyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (184 mg). MS (m/z): 674 [M+H]⁺.

EXAMPLE 313

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in 1,4-dioxane (1 ml), and thereto are added cesium carbonate (205 mg), pyrrolidin-2-one (41 μ l), 4,5-bis-(diphenylphosphino)-9,9-xanthene (81 mg) and tris(dibenzylideneacetone)-dipalladium (41.5 mg). The mixture is heated at 90°C and stirred for 15 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→7:3) to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(2-oxopyrrolidin-1-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-

carboxylic acid ethyl ester (126.6 mg). MS (m/z): 667 [M+H]⁺.

EXAMPLE 314

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-iodopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg), sodium 3-methoxy-3-oxopropan-1-sulfinate (221 mg) and copper (I) iodide (242 mg) are dissolved in dimethylsulfoxide (2 ml). The mixture is stirred under nitrogen flow at 110°C for 3 hours. The reaction solution is cooled to room temperature, and thereto are added water and ethyl acetate. After the precipitated insoluble materials are removed by filtration through Celite™, the organic layer is washed with saturated brine, and then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→2:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonyl-ethanesulfonyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (286 mg). MS (m/z): 734 [M+H]⁺.

EXAMPLE 315

(2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonyl-ethanesulfonyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (141 mg) and 2N aqueous NaOH solution (384 μl) are dissolved in ethanol (3 ml), and the mixture is stirred at 50°C for 30 minutes. To the reaction solution is added 2N aqueous HCl solution (385 μl), and stirred overnight. To the reaction mixture is added ethyl acetate, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 9:1→4:1) to give (2R*,4S*)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-sulfopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid

ethyl ester (64 mg). MS (m/z): 662 [M-H]⁻.

EXAMPLE 316

- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-
amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
5 acid ethyl ester (2 g), sodium 3-methoxy-3-oxopropan-1-sulfinate (2.63 g)
and copper (I) iodide (2.88 g) are dissolved in dimethylsulfoxide (25 ml),
and the mixture is stirred under nitrogen flow at 110°C for 6 hours. The
reaction solution is cooled to room temperature, and thereto are added
water and ethyl acetate. After the precipitated insoluble materials are
10 removed by filtration through Celite™, the organic layer is washed with
saturated brine and dried over magnesium sulfate, and concentrated under
reduced pressure. The resulting residue is purified by column
chromatography (silica gel; hexane:ethyl acetate = 4:1→2:1) to give (2R,4S)-
4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonyl-
15 ethanesulfonyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.92 g). MS (m/z): 734
[M+H]⁺.
- (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonyl-
ethanesulfonyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
20 [1,5]naphthyridine-1-carboxylic acid ethyl ester (1.9 g) and 2N aqueous
NaOH solution (2.6 ml) are dissolved in ethanol (20 ml), and the mixture is
stirred at room temperature for 30 minutes. To the reaction solution are
added 2N aqueous HCl solution (2.7 ml) and hydrogen peroxide solution
(10 ml), and the mixture is stirred overnight. To the reaction mixture is
25 added chloroform, and the organic layer is washed with saturated brine
and dried over magnesium sulfate, then concentrated under reduced
pressure. The resulting residue is purified by column chromatography
(silica gel; chloroform:methanol = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis-
(trifluoromethyl)benzyl]-(5-sulfonylpyrimidin-2-yl)]amino-2-ethyl-6-methoxy-
30 3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.68 g).

MS (m/z): 662 [M-H]⁻.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-sulfopyrimidin-2-yl))-
amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
acid ethyl ester (200 mg) is dissolved in thionyl chloride (2 ml), and stirred
5 at 120°C for 2 hours. The reaction solution is cooled to room temperature,
and then concentrated under reduced pressure. To the resulting residue is
added toluene (2 ml), then added a solution (15 ml) of 0.5M ammonia in
1,4-dioxane under ice-cooling, and the mixture is stirred overnight at room
temperature. The reaction solution is concentrated under reduced
10 pressure, and then to the resulting residue are added water and ethyl
acetate. The organic layer is washed with saturated brine and dried over
magnesium sulfate, then concentrated under reduced pressure. The
resulting residue is purified by column chromatography (silica gel;
hexane:ethyl acetate = 3:1→2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-
15 benzyl]-(5-sulfamoylpyrimidin-2-yl))amino-2-ethyl-6-methoxy-3,4-dihydro-
2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (75 mg). MS (m/z):
663 [M+H]⁺.

EXAMPLE 317

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-sulfopyrimidin-2-yl))-
20 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
acid ethyl ester (927 mg) is dissolved in thionyl chloride (10 ml), and
heated at 100°C and stirred for 2 hours. The reaction solution is
concentrated under reduced pressure and the resulting residue is
dissolved in toluene (10 ml). To the mixture are added glycine tert-butyl
25 ester hydrochloride (468 mg) and triethylamine (389 μ l) under ice-cooling,
and the reaction mixture is stirred for 5 hours with allowing to warm
gradually from under ice-cooling to room temperature. The reaction
mixture is partitioned by adding saturated brine and ethyl acetate. The
organic layer is washed with saturated brine and dried over magnesium
30 sulfate, then concentrated under reduced pressure. The resulting residue

is purified by column chromatography (silica gel; hexane:ethyl acetate = 6:1→2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(tert-butoxycarbonylmethylsulfamoyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (235 mg). MS (m/z): 777 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(tert-butoxycarbonylmethylsulfamoyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (230 mg) is dissolved in ethyl acetate (6 ml), and thereto is added a solution (4 ml) of 4N HCl/ethyl acetate. The mixture is stirred overnight at room temperature, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-carboxymethylsulfamoylpyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (135 mg). MS (m/z): 721 [M+H]⁺.

EXAMPLES 318-319

Corresponding starting compounds are treated in a similar manner to Example 156 (1) to give the compounds listed in Table 33.







Table 33

Example No.	R	R'	Physical properties, etc.
318	Br—		MS (m/z): 619/621 [M+H] ⁺
319	Br—		MS (m/z): 586/588 [M+H] ⁺

EXAMPLE 320

(2R,4S)-4-[(5-Bromopyrimidin-2-yl)-(3-cyano-5-trifluoromethyl-benzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in toluene (4 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (44 mg), sodium tert-butoxide (70 mg), 2-(di-tert-butylphosphino)biphenyl (58 mg) and acetyl piperazine (93 mg). The mixture is stirred at room temperature for 1 hour under nitrogen flow, then heated at 50°C and stirred for 5.5 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→0:1) to give (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-(3-cyano-5-trifluoromethyl-benzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (177 mg). MS (m/z): 667 [M+H]⁺.

EXAMPLE 321




A corresponding starting compound is treated in a similar manner to Example 320 to give the compound of Example 321. MS (m/z): 634 [M+H]⁺
EXAMPLE 322

- 5 (1) (2R,4S)-4-[(5-Bromopyrimidin-2-yl)-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3 g) is dissolved in 1,4-dioxane (30 ml), and thereto are added acrylic acid benzyl ester (1.57 g), tris(dibenzylideneacetone)dipalladium (665 mg), dicyclohexylmethylamine
10 (1.42 g) and tri-tert-butylphosphonium tetrafluoroborate (420 mg). The mixture is stirred at room temperature for 3 days under nitrogen flow, and partitioned by adding aqueous citric acid solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue
15 is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3→3:2) to give (2R,4S)-4-[[5-(2-benzyloxycarbonylvinyl)pyrimidin-2-yl]-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.82 g). MS (m/z): 701 [M+H]⁺.
- 20 (2) (2R,4S)-4-[[5-(2-Benzyloxycarbonylvinyl)pyrimidin-2-yl]-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (800 mg) is dissolved in a mixture of tetrahydrofuran (16 ml) and methanol (4 ml), and thereto is added 10% palladium-carbon (230 mg). The mixture is stirred for 9 hours

under hydrogen. The reaction solution is filtered, and then the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[5-(2-carboxyethyl)pyrimidin-2-yl]-(3-cyano-5-trifluoromethylbenzyl))amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (317 mg). MS (m/z): 613 [M+H]⁺.

EXAMPLE 323



A corresponding starting compound is treated in a similar manner to Example 322 to give the compound of Example 323. MS (m/z): 580 [M+H]⁺.

EXAMPLES 324-325

Corresponding starting compounds are treated in a similar manner to Example 143 to give the compounds listed in Table 34.









Table 34

Example No.	R	R'	Physical properties, etc.
324			MS (m/z): 599 [M+H] ⁺
325			MS (m/z): 566 [M+H] ⁺

EXAMPLE 326



5 A corresponding starting compound is treated in a similar manner to Example 156 (2) to give the compound of Example 326. MS (m/z): 626 [M+H]⁺

EXAMPLE 327

10 (2R,4S)-4-{{3-Cyano-5-trifluoromethylbenzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (315 mg) is dissolved in methanol (9 ml), and thereto is added 1N aqueous NaOH solution (1 ml). The mixture is stirred at room temperature for 1 day, and partitioned by adding 1N HCl and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column


15

chromatography (silica gel; hexane:ethyl acetate = 7:3→3:7→0:1) to give (2R,4S)-2-ethyl-6-methoxy-4-((3-methoxycarbonyl-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (54 mg). MS (m/z): 659 [M+H]⁺.

EXAMPLE 328

(2R,4S)-2-Ethyl-6-methoxy-4-((3-methoxycarbonyl-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (86 mg) is dissolved in methanol (9 ml) and N,N-dimethylformamide (1 ml), and thereto is added 1N aqueous NaOH solution (3 ml). The mixture is stirred at room temperature for 1.5 hours, and partitioned by adding 1N HCl and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by thin layer silica gel chromatography (chloroform:methanol = 9:1) to give (2R,4S)-4-((3-carboxy-5-trifluoromethylbenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (25 mg). MS (m/z): 645 [M+H]⁺.

EXAMPLE 329



A corresponding starting compound is treated in a similar manner to Example 177 (2) to give the compound of Example 329. MS (m/z): 689/691 [M+H]⁺

EXAMPLE 330

(2R*,4S*)-4-((3,5-Dibromobenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in N,N-dimethylformamide (4 ml), and thereto are added zinc cyanide (75 mg), a catalytic amount of tetrakis(triphenylphosphine)palladium. The mixture is heated at 110°C and stirred for 2 hours under nitrogen flow. The reaction solution is cooled to room temperature, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 7:3→1:1) to give (2R*,4S*)-4-((3,5-dicyanobenzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (134 mg). MS (m/z): 583 [M+H]⁺.


EXAMPLE 331

(1) (2R,4S)-4-[(5-Bromopyrimidin-2-yl)-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg), isonipecotic acid ethyl ester (109 μ l), sodium tert-butoxide (70 mg) and 2-(di-tert-butylphosphino)biphenyl (58 mg) are dissolved in toluene (5 ml), and thereto is added tris(dibenzylideneacetone)dipalladium (44 mg). The mixture is stirred overnight under nitrogen at room temperature, and partitioned by adding ethyl acetate and saturated brine to the reaction solution. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:2) to give (2R,4S)-4-[(3-cyano-5-trifluoromethylbenzyl)-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (125 mg). MS (m/z): 696

[M+H]⁺.

(2) (2R,4S)-4-[(3-Cyano-5-trifluoromethylbenzyl)-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (120 mg) is treated in a similar manner to Example 36 to give (2R,4S)-4-[(5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl)-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (65 mg). MS (m/z): 668 [M+H]⁺.


EXAMPLE 332



10

A corresponding starting compound is treated in a similar manner to Example 224 (1) to give the compound of Example 332. MS (m/z): 698 [M+H]⁺

EXAMPLE 333



15

A corresponding starting compound is treated in a similar manner to Example 224 (2) to give the compound of Example 333. MS (m/z): 642 [M+H]⁺

EXAMPLE 334


- (1) (2R,4S)-4-[(5-Bromopyrimidin-2-yl)-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (10 g) is treated in a similar manner to Example 4 to give (2R,4S)-4-[(3-cyano-5-trifluoromethylbenzyl)-(5-iodopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.18 g). MS (m/z): 667 [M+H]⁺.
- (2) (2R,4S)-4-[(3-Cyano-5-trifluoromethylbenzyl)-(5-iodopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in N,N-dimethylformamide (2.5 ml), and thereto are added tetrakis(triphenylphosphine)palladium (104 mg), pyrimidin-5-boronic acid (112 mg) and sodium carbonate (114 mg). The mixture is stirred at 100°C for 4 hours under nitrogen flow. After allowing to cool to room temperature, to the reaction mixture is added water. The mixture is extracted with ethyl acetate, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 2:1) to give (2R,4S)-4-[(5,5'-bipyrimidin-2-yl)-(3-cyano-5-trifluoromethylbenzyl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (116 mg). MS (m/z): 619 [M+H]⁺.

EXAMPLE 335

- (2R,4S)-4-[(3,5-Bis(trifluoromethyl)benzyl)-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is dissolved in dimethylsulfoxide (2 ml), and thereto is added a 2M solution (300 μ l) of dimethylamine in tetrahydrofuran under ice-cooling. The mixture is stirred at 40°C for 72 hours in a closed vessel, and partitioned by adding water and ethyl acetate to the reaction solution. The organic layer is washed with saturated brine and dried over magnesium sulfate, then

concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-6-dimethylamino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (78 mg). MS (m/z): 682 [M+H]⁺.

EXAMPLE 336



A corresponding starting compound is treated in a similar manner to Example 335 to give the compound of Example 336. MS (m/z): 668 [M+H]⁺.

10 EXAMPLE 337

(1) To a suspension of (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.45 g), sodium iodide (4.6 g) and acetonitrile (50 ml) is added dropwise trimethylsilyl chloride (3.8 ml) at 80°C. After dropwise addition, the reaction solution is cooled to room temperature, and thereto are added saturated aqueous sodium thiosulfate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 49:1→19:1) to give (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.09 g). MS (m/z): 696 [M+H]⁺.

(2) (2R,4S)-4-[[5-(4-Acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.05 g) and pyridine (1.06 ml) are dissolved in methylene chloride (20 ml), and thereto is added dropwise trifluoromethanesulfonic anhydride (885 μ l) under ice-cooling. The mixture is stirred at the same temperature for 4 hours, and thereto is added an aqueous citric acid solution. The organic layer is washed with a saturated aqueous sodium hydrogen carbonate solution, followed by saturated brine, and then dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:2→0:1) to give (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.39 g). MS (m/z): 828 [M+H]⁺.

(3) (2R,4S)-4-[[5-(4-Acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in dimethylsulfoxide (4 ml), and thereto is added a 2M solution of dimethylamine in tetrahydrofuran (1.2 ml) under ice-cooling. The mixture is stirred at 40°C for 48 hours in a closed vessel. To the reaction solution are added water and ethyl acetate, and then the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:2→0:1) to give (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-6-dimethylamino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (163 mg). MS (m/z): 723 [M+H]⁺.

EXAMPLE 338

(2R,4S)-4-{{5-(4-Acetylpiperazin-1-yl)pyrimidin-2-yl}-[3,5-bis-(trifluoromethyl)benzyl]}amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg), palladium acetate (34 mg), 1,1'-bis(diphenylphosphino)ferrocene (84 mg)
5 and triethylamine (126 μ l) are dissolved in N,N-dimethylformamide (2 ml), and thereto is added formic acid (28 μ l). The mixture is stirred at 60°C for 1 hour under nitrogen flow. To the reaction solution are added water and ethyl acetate, and then the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced
10 pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 1:2 \rightarrow 0:1) to give (2R,4S)-4-{{5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (195 mg). MS (m/z): 680 [M+H]⁺.


15 EXAMPLE 339

(2R,4S)-4-{{5-(4-Acetylpiperazin-1-yl)pyrimidin-2-yl}-[3,5-bis-(trifluoromethyl)benzyl]}amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) is dissolved in 1,4-dioxane (2 ml), and thereto are added dropwise a catalytic
20 amount of tetrakis(triphenylphosphine)palladium, silver carbonate and copper (I) chloride, and a 1M solution (362 μ l) of trimethylaluminum in hexane under nitrogen flow. The mixture is stirred at 60°C for 1 hour. The reaction solution is cooled to room temperature, and thereto are added water and ethyl acetate. The organic layer is washed with saturated brine
25 and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 1:2 \rightarrow 0:1) to give (2R,4S)-4-{{5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid
30 ethyl ester (142 mg). MS (m/z): 694 [M+H]⁺.

EXAMPLE 340

(2R,4S)-4-[[5-(4-Acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis-(trifluoromethyl)benzyl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg), a
 5 catalytic amount of tetrakis(triphenylphosphine)palladium, zinc cyanide (37 mg) are dissolved in N,N-dimethylformamide (2 ml), and the mixture is stirred at 100°C for 6 hours under nitrogen flow. The reaction solution is cooled to room temperature, and thereto are added water and ethyl acetate. The mixture is washed with saturated brine and dried over magnesium
 10 sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 3:7→0:1) to give (2R,4S)-4-[[5-(4-acetylpiperazin-1-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-6-cyano-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (149 mg). MS (m/z): 705
 15 [M+H]⁺.

EXAMPLE 341



A corresponding starting compound is treated in a similar manner to
 Example 337 (1) to give the compound of Example 341. MS (m/z): 700
 20 [M+H]⁺.

EXAMPLE 342

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonyl-propoxy)pyrimidin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.5 g) and pyridine (519

μl) are dissolved in methylene chloride (10 ml), and thereto is added trifluoromethanesulfonic anhydride (432 μl) under ice-cooling under nitrogen. The mixture is stirred for 1 hour, and partitioned by adding methylene chloride and a saturated aqueous citric acid solution to the
5 reaction solution. The organic layer is washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-
10 [1,5]naphthyridine-1-carboxylic acid ethyl ester (1.56 g). MS (m/z): 832 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.27 g) is
15 dissolved in N,N-dimethylformamide (10 ml), and thereto are added palladium acetate (34 mg), 1,1'-bis(diphenylphosphino)ferrocene (169 mg), benzyl alcohol (3.16 ml) and triethylamine (2.13 ml). The mixture is purged by carbon monoxide at room temperature for 5 minutes, then is
20 heated at 80°C and stirred for 1.5 hours under carbon monoxide. The reaction solution is cooled to room temperature, and thereto is added saturated brine. The mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is
25 purified by column chromatography (silica gel; hexane:ethyl acetate = 19:1→3:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]]amino-6-benzyloxycarbonyl-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (520 mg) MS
30 (m/z): 818 [M+H]⁺ and (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-

ethoxycarbonylpropoxy)pyrimidin-2-yl]amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (330 mg) MS (m/z): 684 [M+H]⁺.

EXAMPLE 343

- 5 (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]amino-6-benzyloxycarbonyl-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (500 mg) is dissolved in ethanol (2 ml), and thereto is added 10% palladium-carbon (50 mg). The mixture is stirred at room temperature for 1.5 hours under hydrogen.
- 10 Palladium-carbon is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:7) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1,6-dicarboxylic
- 15 acid 1-ethyl ester (323 mg). MS (m/z): 728 [M+H]⁺.
- (2) A mixture of (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1,6-dicarboxylic acid 1-ethyl ester (300 mg) and bis(2-methoxyethyl)aminosulfur trifluoride (1.6 ml) is stirred overnight at 80°C.
- 20 The reaction solution is cooled to room temperature, and thereto is added ethyl acetate for dilution. The mixture is poured into a saturated aqueous sodium hydrogen carbonate solution. The organic layer is washed with 1N HCl and saturated brine, and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by
- 25 thin layer silica gel chromatography (hexane:ethyl acetate = 2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (77 mg) MS (m/z): 752 [M+H]⁺, and (2R,4S)-6-[bis(2-methoxyethyl)carbamoyl]-4-[[3,5-bis-
- 30 (trifluoromethyl)benzyl]-[5-(3-ethoxycarbonylpropoxy)pyrimidin-2-yl]-

amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (184 mg) MS (m/z): 843 [M+H]⁺.

EXAMPLES 344-346

Corresponding starting compounds are treated in a similar manner to Example 36 to give the compounds listed in Table 35.




Table 35

Example No.	R	R'	Physical properties, etc.
344		F ₃ C—	MS (m/z): 724 [M+H] ⁺
345			MS (m/z): 815 [M+H] ⁺
346		H—	MS (m/z): 656 [M+H] ⁺

10 EXAMPLE 347

(1) To an aqueous solution (650 ml) of sodium azide (101.4 g) is added dropwise a solution (390 ml) of acrylic acid chloride (117.7 ml) in toluene under ice-cooling, and the mixture is stirred at the same temperature for 1

hour. Then the ice-water bath is removed and the mixture is stirred until cooling to room temperature. The solution of the reaction mixture is washed with a saturated aqueous sodium hydrogen carbonate solution and dried over magnesium sulfate. The resulting solution in toluene is added dropwise into a mixture of (R)-1-phenylethyl alcohol (173 ml), pyridine (52.6 ml) and hydroquinone (7.90 g) which is warmed to 85°C, and the mixture is stirred at the same temperature for 1 hour. The reaction mixture is cooled to room temperature. The mixture is washed with a saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 10:1→9:1) to give vinylcarbamic acid (R)-1-phenylethyl ester (167.3 g). MS (m/z): 191[M]⁺.

(2) {[1-(Benzotriazol-1-yl)propyl]-(6-methoxypyridin-3-yl)}amine (212.5 g), vinylcarbamic acid (R)-1-phenylethyl ester (143.4 g) and p-toluenesulfonic acid monohydrate (1.43 g) are dissolved in toluene (2.80 l), and the mixture is stirred at 85°C for 3 hours. After the mixture is allowed to stand for cooling to room temperature, the reaction solution is washed with a saturated aqueous sodium hydrogen carbonate solution, water and saturated brine. The organic layer is dried over magnesium sulfate, and then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1). To the residue is added hexane-ethyl acetate (9:1), and the precipitated crystals are removed by filtration. To the resulting mixture of diastereomers is added ether and the mixture is stirred, and the precipitated crystals are removed by filtration. To the resulting crystals are added a mixture of hexane-ethyl acetate (4:1) and the mixture is stirred. The resulting crystals are removed by filtration to give (2R,4S)-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)carbamic acid (R)-1-phenylethyl ester (38.7 g). MS (m/z): 356 [M+H]⁺.

- (3) ((2R,4S)-2-Ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)carbamic acid (R)-1-phenylethyl ester (200 mg) is dissolved in tetrahydrofuran (3 ml), and thereto is added di-tert-butyl dicarbonate (395 mg). The mixture is stirred overnight at 70°C. After the mixture is allowed to stand for cooling to room temperature, to the reaction solution is added a saturated aqueous sodium hydrogen carbonate solution and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 6:1→4:1) to give (2R,4S)-2-ethyl-6-methoxy-4-((R)-1-phenylethoxycarbonyl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (270 mg). MS (m/z): 456 [M+H]⁺.
- (4) (2R,4S)-2-Ethyl-6-methoxy-4-((R)-1-phenylethoxycarbonyl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (39.10 g) is dissolved in methanol (550 ml), and thereto is added 10% palladium-carbon (20.0 g). The mixture is stirred at room temperature for 2 hours under hydrogen flow. The reaction mixture is filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→chloroform:methanol = 9:1) to give (2R,4S)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (24.87g). MS (m/z): 308 [M+H]⁺.
- (5) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (24.80 g) is dissolved in 1,4-dioxane (450 ml), and thereto are added 5-bromo-2-chloropyrimidine (39.01 g) and N,N-diisopropylethylamine (35.1 ml). The mixture is stirred overnight at 80°C. After the mixture is allowed to stand for cooling to room temperature, the mixture is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel;

hexane:ethyl acetate = 6:1) to give (2R,4S)-4-(5-bromopyrimidin-2-yl)-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (27.48 g). MS (m/z): 466/464 [M+H]⁺.

(6) (2R,4S)-4-(5-Bromopyrimidin-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (20.00 g) is dissolved in N,N-dimethylformamide (150 ml), and thereto is added sodium hydride (62.7%, 2.46g) under ice-cooling. The mixture is stirred at the same temperature for 30 minutes. Subsequently, 3,5-bis(trifluoromethyl)benzyl bromide (11.8 ml) is added to the mixture, and the mixture is stirred at room temperature for 1 hour. After the reaction solution is neutralized by adding 10% aqueous citric acid solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. To the resulting residue are added ether and hexane. The precipitated crystals are removed by filtration to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (28.13 g). MS (m/z): 692/690 [M+H]⁺.

(7) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (6.00 g) is dissolved in toluene (60 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (796 mg), 2-(di-tert-butylphosphino)biphenyl (1.04 g), morpholine (1.52 ml) and sodium tert-butoxide (1.67 g). The mixture is stirred at room temperature for 7 hours under nitrogen flow. After the reaction mixture is neutralized by adding 10% aqueous citric acid solution, the mixture is extracted with ethyl acetate. The organic layer is washed with water and saturated brine, and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-

benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (5.37 g). MS (m/z): 697 [M+H]⁺.

- (8) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (5.36 g) is dissolved in 1,4-dioxane (15 ml), and thereto is added a solution (40 ml) of 4N HCl/1,4-dioxane under water-cooling. The mixture is stirred at room temperature for 3 hours. After the reaction mixture is neutralized by adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (4.48 g). MS (m/z): 597 [M+H]⁺.
- (9) (2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (233 mg) is dissolved in methylene chloride (2 ml), and thereto is added triethylamine (65 μ l), then added triphosgene (46 mg) under water-cooling. The mixture is stirred at the same temperature for 30 minutes. To the reaction mixture is added water and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. To the resulting residue are added tetrahydrofuran (2 ml), ethylene glycol (1.0 ml), triethylamine (0.40 ml) and dimethylaminopyridine (10 mg), and the mixture is stirred at room temperature for 5 days. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel;

hexane:ethyl acetate = 1:2) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)-benzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-hydroxyethyl ester (192 mg). MS (m/z): 685 [M+H]⁺.

5 EXAMPLES 348-353

Corresponding starting compounds are treated in a similar manner to Example 347 (9) to give the compounds listed in Table 36.








Table 36

Example No.	R	R'	Physical properties, etc.
348			MS (m/z): 699 [M+H] ⁺
349			MS (m/z): 695 [M+H] ⁺
350			MS (m/z): 723 [M+H] ⁺
351			MS (m/z): 715 [M+H] ⁺

352			MS (m/z): 747 [M+H] ⁺
353			MS (m/z): 726 [M+H] ⁺

EXAMPLE 354

- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (3.00 g) is dissolved in 1,4-dioxane (25 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (596 mg), tri-tert-butylphosphine-tetrafluoroborate complex (378 mg), methyl acrylate (0.78 ml) and N,N-dicyclohexylmethylamine (1.27 g). The mixture is stirred at 40°C for 7 hours under nitrogen flow. To the reaction mixture is added 10% aqueous citric acid solution, and then the mixture is extracted with ethyl acetate. The organic layer is washed with water and saturated brine, and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylvinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.93 g). MS (m/z): 696 [M+H]⁺.
- (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylvinyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.92 g) is dissolved in methanol (60 ml), and thereto is added 10% palladium-carbon (3.00 g). The mixture is stirred at room temperature for 2 hours under hydrogen flow. The reaction mixture is filtered and the filtrate is concentrated under

reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 8:1→6:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.19 g). MS (m/z): 698 [M+H]⁺.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.18 g) is dissolved in 1,4-dioxane (5 ml), and thereto is added a solution (10 ml) of 4N HCl in 1,4-dioxane. The mixture is stirred at room temperature for 1.5 hours. After the reaction solution is neutralized by adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (1.90 g). MS (m/z): 598 [M+H]⁺.

(4) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxycarbonylethyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (220 mg) is dissolved in methylene chloride (1.5 ml), and thereto is added triethylamine (62 μ l), then added triphosgene (44 mg) under water-cooling. The mixture is stirred at the same temperature for 30 minutes. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. To the resulting residue are added tetrahydrofuran (2.5 ml), ethylene glycol (1.0 ml), triethylamine (0.40 ml) and dimethylaminopyridine (10 mg), the mixture is stirred overnight at room temperature under nitrogen flow. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated

brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:2) to give (2R,4S)-4-{{3,5-bis-(trifluoromethyl)benzyl}-[5-(2-methoxycarbonylethyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-hydroxyethyl ester (145 mg). MS (m/z): 686 [M+H]⁺.

(5) (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxycarbonyl-ethyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-hydroxyethyl ester (141 mg) is dissolved in 1,4-dioxane (3 ml), and thereto is added 1N aqueous NaOH solution (1 ml). The mixture is stirred at room temperature for 1 hour. After the reaction solution is acidified by adding 10% aqueous citric acid solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-{{3,5-bis-(trifluoromethyl)benzyl}-[5-(2-carboxyethyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-hydroxyethyl ester (138 mg). MS (m/z): 672 [M+H]⁺.

EXAMPLES 355-357

Corresponding starting compounds are treated in a similar manner to Example 354 (4)-(5) to give the compounds listed in Table 37.










Table 37

Example No.	R	R'	Physical properties, etc.
355			MS (m/z): 682 [M+H] ⁺
356			MS (m/z): 710 [M+H] ⁺
357			MS (m/z): 702 [M+H] ⁺


EXAMPLE 358

- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (4.00 g) is dissolved in toluene (40 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (530 mg), 2-(di-tert-butylphosphino)biphenyl (691 mg), 4-ethoxycarbonylpiperidine (1.37 g) and sodium tert-butoxide (835 mg). The mixture is stirred overnight at room temperature under nitrogen flow. After the reaction mixture is neutralized by adding 10% aqueous citric acid solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 9:1→6:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.16 g). MS (m/z): 767 [M+H]⁺.
- (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-(4-ethoxycarbonyl-

piperidin-1-yl)pyrimidin-2-yl}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester (2.03 g) is dissolved in 1,4-dioxane (6 ml), and thereto is added a solution (15 ml) of 4N HCl in 1,4-dioxane. The mixture is stirred at room temperature for 1 hour. After
5 the reaction mixture is neutralized by adding a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-
10 [1,5]naphthyridine (1.79 g). MS (m/z): 667 [M+H]⁺.
(3) (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(4-ethoxycarbonylpiperidin-1-yl)pyrimidin-2-yl}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (130 mg) is dissolved in methylene chloride (2 ml), and
15 thereto is added pyridine (47 µl), then added dropwise propyl chloroformate (77 µl) under ice-cooling. The mixture is stirred at the same temperature for 2 hours under nitrogen flow. To the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with
20 saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is dissolved in ethanol (1 ml), and thereto is added 2M aqueous NaOH solution (1 ml). The mixture is stirred at 50°C for 1 hour. After 10% aqueous citric acid solution is added to the reaction mixture, the mixture is extracted with ethyl acetate.
25 The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified column chromatography (silica gel; chloroform:methanol = 19:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-
30

carboxylic acid propyl ester (115 mg). MS (m/z): 725 [M+H]⁺.

EXAMPLE 359



A corresponding starting compound is treated in a similar manner to
 5 Example 358 to give the compound of Example 359. MS (m/z): 723 [M+H]⁺
 EXAMPLE 360

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-ethoxycarbonyl-
 piperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
 [1,5]naphthyridine-1-carboxylic acid tert-butyl ester (120 mg) is dissolved
 10 in 1,4-dioxane (1 ml), and thereto is added 1M aqueous NaOH solution (1
 ml). The mixture is stirred at 50°C for 1 hour. After 10% aqueous citric
 acid solution is added to the reaction mixture, the mixture is extracted
 with ethyl acetate. The organic layer is washed with saturated brine and
 dried over magnesium sulfate, then concentrated under reduced pressure.
 15 The resulting residue is purified by column chromatography (silica gel;
 chloroform:methanol = 19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-
 benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-
 methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl
 ester (77 mg). MS (m/z): 739 [M+H]⁺.

20 EXAMPLES 361-364

Corresponding starting compounds are treated in a similar manner
 to Example 354 (4)-(5) to give the compounds listed in Table 38.




Table 38

Example No.	R	R'	Physical properties, etc.
361			MS (m/z): 729 [M+H] ⁺
362			MS (m/z): 725 [M+H] ⁺
363			MS (m/z): 765 [M+H] ⁺
364			MS (m/z): 737 [M+H] ⁺

5 EXAMPLE 365

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-

[1,5]naphthyridine (100 mg) is dissolved in methylene chloride (1.0 ml), and thereto is added triethylamine (28 μ l), then added triphosgene (20 mg)

10 under water-cooling. The mixture is stirred at the same temperature for 5

minutes under nitrogen flow. The reaction mixture is concentrated under reduced pressure, and to the resulting residue are added methylene chloride (1.5 ml), triethylamine (28 μ l) and 2-aminoethanol (24 μ l). The mixture is stirred overnight at room temperature under nitrogen flow. To
5 the reaction mixture is added saturated brine, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 19:1) to give (2R,4S)-4- $\{[3,5$ -bis-
10 (trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid (2-hydroxyethyl)amide (97 mg). MS (m/z): 684 [M+H]⁺.

EXAMPLE 366

(2R,4S)-4- $\{[3,5$ -Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-
15 pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (150 mg) is dissolved in toluene (2.0 ml), and thereto is added 2-chloroethyl isocyanate (40 mg). The mixture is stirred at 60°C for 9 hours under nitrogen flow. To the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted
20 with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1 \rightarrow 1:9) to give (2R,4S)-4- $\{[3,5$ -bis(trifluoromethyl)-benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-
25 dihydro-2H-[1,5]naphthyridine-1-carboxylic acid (2-chloroethyl)amide (160 mg). MS (m/z): 702/704 [M+H]⁺.

EXAMPLE 367

(2R,4S)-4- $\{[3,5$ -Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-
pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-
30 [1,5]naphthyridine (250 mg) is dissolved in methylene chloride (2.0 ml),

and thereto is added triethylamine (118 μ l), then added triphosgene (50 mg) under water-cooling. The mixture is stirred at the same temperature for 30 minutes under nitrogen flow. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is dissolved in a mixture of tetrahydrofuran (2.5 ml) and N,N-dimethylformamide (1 ml), and thereto are added O-methylhydroxylamine hydrochloride (70 mg) and triethylamine (230 μ l). The mixture is stirred at room temperature for 4 days under nitrogen flow. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1→chloroform:methanol = 19:1) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid methoxyamide (57 mg). MS (m/z): 670 [M+H]⁺.

EXAMPLE 368

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid (2-chloroethyl)amide (147 mg) is dissolved in acetonitrile (2.0 ml), and thereto is added 40% alumina-supported potassium fluoride (121 mg). The mixture is stirred overnight at 50°C. The reaction mixture is filtered through Celite™, and the filtered insoluble materials are washed with ethyl acetate. The filtrate and the washing are combined, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→chloroform:methanol = 19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-1-

(4,5-dihydroxazol-2-yl)-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine (51 mg). MS (m/z): 666 [M+H]⁺.

EXAMPLE 369

- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-
5 [1,5]naphthyridine (250 mg) is dissolved in methylene chloride (2.0 ml), and thereto is added triethylamine (118 μ l), then added triphosgene (50 mg) under water-cooling. The mixture is stirred at the same temperature for 30 minutes under nitrogen flow. To the reaction mixture is added
10 water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is dissolved in a mixture of tetrahydrofuran (2.5 ml) and N,N-dimethylformamide (1 ml), and thereto are added O-tert-butyl-L-serine methyl ester hydrochloride
15 (178 mg) and triethylamine (230 μ l). The mixture is stirred at room temperature for 4 days under nitrogen flow. To the reaction mixture is added water, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is
20 purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ((S)-2-tert-butoxy-1-methoxycarbonyl-ethyl)amide (309 mg). MS (m/z): 798 [M+H]⁺.
- (2) To (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
25 [1,5]naphthyridine-1-carboxylic acid ((S)-2-tert-butoxy-1-methoxycarbonyl-ethyl)amide (298 mg) is added a solution (5 ml) of 4N HCl in 1,4-dioxane. The mixture is stirred at room temperature for 5 hours. After the reaction
30 mixture is neutralized by adding a saturated aqueous sodium hydrogen

carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ((S)-2-hydroxy-1-methoxycarbonyl-ethyl)amide (237 mg). MS (m/z): 742 [M+H]⁺.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ((S)-2-hydroxy-1-methoxycarbonyl-ethyl)amide (214 mg) is dissolved in methylene chloride (3.0 ml), and thereto is added pyridine (28 μ l), then added trifluoromethanesulfonic anhydride (58 μ l) at -20°C. The mixture is stirred at the same temperature for 40 minutes under nitrogen flow. To the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→1:9) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1-((S)-4-methoxycarbonyl-4,5-dihydroxazol-2-yl)-3,4-dihydro-2H-[1,5]naphthyridine (172 mg). MS (m/z): 724 [M+H]⁺.

(4) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1-((S)-4-methoxycarbonyl-4,5-dihydroxazol-2-yl)-3,4-dihydro-2H-[1,5]naphthyridine (85 mg) is dissolved in tetrahydrofuran (2.0 ml), and thereto is slowly added a 1M solution (0.4 ml) of diisobutylaluminum hydride in tetrahydrofuran under ice-cooling. The mixture is stirred at the same temperature for 30 minutes under nitrogen flow. To the reaction mixture is added saturated brine, and the

mixture is stirred at room temperature for 1 hour, and then extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-1-((R)-4-hydroxymethyl-4,5-dihydroazol-2-yl)-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine (61 mg). MS (m/z): 696 [M+H]⁺.


EXAMPLE 370

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (200 mg) is dissolved in methylene chloride (1.5 ml), and thereto is added pyridine (54 μ l), then added chloroacetyl chloride (40 μ l) under water-cooling. The mixture is stirred at room temperature for 1 hour under nitrogen flow. To the reaction mixture is added a saturated aqueous sodium hydrogen carbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-1-chloroacetyl-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine (156 mg). MS (m/z): 675/673 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-1-chloroacetyl-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine (80 mg) is dissolved in N,N-dimethylformamide (1.5 ml), and thereto are added morpholine (52 μ l) and potassium carbonate (49 mg). The mixture is stirred at room temperature for 3 hours. To the reaction mixture is added saturated brine, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated brine and dried over

magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give (2R,4S)-4-[[3,5-bis-(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1-(morpholin-4-yl)acetyl-3,4-dihydro-2H-[1,5]naphthyridine (60 mg). MS (m/z): 724 [M+H]⁺.

EXAMPLE 371




A corresponding starting compound is treated in a similar manner to Example 370 (1) to give the compound of Example 371. MS (m/z): 703 [M+H]⁺.

EXAMPLE 372

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (300 mg) is dissolved in N,N-dimethylformamide (3 ml), and thereto is added sodium hydride (62.7%, 21 mg) under ice-cooling, then after 1 hour added ethyl iodoacetate (71 μ l). The mixture is stirred at room temperature for 24 hours. The reaction solution is partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by NH-column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-1-ethoxycarbonylmethyl-2-ethyl-6-methoxy-3,4-dihydro-2H-


[1,5]naphthyridine (107 mg). MS (m/z): 683 [M+H]⁺.

EXAMPLE 373




A corresponding starting compound is treated in a similar manner to
5 Example 370 (1) and Example 36 to give the compound of Example 373.
MS (m/z): 709 [M+H]⁺

EXAMPLE 374




A corresponding starting compound is treated in a similar manner to
10 Example 322 (1) to give the compound of Example 374. MS (m/z): 730
[M+H]⁺

EXAMPLE 375




A corresponding starting compound is treated in a similar manner to Example 322 (2) to give the compound of Example 375. MS (m/z): 642 [M+H]⁺

5 EXAMPLE 376



A corresponding starting compound is treated in a similar manner to Example 143 to give the compound of Example 376. MS (m/z): 628 [M+H]⁺


EXAMPLE 377



10


A corresponding starting compound is treated in a similar manner to Example 15 to give the compound of Example 377. MS (m/z): 725 [M+H]⁺

EXAMPLE 378



A corresponding starting compound is treated in a similar manner to Example 36 to give the compound of Example 378. MS (m/z): 697 [M+H]⁺

5 EXAMPLE 379



A corresponding starting compound is treated in a similar manner to Example 200 to give the compound of Example 379. MS (m/z): 608 [M+H]⁺

EXAMPLE 380

10 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-cyanopyridin-2-yl]]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg), hydroxylammonium chloride (170 mg) and triethylamine (340 μ l) are dissolved in ethanol (2 ml), and the mixture is stirred under reflux for 2 hours. The reaction solution is cooled to room
15 temperature, and thereto are added water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and then concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(N-hydroxycarbamimidoyl)pyridin-2-yl]]-

amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (360 mg). MS (m/z): 641 [M+H]⁺.

EXAMPLE 381


(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(N-hydroxy-
5 carbamimidoyl)pyridin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-
[1,5]naphthyridine-1-carboxylic acid ethyl ester (193 mg) and triethylamine
(126 μ l) are dissolved in dichloromethane (3 ml), and thereto is added
triphosgene (268 mg) at 0°C. The mixture is stirred at room temperature
for 30 minutes. To the reaction solution are added water and
10 dichloromethane, and the organic layer is washed with saturated brine.
Then the organic layer is dried over sodium sulfate, and then concentrated
under reduced pressure. The resulting residue is purified by column
chromatography (silica gel; chloroform:methanol = 1:0→97:3) to give
(2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(5-oxo-4,5-dihydro-
15 [1,2,4]oxadiazol-3-yl)pyridin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-
2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (33 mg). MS (m/z):
667 [M+H]⁺.

EXAMPLE 382

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-bromopyridin-2-yl]]-
20 amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
acid ethyl ester (276 mg), tris(dibenzylideneacetone)dipalladium (76 mg),
sodium tert-butoxide (80 mg), 2-(di-tert-butylphosphino)biphenyl (50 mg)
and ethyl isonipeccotate (131 mg) are dissolved in toluene (3 ml), and the
mixture is stirred at room temperature for 22 hours under nitrogen flow.
25 To the reaction solution are added water and ethyl acetate. The organic
layer is washed with saturated brine and dried over magnesium sulfate,
then concentrated under reduced pressure. The resulting residue is
purified by column chromatography (silica gel; hexane:ethyl acetate =
9:1→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[4-ethoxy-
30 carbonyl-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-yl]]amino-2-ethyl-6-

methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (109 mg). MS (m/z): 738 [M+H]⁺.

EXAMPLE 383



5 A corresponding starting compound is treated in a similar manner to Example 36 to give the compound of Example 383. MS (m/z): 710 [M+H]⁺

EXAMPLE 384

(1) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (10 g) is dissolved in
 10 toluene (100 ml), and thereto are added 2-bromopyridine (6.8 ml), tris-(dibenzylideneacetone)dipalladium (328 mg), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (282 mg) and sodium tert-butoxide (6.9 g). The mixture is stirred at room temperature for 3.5 hours under nitrogen, then heated at 80°C and stirred for 4 hours. The reaction solution is
 15 cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give a crude (6.4 g) of (2R,4S)-2-ethyl-6-methoxy-4-(pyridin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-
 20 carboxylic acid ethyl ester. MS (m/z): 357 [M+H]⁺.

(2) The crude (6.3 g) of (2R,4S)-2-ethyl-6-methoxy-4-(pyridin-2-yl)-amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in methylene chloride (80 ml), and thereto is added N-

bromosuccinimide (3.15 g). The mixture is stirred at room temperature for 15 minutes. The reaction solution is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-2-ethyl-6-methoxy-4-(5-bromopyridin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.0 g). MS (m/z): 435/ 437 [M+H]⁺.

(3) (2R,4S)-2-Ethyl-6-methoxy-4-(5-bromopyridin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3 g) is dissolved in N,N-dimethylformamide (20 ml), and thereto is added sodium hydride (62.7%, 580 mg) under ice-cooling. The mixture is stirred for 30 minutes, and then to the mixture is added 3,5-bis(trifluoromethyl)benzyl bromide (3.2 ml). The mixture is stirred at room temperature for 24 hours, and partitioned by adding water and ethyl acetate under ice-cooling. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-bromopyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.7 g). MS (m/z): 661/663 [M+H]⁺.

(4) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyridin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.7 g) is dissolved in toluene (15 ml), and thereto are added morpholine (0.45 ml), tris(dibenzylideneacetone)dipalladium (238 mg), 2-(di-tert-butylphosphino)biphenyl (152 mg) and sodium tert-butoxide (494 mg). The mixture is stirred at room temperature for 85 minutes under nitrogen, then heated at 80°C and stirred for 3.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced

pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.26 g). MS (m/z): 668 [M+H]⁺.

(5) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.25 g) and sodium iodide (1.68 g) are dissolved in acetonitrile (15 ml). Then the mixture is heated at 80°C and thereto is added dropwise trimethylsilyl chloride (1.4 ml) under nitrogen, and the mixture is stirred for 19.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (642 mg). MS (m/z): 654 [M+H]⁺.

(6) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-hydroxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (585 mg) is dissolved in methylene chloride (5 ml), and thereto are added pyridine (218 µl) and trifluoromethanesulfonic anhydride (180 µl) under nitrogen under ice-cooling. The reaction solution is stirred for 75 minutes, and partitioned by adding a saturated aqueous citric acid solution and ethyl acetate. The organic layer is washed with water and saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]-

amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (657 mg). MS (m/z): 786 [M+H]⁺

- (7) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyridin-2-yl]]amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (650 mg) is dissolved in dimethylsulfoxide (20 ml), and thereto are added triethylamine (1 ml) and a 2M solution (20 ml) of methylamine in tetrahydrofuran. The mixture is heated at 100°C and stirred for 5 hours in a sealed tube under nitrogen.
- 10 The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine and dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 9:1→7:3) to give
- 15 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl]]amino-2-ethyl-6-methylamino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (45 mg). MS (m/z): 667 [M+H]⁺

EXAMPLE 385

- (1) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2 g), 2-chlorooxazole-4-carboxylic acid ethyl ester (3.77 g) and diisopropylethylamine (2.5 ml) are dissolved in 1,4-dioxane (15 ml), and the mixture is stirred for 9 hours under reflux. The reaction solution is cooled to room temperature, and thereto are added water and ethyl acetate. The organic layer is washed
- 25 with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→2:1) to give (2R,4S)-4-(4-ethoxycarbonyloxazol-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.85 g). MS (m/z): 419
- 30 [M+H]⁺.

(2) (2R,4S)-4-(4-Ethoxycarbonyloxazol-2-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.75 g) is dissolved in N,N-dimethylformamide (30 ml), and thereto is added sodium hydride (62.7%, 315 mg) under ice-cooling. The mixture is stirred at room temperature for 30 minutes. To the mixture is added 3,5-bis(trifluoromethyl)benzyl bromide (1.8 ml) under ice-cooling, and the mixture is stirred overnight at room temperature. To the reaction solution are added water and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(4-ethoxycarbonyloxazol-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.53 g). MS (m/z): 645 [M+H]⁺.

15 EXAMPLE 386

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(4-ethoxycarbonyloxazol-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) and lithium hydroxide monohydrate (78 mg) are dissolved in a mixture of methanol (3 ml) and water (500 μ l), and the mixture is stirred at room temperature for 2 hours. The reaction solution is acidified by adding 2N aqueous HCl solution, then added ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(4-carboxyoxazol-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (190 mg). MS (m/z): 617 [M+H]⁺.

25 EXAMPLE 387

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(4-carboxyoxazol-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg) and 1-hydroxybenzotriazole hydrate (53 mg) are

30

dissolved in N,N-dimethylformamide (3 ml), and thereto is added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (311 mg). The mixture is stirred at room temperature for 30 minutes. To the mixture is added concentrated ammonia water (3 ml) under ice-cooling, and the mixture is stirred at room temperature for 3 hours. To the reaction mixture are added water and ethyl acetate. The organic layer is washed with saturated brine, and then dried over magnesium sulfate and concentrated under reduced pressure to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(4-carbamoyloxazol-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (200 mg). MS (m/z): 616 [M+H]⁺.

EXAMPLE 388

- (1) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3.0 g) is dissolved in 1,2-dichloroethane (50 ml), and thereto is added 3,5-bis(trifluoromethyl)benzaldehyde (1.9 ml). The mixture is stirred at room temperature for 1 hour, then added 95% sodium triacetoxyborohydride (4.6 g). The mixture is stirred for 17 hours, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, and then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-[3,5-bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.92 g). MS (m/z): 506 [M+H]⁺.
- (2) (2R,4S)-4-[3,5-Bis(trifluoromethyl)benzyl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.9 g) is dissolved in ethanol (30 ml), and thereto are added sodium bicarbonate (2.5 g) and cyanogen bromide (1.1 g). The mixture is stirred at room temperature for 16 hours, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, and then dried

over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→13:7) to give (2R,4S)-4-{{3,5-bis-(trifluoromethyl)benzyl}-cyano}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.35 g). MS (m/z): 531 [M+H]⁺.


(3) (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-cyano}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (3 g) is dissolved in N,N-dimethylformamide (30 ml), and thereto are added ammonium chloride (3 g) and sodium azide (3.7 g). The mixture is heated at 100°C and stirred for 24 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→19:1), and the eluent is concentrated, followed by recrystallized (hexane:isopropanol) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-(tetrazol-5-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.2 g). MS (m/z): 574 [M+H]⁺.

EXAMPLE 389

(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-(tetrazol-5-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (230 mg) is dissolved in tetrahydrofuran (3 ml), and thereto are added 3-hydroxy-2,2-dimethylpropionic acid methyl ester (58 µl), a solution (0.18 ml) of 40% diethyl azodicarboxylate in toluene and triphenylphosphine (121 mg). The mixture is stirred at room temperature for 19 hours, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column


chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[2-(2-methoxycarbonyl-2-methylpropyl)-2H-tetrazol-5-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (243 mg). MS (m/z): 688 [M+H]⁺.

EXAMPLE 390



A corresponding starting compound is treated in a similar manner to Example 386 to give the compound of Example 390. MS (m/z): 674 [M+H]⁺

EXAMPLE 391



A corresponding starting compound is treated in a similar manner to Example 240 to give the compound of Example 391. MS (m/z): 590 [M+H]⁺

EXAMPLE 392

(1) (2R,4S)-4-[[N-Hydroxycarbamimidoyl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (513 mg) and diisopropylethylamine (317 μ l) are dissolved in dichloroethane (5 ml), and thereto is added acetoxyacetyl chloride (127 μ l) at 0°C. The mixture is stirred overnight at room temperature. To the reaction solution is added a saturated aqueous citric

acid solution, and the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→1:1) to give (2R,4S)-4-(((acetyloxyacetyl)amino-(acetyloxyacetyloxy)iminomethyl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (330 mg). MS (m/z): 764 [M+H]⁺.

(2) (2R,4S)-4-(((Acetyloxyacetyl)amino-(acetyloxyacetyloxy)iminomethyl)-[3,5-bis(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (320 mg) and potassium carbonate (579 mg) are suspended in ethanol (5 ml), and the mixture is stirred overnight at room temperature. To the reaction solution are added water and ethyl acetate, and the organic layer is washed with saturated brine and then dried over sodium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 2:1→0:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(5-hydroxymethyl-[1,2,4]oxadiazol-3-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (52 mg). MS (m/z): 604 [M+H]⁺.

EXAMPLE 393

(1) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.0 g) is dissolved in 1,4-dioxane (90 ml), and thereto are added triethylamine (7.5 ml) and 4,6-dichloropyrimidine (5.3 g). The mixture is heated at 80°C and is stirred for 18.5 hours. The reaction solution is cooled to room temperature, and then concentrated under reduced pressure, and partitioned by adding 1N HCl and diethyl ether. The organic layer is washed with water, a saturated aqueous sodium hydrogen carbonate solution, water and saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography

(silica gel; hexane:ethyl acetate = 9:1→1:1) to give (2R,4S)-4-(6-chloropyrimidin-4-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.92 g). MS (m/z): 392/394 [M+H]⁺.


5 (2) (2R,4S)-4-(6-Chloropyrimidin-4-yl)amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (4.0 g) is dissolved in acetonitrile (50 ml), and thereto is added sodium hydride (62.7%, 428.7 mg) under ice-cooling. The mixture is stirred for 5 minutes, and then thereto is added 3,5-bis(trifluoromethyl)benzyl bromide (2.8 ml).
10 The mixture is stirred at room temperature for 14 hours, and partitioned by adding water and diethyl ether under ice-cooling. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give
15 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(6-chloropyrimidin-4-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (5.1 g). MS (m/z): 618/620 [M+H]⁺.

(3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(6-chloropyrimidin-4-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
20 acid ethyl ester (140 mg) is dissolved in 1,3-dimethyl-2-imidazolidinone (2 ml), and thereto are added diisopropylethylamine (0.4 ml) and 3-methylaminopropionic acid tert-butyl ester (150 mg). The mixture is heated at 80°C and stirred for 56.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and diethyl ether. The
25 organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→3:2) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-(6-(2-tert-butoxycarbonyl-ethyl)methylaminopyrimidin-4-yl)]amino-2-ethyl-6-
30 methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester

(113.2 mg). MS (m/z): 741 [M+H]⁺.


- (4) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[6-(2-tert-butoxy-carbonylethyl)methylaminopyrimidin-4-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (100 mg) is dissolved in a 2N solution (2 ml) of HCl/1,4-dioxane, and the mixture is stirred at room temperature for 3 hours. The reaction solution is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[6-(2-carboxyethyl)methylaminopyrimidin-4-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (29 mg). MS (m/z): 685 [M+H]⁺.

EXAMPLE 394




- 15 A corresponding starting compound is treated in a similar manner to Example 393 (3) to give the compound of Example 394. MS (m/z): 657 [M+H]⁺

EXAMPLE 395



A corresponding starting compound is treated in a similar manner to Example 393 (3) to give the compound of Example 395. MS (m/z): 699 [M+H]⁺

5 EXAMPLE 396



A corresponding starting compound is treated in a similar manner to Example 36 to give the compound of Example 396. MS (m/z): 671 [M+H]⁺
EXAMPLE 397

- 10 (1) 4-Chloro-2-methylsulfanylpurimidine-5-carboxylic acid ethyl ester (5 g) is dissolved in ethanol (100 ml), and thereto are added sodium carbonate (11.4 g) and 2-methylaminoethanol (4.6 ml). The mixture is heated at 80°C and stirred for 3 hours. The reaction solution is cooled to room temperature, then concentrated under reduced pressure, and partitioned
15 by adding water and chloroform. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column

chromatography (silica gel; chloroform:methanol = 1:0→19:1) to give 9-methyl-2-methylsulfanyl-8,9-dihydro-7H-pyrimido[4,5-e][1,4]oxazepin-5-one (2.92 g). MS (m/z): 226 [M+H]⁺.


(2) 9-Methyl-2-methylsulfanyl-8,9-dihydro-7H-pyrimido[4,5-e][1,4]oxazepin-5-one (1 g) is dissolved in tetrahydrofuran (50 ml), and thereto is added meta-chloroperbenzoic acid (1 g) under ice-cooling. The mixture is stirred at room temperature for 20 hours, and partitioned by adding a saturated aqueous sodium hydrogen carbonate solution and chloroform. The organic layer is dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give 2-methanesulfinyl-9-methyl-8,9-dihydro-7H-pyrimido[4,5-e][1,4]oxazepin-5-one (765 mg). MS (m/z): 242 [M+H]⁺.

(3) (2R,4S)-4-Amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (931 mg) is dissolved in 1,4-dioxane (30 ml), and thereto are added diisopropylethylamine (2.7 ml) and 2-methanesulfinyl-9-methyl-8,9-dihydro-7H-pyrimido[4,5-e][1,4]oxazepin-5-one (750 mg). The mixture is heated at 80°C and stirred for 19 hours. The reaction solution is cooled to room temperature and partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is washed with hexane:ethyl acetate to give a crude material (1.13 g) of (2R,4S)-2-ethyl-6-methoxy-4-(9-methyl-5-oxo-5,7,8,9-tetrahydropyrimido[4,5-e][1,4]oxazepin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester. MS (m/z): 457 [M+H]⁺.

(4) The crude material (500 mg) of (2R,4S)-2-Ethyl-6-methoxy-4-(9-methyl-5-oxo-5,7,8,9-tetrahydropyrimido[4,5-e][1,4]oxazepin-2-yl)amino-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in N,N-dimethylformamide (10 ml), and thereto is added sodium

hydride (62.7%, 46 mg) under ice-cooling. The mixture is stirred for 10 minutes, and then thereto is added 3,5-bis(trifluoro)benzyl bromide (0.3 ml). The mixture is stirred at room temperature for 15 hours. The reaction solution is partitioned by adding water and diethyl ether under ice-cooling. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 1:1→1:4) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)-benzyl]-(9-methyl-5-oxo-5,7,8,9-tetrahydropyrimido[4,5-e][1,4]oxazepin-2-yl)]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (331.3 mg). MS (m/z): 683 [M+H]⁺.

EXAMPLE 398



A corresponding starting compound is treated in a similar manner to Example 36 to give the compound of Example 398. MS (m/z): 701 [M+H]⁺

EXAMPLE 399

(1) 5-Bromo-2,4-dichloropyrimidine (500 mg) is dissolved in tetrahydrofuran (10 ml), and thereto is added sodium hydride (62.7%, 92.2 mg) under ice-cooling. The mixture is stirred for 10 minutes, and thereto are added benzyl alcohol (236.8 mg) and a few drops of N,N-dimethylformamide. The mixture is stirred at room temperature for 21 hours, and heated at 80°C and stirred for 3.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and diethyl


ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) and the eluent is dried under reduced pressure, then the residue is dissolved in 1,4-dioxane (10 ml), and thereto are added (2R,4S)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) and diisopropylethylamine (0.52 ml). The mixture is heated at 80°C and stirred for 4 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) and the eluent is dried under reduced pressure, then the residue is dissolved in acetonitrile (6 ml), and thereto is added sodium hydride (62.7%, 23 mg) under ice-cooling. The mixture is stirred for 10 minutes, and then thereto is added 3,5-bis(trifluoro)benzyl bromide (0.15 ml). The mixture is stirred at room temperature for 14.5 hours. The reaction solution is partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→4:1) to give (2R,4S)-4-((4-benzyloxy-5-bromopyrimidin-2-yl)-[3,5-bis(trifluoromethyl)benzyl])-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (45 mg). MS (m/z): 768/770 [M+H]⁺.

(2) (2R,4S)-4-((4-Benzyloxy-5-bromopyrimidin-2-yl)-[3,5-bis-(trifluoromethyl)benzyl])amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (40 mg) is dissolved in toluene (1 ml), and thereto are added morpholine (10.6 µl), tris-(dibenzylideneacetone)dipalladium (11.0 mg), 2-(di-tert-butylphosphino)-

biphenyl (14.3 mg) and sodium tert-butoxide (11.6 mg). The mixture is stirred at room temperature for 30 minutes under nitrogen, then heated at 80°C and stirred for 7 hours. The reaction solution is cooled to room temperature, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by NH-column chromatography (silica gel; hexane:ethyl acetate = 9:1→3:1) to give (2R,4S)-4-[[4-benzyloxy-5-(morpholin-4-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (12.6 mg). MS (m/z): 775 [M+H]⁺.

(3) (2R,4S)-4-[[4-Benzyloxy-5-(morpholin-4-yl)pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (10 mg) is dissolved in a solution (1 ml) of tetrahydrofuran:methanol = 1:1 mixture, and thereto is added 10% palladium-carbon (5 mg). The mixture is stirred at room temperature for 18 hours under hydrogen. The reaction solution is filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[4-hydroxy-5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (8.3 mg). MS (m/z): 685 [M+H]⁺.

EXAMPLE 400



A corresponding starting compound is treated in a similar manner to Example 322 to give the compound of Example 400. MS (m/z): 672 [M+H]⁺
EXAMPLE 401

5 (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)-4-hydroxypyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (155 mg) is dissolved in tetrahydrofuran (2.5 ml), and thereto are added triethylamine (192 μ l) and ethyl chlorocarbonate (132 μ l) under ice-cooling. The mixture is stirred at
10 room temperature for 1.5 hours, and then thereto is added sodium borohydride (87.3 mg) under ice-cooling. The mixture is stirred at room temperature for 2 hours. The reaction solution is partitioned by adding water and methylene chloride under ice-cooling. The organic layer is washed with 1N HCl and saturated brine, then dried over magnesium
15 sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0 \rightarrow 19:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[4-ethoxycarbonyloxy-5-(3-hydroxypropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester
20 (59 mg). MS (m/z): 730 [M+H]⁺.

(2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[4-ethoxycarbonyloxy-5-(3-hydroxypropyl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (50 mg) is dissolved in ethanol (1 ml), and thereto is added 5N aqueous NaOH solution (1 ml). The

mixture is stirred at room temperature for 2 hours. The reaction solution is partitioned by adding 6N HCl under ice-cooling and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 7:3→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[4-hydroxy-5-(3-hydroxypropyl)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (24 mg). MS (m/z): 658 [M+H]⁺.

EXAMPLE 402


- (1) (2R,4S)-4-[[4-benzyloxy-5-bromopyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (300 mg) is dissolved in toluene (2 ml), and thereto are added 2-methylaminoethanol (73 μ l), tris(dibenzylideneacetone)dipalladium (82 mg), 2-(di-tert-butylphosphino)-biphenyl (107 mg) and sodium tert-butoxide (109 mg). The mixture is stirred at room temperature for 30 minutes under nitrogen, then heated at 80°C and stirred for 17.5 hours. The reaction solution is cooled to room temperature, and thereto are added water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→1:1) to give a crude material (130 mg) of (2R,4S)-4-[[4-benzyloxy-pyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester. MS (m/z): 690 [M+H]⁺.
- (2) The crude material (120 mg) of (2R,4S)-4-[[4-benzyloxypyrimidin-2-yl]-[3,5-bis(trifluoromethyl)benzyl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester is dissolved in a solution (10 ml) of tetrahydrofuran:methanol = 1:1 mixture, and thereto is added 10% palladium-carbon (60 mg). The mixture is stirred at room

temperature for 34.5 hours under hydrogen. The reaction solution is filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)-benzyl}-(4-hydroxypyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (72.4 mg). MS (m/z): 600 [M+H]⁺.

EXAMPLE 403


(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-(4-hydroxypyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (85 mg) is dissolved in acetone (3 ml), and thereto are added potassium carbonate (98.1 mg) and para-toluenesulfonyl chloride (32.4 mg). The mixture is stirred at room temperature for 2 hours. The reaction solution is concentrated under reduced pressure, and partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is dissolved in 1,4-dioxane (3 ml), and thereto are added diisopropylethylamine (0.5 ml) and (2-methoxyethyl)methylamine (15.15 mg). The mixture is heated at 50°C and stirred for 3 hours, then heated at 100°C and stirred for 16.5 hours. The reaction solution is cooled to room temperature, and partitioned by adding 1N HCl and diethyl ether. The organic layer is washed with water and saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 9:1→7:3) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-(4-[(2-methoxyethyl)methylamino]pyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (68 mg). MS (m/z): 671 [M+H]⁺.

EXAMPLE 404



A corresponding starting compound is treated in a similar manner to Example 403 to give the compound of Example 404. MS (m/z): 741 [M+H]⁺


EXAMPLE 405



5


A corresponding starting compound is treated in a similar manner to Example 242 (2) to give the compound of Example 405. MS (m/z): 685 [M+H]⁺

EXAMPLE 406



A corresponding starting compound is treated in a similar manner to Example 270 to give the compound of Example 406. MS (m/z): 686 [M+H]⁺

EXAMPLE 407



5

A corresponding starting compound is treated in a similar manner to Example 93 to give the compound of Example 407. MS (m/z): 674 [M+H]⁺

EXAMPLE 408


- (1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl)]-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (10 g) is dissolved in toluene (50 ml), and thereto are added tris(dibenzylideneacetone)dipalladium (1.4 g), 2-(di-tert-butylphosphino)-biphenyl (901 mg), sodium tert-butoxide (3.1 g) and morpholine (2.6 ml). The mixture is stirred at room temperature for 16 hours. The reaction solution is partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate =
- 10
- 15

4:1→1:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (9.84 g). MS (m/z): 669 [M+H]⁺.

- 5 (2) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (2.5 g) is dissolved in tetrahydrofuran:ethanol (1:1, 20 ml), and thereto is added sodium hydroxide (1.5 g). The mixture is stirred at 85°C for 16 hours. The
10 reaction solution is cooled to room temperature, and then partitioned by adding water and diethyl ether. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane:ethyl acetate = 9:1→7:3) to give
15 (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (1.45 g). MS (m/z): 597 [M+H]⁺.
- (3) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-
20 [1,5]naphthyridine (160 mg) is dissolved in dichloromethane (1.5 ml), and thereto are added triethylamine (93 µl) and triphosgene (62 mg). The mixture is stirred at room temperature for 30 minutes. The reaction solution is concentrated under reduced pressure, and thereto is added diethyl ether. The insoluble materials are removed by filtration and the
25 filtrate is concentrated under reduced pressure. The resulting residue is dissolved in tetrahydrofuran (1.5 ml), and thereto are added 60% sodium hydride (32 mg) and 2,2-difluoro-3-hydroxy-propionic acid ethyl ester (123 mg) under ice-cooling. The mixture is stirred at room temperature for 1.5 hours. The reaction solution is partitioned by adding water and diethyl
30 ether. The organic layer is washed with saturated brine, then dried over

magnesium sulfate and concentrated under reduced pressure. The resulting crude product is dissolved in tetrahydrofuran:methanol (1:1, 3 ml), and thereto is added 2N aqueous NaOH solution (0.5 ml). The mixture is stirred at room temperature for 1 hour. To the reaction solution is added 1N-HCl (1.0 ml). The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2,2-difluoroethyl ester (150 mg). MS (m/z): 749 [M+H]⁺.

EXAMPLE 409



A corresponding starting compound is treated in a similar manner to Example 408 to give the compound of Example 409. MS (m/z): 741 [M+H]⁺

EXAMPLE 410

(1) (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine (290 mg) is dissolved in dichloromethane (1.5 ml), and thereto are added triethylamine (203 ml) and triphosgene (145 mg). The mixture is stirred at room temperature for 15 minutes. The reaction solution is concentrated under reduced pressure, and then the insoluble materials are removed by filtration using tetrahydrofuran and the filtrate is

concentrated under reduced pressure. The resulting residue is dissolved in tetrahydrofuran (1.5 ml), and thereto are added 60% sodium hydride (20 mg) and 3-hydroxy-propionic acid tert-butyl ester (72 ml) under ice-cooling. The mixture is stirred at room temperature for 1.5 hours. The reaction solution is partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1→1:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-tert-butoxycarbonyl ethyl ester (180 mg). MS (m/z): 769 [M+H]⁺.

(2) To (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-tert-butoxycarbonyl ethyl ester (165 mg) is added 4N HCl-ethyl acetate solution (2 mL), and the mixture is stirred for 1.5 hours. The reaction solution is concentrated and the resulting residue is partitioned by adding water and ethyl acetate. The organic layer is washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; chloroform:methanol = 1:0→9:1) to give (2R,4S)-4-{{3,5-bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester (145 mg). MS (m/z): 713 [M+H]⁺.

REFERENCE EXAMPLE 1

2-(Benzyloxy)ethanol (0.75 ml) is dissolved in N,N-dimethylformamide (3 ml), and added dropwise to a solution of sodium hydride (400 mg) in N,N-dimethylformamide under ice-cooling. The mixture is stirred for 40 minutes. To the reaction solution is added

chloroacetic acid (500 mg) under ice-cooling, and the mixture is stirred at room temperature for 1 day. To the reaction solution is added ice-water, and the mixture is extracted with ethyl acetate. To the aqueous layer is added 6N HCl, and the solution is adjusted to pH 2 and extracted with
5 ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure to give 2-(benzyloxy)ethoxy acetic acid (895 mg). MS (m/z): 211 [M+H]⁺.

REFERENCE EXAMPLE 2

(1) 5-Bromo-2-chloropyrimidine (5 g) is dissolved in 1,4-dioxane (100
10 ml), and thereto are added diisopropylethylamine (0.81 ml) and morpholine (4.5 ml). The mixture is heated at 60°C under nitrogen flow and stirred for 4 hours. To the mixture is added distilled water, and the mixture is extracted with ether. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure.
15 The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 19:1→9:1) to give 4-(5-bromopyrimidin-2-yl)morpholine (6.74 g). MS (m/z): 244/246 [M+H]⁺.

(2) 4-(5-Bromopyrimidin-2-yl)morpholine (3 g) is dissolved in 1,4-dioxane (60 ml), and thereto are added copper iodide (700 mg), sodium
20 iodide (22 g), N,N'-dimethylethan-1,2-diamine (0.8 ml). The mixture is heated at 110°C and stirred for 6 days. To the mixture is added distilled water, and the mixture is extracted with ether. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by
25 column chromatography (silica gel), eluted with hexane:ethyl acetate (19:1→7:3) as an elution solvent, to give 4-(5-iodopyrimidin-2-yl)-morpholine (2.33 g). MS (m/z): 292 [M+H]⁺.

REFERENCE EXAMPLE 3

(S)-1-Phenylethyl alcohol (1.0 g) and 1,1'-carbonyldiimidazole (1.33
30 g) are dissolved in tetrahydrofuran (20 ml), and the mixture is stirred at

80°C for 2 hours. To the reaction solution are added (2R*,4S*)-4-amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (1.91 g) and triethylamine (1.14 ml), and the mixture is heated to reflux for 3 days. The reaction solution is partitioned by adding ethyl acetate and a saturated aqueous sodium bicarbonate solution, and then the organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 90:10→70:30). The resulting mixture of diastereomers is recrystallized from hexane to give (2R,4S)-2-ethyl-6-methoxy-4-((S)-1-phenylethoxycarbonylamino)-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (345 mg). The physical property data are the same as the compound obtained in Example 2 (3).

REFERENCE EXAMPLE 4

- (1) To an aqueous solution (1000 ml) of sodium azide (157.6 g) is added dropwise a solution (605 ml) of acrylyl chloride (182.4 ml) in toluene under ice-cooling. The mixture is stirred at the same temperature for 3 hours. To the mixture is added a saturated aqueous sodium bicarbonate solution, and the organic layer is washed with saturated brine and dried over magnesium sulfate. The resulting solution in toluene is added dropwise into a mixture of (S)-1-phenylethyl alcohol (268 ml), pyridine (81.5 ml) and hydroquinone (12.21 g) which is warmed to 85°C, and the mixture is stirred at the same temperature for 2 hours. To the mixture is added a saturated aqueous sodium bicarbonate solution, and the organic layer is washed with saturated brine and dried over sodium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 10:1→8:1) to give vinylcarbamic acid (S)-1-phenylethyl ester (240.2 g). MS (m/z): 191 [M]⁺.
- (2) {[1-(Benzotriazol-1-yl)propyl]-(6-methoxypyridin-3-yl)}amine (218 g),

vinylcarbamic acid (S)-1-phenylethyl ester (147.1 g) and p-toluenesulfonic acid monohydrate (1.47 g) are dissolved in toluene (2.88 l), and the mixture is stirred overnight at 85°C. After the mixture is allowed to stand for cooling to room temperature, to the mixture are added a saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer is washed with saturated brine and dried over magnesium sulfate, then concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 3:1→1:1). To the resulting mixture of diastereomers is added hexane-ethyl acetate (4:1). The mixture is allowed to stand and the precipitated crystals are collected by filtration to give (2S,4R)-(2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)carbamic acid (S)-1-phenylethyl ester (69.0 g). MS (m/z): 356 [M+H]⁺.

The filtrate is concentrated under reduced pressure to use in the following process (3).

(3) The concentrate (194.7 g) obtained in (2) described above and pyridine (183 ml) are dissolved in methylene chloride (1.65 l). To the mixture is added dropwise a solution (540 ml) of ethyl chloroformate (180 ml) in methylene chloride under ice-cooling, and the mixture is stirred at the same temperature for 2 hours. The reaction solution is washed with 10% aqueous citric acid solution and saturated brine, then dried over sodium sulfate and concentrated under reduced pressure. The resulting residue is purified by column chromatography (silica gel; hexane:ethyl acetate = 4:1), and the resulting compound is recrystallized from hexane (350 ml) to give (2R,4S)-2-ethyl-6-methoxy-4-((S)-1-phenylethoxy-carbonylamino)-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (133 g). The physical property data are the same as the compound obtained in Example 2 (3).

REFERENCE EXAMPLE 5

tert-Butyl acrylate (4.4 ml) is dissolved in methanol (5 ml), and


thereto is added 2-methoxyethylamine (3.1 ml). The mixture is stirred at room temperature for 3 hours. The reaction solution is concentrated under reduced pressure. The resulting residue is purified by distillation under reduced pressure to give tert-butyl 3-(2-methoxyethylamino)-
5 propionate (4.61 g). Boiling point 98.0-102.0°C (5.8 mmHg), MS (m/z): 204 [M+H]⁺.

REFERENCE EXAMPLE 6

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-(5-bromopyrimidin-2-yl))-
amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic
10 acid ethyl ester (8.0 g), [1,1'-bis(diphenylphosphino)ferrocene]-
dichloropalladium (265 mg), potassium acetate (3.56 g) and bis(pinacolato)-
diboron (4.6 g) are dissolved in dimethylsulfoxide (50 ml), and the mixture
is heated at 80°C under nitrogen and stirred for 1 hour. After the reaction
solution is cooled to room temperature, the mixture is partitioned by
15 adding water and ethyl acetate. The organic layer is washed with
saturated brine and dried over magnesium sulfate, then concentrated
under reduced pressure. The resulting residue is dissolved in
tetrahydrofuran (80 ml), and thereto is added dropwise 30% hydrogen
peroxide solution (80 ml) under ice-cooling. After 1 hour, to the mixture is
20 added a saturated aqueous sodium thiosulfate solution under ice-cooling
to decompose excessive hydrogen peroxide. The mixture is partitioned by
adding water and ethyl acetate. The organic layer is washed with
saturated brine and dried over magnesium sulfate, then concentrated
under reduced pressure. The resulting residue is purified by column
25 chromatography (silica gel; hexane:ethyl acetate = 19:1→3:1) to give
(2R,4S)-4-([3,5-bis(trifluoromethyl)benzyl]-(5-hydroxypyrimidin-2-yl))amino-
2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid
ethyl ester (4.41 g). The physical property data are the same as the
compound obtained in Example 83.

CLAIMS

1. A compound of the formula (I):



wherein R¹ is a hydrogen atom, an optionally substituted alkoxy carbonyl group, an optionally substituted carbamoyl group, an optionally substituted alkyl group, an optionally substituted alkanoyl group, a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted), or a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted);

R² is a hydrogen atom or an optionally substituted alkyl group;

R³ is a hydrogen atom or an optionally substituted alkyl group;

R⁴ is an optionally substituted alkylene group;

R⁵ is a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, said heterocyclic group being optionally substituted, R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a cyano group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkylsulfonyloxy group, an optionally substituted mono- or dialkylcarbamoyl group or an optionally substituted amino group; or

R⁶ and R⁷, or R⁷ and R⁸ may combine at the ends to form an alkylene group which alkylene group optionally contains 1 to 3 heteroatoms selected independently from nitrogen, sulfur and oxygen atoms, and may have a substituent(s); and

- 5 R¹⁰ is an aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the aromatic ring is optionally substituted), or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R⁵ is a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4
10 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, wherein the heterocyclic group is optionally substituted by 1 to 5 substituents selected from the following group:

halogen atom, oxo group, hydroxy group, cyano group, nitro group, carboxyl group, sulfo group, optionally substituted alkyl group,
15 optionally substituted cycloalkyl group, optionally substituted alkenyl group, optionally substituted alkoxy group, optionally substituted cycloalkoxy group, optionally substituted alkoxycarbonyl group, carbamoyl group, optionally substituted mono- or di-alkylcarbamoyl group, optionally substituted carbamimidoyl group, optionally
20 substituted alkylthio group, optionally substituted alkylsulfinyl group, optionally substituted alkylsulfonyl group, amino group, optionally substituted mono- or di-alkylamino group, optionally substituted alkanoylamino group, optionally substituted alkoxycarbonylamino group, optionally substituted alkylsulfonylamino group, optionally
25 substituted mono- or di-alkylcarbamoylamino group, a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonylamino group is optionally substituted), sulfamoyl group, optionally substituted mono-
30 or di-alkyl sulfamoyl group, optionally substituted alkanoyl group, a

saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted), a saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic oxy group is optionally substituted), and a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonyl group is optionally substituted); and


R¹⁰ is an aromatic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, which aromatic ring is optionally substituted by 1 to 4 substituents selected from the following groups: halogen atom, carboxyl group, optionally substituted alkoxy carbonyl group, carbamoyl group, optionally substituted mono- or di-alkylcarbamoyl group, optionally substituted alkyl group, optionally substituted alkoxy group, hydroxy group, nitro group, cyano group, amino group, optionally substituted mono- or di-alkylamino group, optionally substituted alkanoyl group, optionally substituted alkylthio group, and a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted).

3. The compound of claim 2, wherein the substituent(s) for substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted alkenyl group, optionally substituted alkoxy group, optionally substituted cycloalkoxy group, optionally substituted alkoxy carbonyl group, optionally substituted mono- or di-alkylcarbamoyl group, optionally substituted alkylthio group, optionally substituted alkylsulfinyl group, optionally substituted alkylsulfonyl group, optionally substituted mono- or

di-alkylamino group, optionally substituted alkanoylamino group, optionally substituted alkoxycarbonylamino group, optionally substituted alkylsulfonylamino group, optionally substituted mono- or di-alkylcarbonylamino group, optionally substituted mono- or di-alkylsulfamoyl group, optionally substituted alkanoyl group, optionally substituted alkylene group, a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonylamino group is optionally substituted), a saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic group is optionally substituted), a saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic oxy group is optionally substituted), and a saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms (the heterocyclic carbonyl group is optionally substituted) may be 1-5 groups selected from the following groups:

halogen atom; cyano group; hydroxy group; nitro group; carboxyl group; oxo group; thioxo group; sulfo group; cycloalkyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkoxycarbonyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; carbamoyl group; mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkyl group optionally substituted by hydroxy

group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkanoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkoxy group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkanoyloxy group optionally substituted by halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylthio group optionally substituted by halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylsulfonyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; alkylsulfinyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; mono- or di-alkylsulfamoyl group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; amino group; mono- or di-alkylamino group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; mono- or di-alkylsulfamoylamino group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; mono- or di-alkylureido group optionally substituted by hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, mono- or di-alkylamino group, phenyl group or morpholinyl group; and a group of the formula:



wherein X^1 and X^3 are independently CH_2 , NH , O , S , SO or SO_2 ; X^2 and X^5 are independently CH_2 , O , S , SO or SO_2 ; X^4 is NH , O , S , SO or SO_2 ; X^6 and X^7 are independently O or S ; X^8 is S , CO or SO ; and n , o , p , q and r are independently an integer of 1 to 4, wherein each group of the above formula is optionally substituted by 1 to 3 substituents selected from the following groups:

halogen atom, carboxyl group, hydroxy group, cyano group, oxo group, thioxo group, alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkyl group substituted by halogen, morpholinylalkyl group, phenylalkyl group, alkanoyl group, hydroxyalkanoyl group, alkoxyalkanoyl group, alkoxy group, phenylalkoxy group, alkoxycarbonyl group, benzyloxycarbonyl group, mono- or di-alkylamino group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group and tetrazolyl group.

4. The compound of claim 3, wherein the "aromatic ring optionally containing 1 to 3 heteroatoms selected independently from

oxygen, sulfur and nitrogen atoms" is a phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, furyl, pyrimidinyl, triazolyl or thienyl group;

the "saturated or unsaturated monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur

5 and nitrogen atoms" is a morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, hexahydroazepinyl, pyrrolinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolanyl, oxiranyl, pyrimidinyl, pyridyl, triazolyl, tetrazolyl, oxadiazolyl, dihydropyrimidinyl, pyrazinyl, thiazolyl, oxazolinyl, oxazolyl, pyridazinyl, imidazolinyl, imidazolyl, pyrazinyl, thienyl, pyrrolyl, furyl or dihydrooxazinyl group;

the "saturated or unsaturated monocyclic or bicyclic heterocyclic oxy group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a morpholinylloxy, thiomorpholinylloxy, piperazinylloxy, pyrrolidinylloxy, piperidinylloxy, hexahydroazepinylloxy, pyrrolinylloxy, imidazolidinylloxy, oxazolidinylloxy, tetrahydropyranylloxy, tetrahydrofuranylloxy, dioxolanylloxy, oxiranylloxy, pyrimidinylloxy, pyridylloxy, triazolylloxy, tetrazolylloxy, oxadiazolylloxy, dihydropyrimidinylloxy, pyrazinylloxy, thiazolylloxy, oxazolinylloxy, oxazolylloxy, pyridazinylloxy, imidazolinylloxy, imidazolylloxy, pyrazinylloxy, thienylloxy, pyrrolyloxy, furyloxy or dihydrooxazinylloxy group;

the "saturated or unsaturated monocyclic or bicyclic heterocyclic carbonyl group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a morpholinylcarbonyl, thiomorpholinylcarbonyl, piperazinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, hexahydroazepinylcarbonyl, pyrrolinylcarbonyl, imidazolidinylcarbonyl, oxazolidinylcarbonyl, tetrahydropyranylcarbonyl, tetrahydrofuranylcarbonyl, dioxolanylcarbonyl, oxiranylcarbonyl, pyrimidinylcarbonyl, pyridylcarbonyl, triazolylcarbonyl, tetrazolylcarbonyl, oxadiazolylcarbonyl, dihydropyrimidinylcarbonyl, pyrazinylcarbonyl, thiazolylcarbonyl, oxazolinylcarbonyl, oxazolylcarbonyl, pyridazinyl-

30

carbonyl, imidazolinyldicarbonyl, imidazolylcarbonyl, pyrazinyldicarbonyl, thienyldicarbonyl, pyrrolyldicarbonyl, furyldicarbonyl or dihydrooxazinyldicarbonyl group; and

the "saturated or unsaturated monocyclic or bicyclic heterocyclic carbonylamino group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a morpholinylcarbonylamino, 5 thiomorpholinylcarbonylamino piperazinylcarbonylamino, pyrrolidinylcarbonylamino, piperidinylcarbonylamino, hexahydroazepinyldicarbonylamino, pyrrolinyldicarbonylamino, imidazolidinyldicarbonylamino, 10 oxazolidinyldicarbonylamino, tetrahydropyranyldicarbonylamino, tetrahydrofuranlyldicarbonylamino, dioxolanyldicarbonylamino, oxiranyldicarbonylamino, pyrimidinylcarbonylamino, pyridyldicarbonylamino, triazolylcarbonylamino, tetrazolylcarbonylamino, oxadiazolylcarbonylamino, dihydropyrimidinylcarbonylamino, pyrazinyldicarbonylamino, thiazolylcarbonylamino, 15 oxazolinyldicarbonylamino, oxazolylcarbonylamino, pyridazinylcarbonylamino, imidazolinyldicarbonylamino, imidazolylcarbonylamino, pyrazinyldicarbonylamino, thienyldicarbonylamino, pyrrolyldicarbonylamino, furyldicarbonylamino or dihydrooxazinyldicarbonylamino group.

5. The compound of claim 1, wherein R¹ is a hydrogen atom; an 20 alkoxyldicarbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxyldicarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl 25 group, alkoxyldicarbonyl group, carboxyalkoxy group and alkoxyldicarbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents 30 selected independently from carboxyl group and alkoxyldicarbonyl group),

alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, hydroxy group and halogen atom), halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), morpholinyl group optionally substituted by oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), and pyrimidinyl group (said pyrimidinyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group); a carbamoyl group optionally substituted by alkoxy group; a dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxy carbonyl group, alkyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl

group; a dihydroimidazolyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, alkyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl group; a dihydrooxazinyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, alkyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl group; mono- or di-alkyl carbamoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, halogen atom, amino group and hydroxy group); an alkyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, halogen atom, amino group and hydroxy group); an alkanoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected

- independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group); a morpholinylcarbonyl group; a piperazinylcarbonyl group optionally substituted by alkyl group, carboxyalkyl group or alkoxycarbonylalkyl group;
- a pyrrolidinylcarbonyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group; or a piperidinylcarbonyl group optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group;
- R⁵ is a saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms; wherein said heterocyclic group is optionally substituted by 1 to 4 substituents selected from the following groups:
- halogen atom
 - oxo group;
 - hydroxy group;
 - cyano group;
 - nitro group;
 - carboxyl group;
 - sulfo group;
 - alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl, cycloalkyl group optionally substituted by carboxyl or alkoxycarbonyl group, phenyl group (said phenyl group is optionally substituted by alkoxy, carboxyl or alkoxycarbonyl group), sulfo group, sulfamoyl group, mono- or di-alkylcarbamoyl group, alkoxy group (said

alkoxy group is optionally substituted by carboxyl, alkoxycarbonyl, hydroxy, alkoxy or phenyl group), alkanoyl group, alkanoyloxy group, alkylthio group, alkylsulfonyl group, alkylsulfinyl group, amino group, mono- or di-alkylamino group optionally substituted by alkoxy group, 5 mono- or di-alkylsulfamoylamino group, mono- or di-alkylureido group optionally substituted by morpholinyl group, oxiranyl group, dioxolanyl group optionally substituted by alkyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by oxo, alkoxycarbonyl or carboxyl group), piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group 10 optionally substituted by alkyl group, hexahydroazepinyl group optionally substituted by carboxyl or alkoxycarbonyl group, morpholinyl group, and piperidinyloxy group optionally substituted by alkyl group;

15 alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, benzyloxycarbonyl group and tetrazolyl group;

alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl 20 group, carbamoyl group, cycloalkyl group optionally substituted by carboxyl or alkoxycarbonyl group, phenyl group (said phenyl group is optionally substituted by alkoxy, carboxyl or alkoxycarbonyl group), sulfo group, sulfamoyl group, alkoxy group (said alkoxy group is optionally substituted by carboxyl, alkoxycarbonyl, hydroxy, alkoxy or 25 phenyl group), alkanoyl group, alkanoyloxy group, alkylthio group, alkylsulfonyl group, alkylsulfinyl group, amino group, mono- or di-alkylamino group substituted by alkoxy group, mono- or di-alkylsulfamoylamino group, mono- or di-alkylureido group optionally substituted by morpholinyl group, oxiranyl group, dioxolanyl group 30 optionally substituted by alkyl group, pyrrolidinyl group (said

pyrrolidinyl group is optionally substituted by oxo, alkoxycarbonyl or carboxyl group), piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group, hexahydroazepinyl group optionally substituted by carboxyl or
5 alkoxycarbonyl group, morpholinyl group, piperidinyl group optionally substituted by alkyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, pyrimidinyl group, pyridyl group and morpholinylcarbonyl group;
alkoxycarbonyl group optionally substituted by hydroxy group,
10 carboxyl group, alkoxycarbonyl group or phenyl group;
carbamoyl group;
mono- or di-alkylcarbamoyl group optionally substituted by a group selected from carboxyl group, morpholinyl group, hydroxy group and alkoxy group;
15 hydroxycarbamoyl group;
alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group;
alkylsulfinyl group;
alkylsulfonyl group optionally substituted by a group selected from
20 hydroxy group, carboxyl group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group;
amino group;
mono- or di-alkylamino group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;
25 mono- or di-alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group, alkoxycarbonyl group and amino group;
mono- or di-alkylcarbamoylamino group optionally substituted by
30 alkoxy group;

morpholinylcarbonylamino group;




sulfamoyl group;

mono- or di-alkylsulfamoyl group;

5 alkanoyl group optionally substituted by a group selected from hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;

alkoxycarbonylamino group optionally substituted by carboxyl group, hydroxy group, or alkoxy carbonyl group; or

a group selected from the following groups:



10

wherein X^1 and X^3 are independently CH_2 , NH , O , S , SO or SO_2 ; X^2 and X^5 are independently CH_2 , O , S , SO or SO_2 ; X^4 is NH , O , S , SO or SO_2 ; and n , o , p , q and r are independently an integer of 1 to 4, wherein

15 each group of the above formula is optionally substituted by a substituent(s) selected from the following groups:

carboxyl group, halogen atom, hydroxy group, cyano group, oxo group, alkyl group, hydroxyalkyl group, alkoxy carbonylalkyl group, carboxyalkyl group, morpholinylalkyl group, phenylalkyl group,

20 alkanoyl group, hydroxyalkanoyl group, alkoxyalkanoyl group, alkoxy group, phenylalkoxy group, alkoxy carbonyl group, benzyloxycarbonyl group, mono- or di-alkylamino group, mono- or di-alkylcarbamoyl

group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, dihydrooxadiazolyl group optionally substituted by oxo group, and tetrazolyl group;

5 R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a cyano group, an alkyl group, an alkoxy group, an alkoxycarbonyl group, a benzyloxycarbonyl group, a mono- or di-alkylcarbamoyl group or a mono- or di-alkylamino group, wherein said alkyl, alkoxy, alkoxycarbonyl, benzyloxycarbonyl, mono- or di-alkylcarbamoyl and mono- or di-alkylamino groups are optionally
10 substituted by 1 to 6 substituents selected independently from halogen atom, hydroxy group, alkoxy group, alkylthio group, amino group, nitro group, cyano group, oxo group, carboxyl group, alkoxycarbonyl group and mono- or di-alkylamino group; or

R⁶ and R⁷, or R⁷ and R⁸ may combine at the ends to form an alkylene group
15 which alkylene group optionally contains 1 to 3 heteroatoms selected independently from nitrogen, sulfur and oxygen atoms;

R¹⁰ is an aromatic monocyclic ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms;

wherein the monocyclic aromatic ring is optionally substituted by 1 to
20 4 substituents selected independently from halogen atom, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group, alkyl group, alkoxy group, hydroxy group, nitro group, cyano group, amino group, mono- or di-alkylamino group, alkanoyl group, alkylthio group, tetrazolyl group and dihydrooxazolyl
25 group, wherein the alkyl, alkoxy, mono- or di-alkylamino, mono- or di-alkylcarbamoyl, alkanoyl and alkylthio groups are optionally substituted by a substituent(s) selected independently from halogen atom, and hydroxy, alkoxy, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, alkylpiperazinyl and alkanoylpiperazinyl groups.

30 6. The compound of claim 5, wherein the "aromatic monocyclic

ring optionally containing 1 to 3 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a phenyl group, a pyridyl group, a pyrimidinyl group, a furyl group or a thienyl group; and the "saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms" is a pyrimidinyl group, a pyridyl group, a triazolyl group, a tetrazolyl group, a oxadiazolyl group, a dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an oxazolyl group, an imidazolyl group, a dihydrooxazinyl group, a dihydropyrazinyl group or a pyrazolyl group.

- 10 7. The compound of claim 6, wherein R¹ is a hydrogen atom; an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group and alkoxycarbonyl group), alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, hydroxy group and halogen atom), halogen atom, 25 cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected
- 30

independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), morpholinyl group optionally substituted by
5 oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group),
10 pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), and
15 pyrimidinyl group (said pyrimidinyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group); dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl
20 group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; or a mono- or di-alkylcarbamoyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl
25 group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom,
30 amino group and hydroxy group);

R² is an alkyl group;

R³ is a hydrogen atom;

R⁴ is an alkylene group;

R⁵ is a heterocyclic group selected from a pyrimidinyl group, pyridyl group,
5 triazolyl group, tetrazolyl group, oxadiazolyl group, dihydropyrimidinyl
group, pyrazinyl group, thiazolyl group, oxazolyl group, imidazolyl group,
dihydrooxazinyl group, pyrazolyl group and dihydropyrazinyl group,
wherein said heterocyclic group is substituted by 1 to 4 substituents
selected from the following groups:

10 halogen atom,
hydroxy group;
oxo group;
cyano group;
carboxyl group;

15 sulfo group;
alkyl group optionally substituted by a group selected from halogen
atom, cyano group, hydroxy group, carboxyl group, alkoxy group
optionally substituted by hydroxy or alkoxy group, alkoxycarbonyl
group, mono- or di-alkylcarbonyl group, mono- or di-alkylamino
20 group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl
group optionally substituted by carboxyl or alkoxycarbonyl group,
piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl
group, piperazinyl group optionally substituted by alkyl group,
morpholinyl group, alkanoyloxy group and alkylsulfonyl group;

25 alkenyl group optionally substituted by a group selected from cyano
group, hydroxy group, carboxyl group, alkoxycarbonyl group,
benzyloxycarbonyl group, and tetrazolyl group;
alkoxy group optionally substituted by a group selected from halogen
atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl
30 group, carbonyl group, mono- or di-alkylcarbonyl group optionally

- substituted by hydroxy group, alkoxy group (said alkoxy group is optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group optionally substituted by carboxyl or alkoxy group, morpholinyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group optionally substituted by carboxyl or alkoxy group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group, and morpholinylcarbonyl group;
- 5
- 10 cycloalkyl group optionally substituted by carboxyl group or alkoxy carbonyl group;
alkoxy carbonyl group optionally substituted by phenyl group;
carbamoyl group;
mono- or di-alkylcarbamoyl group optionally substituted by a group
- 15 selected from morpholinyl group, carboxyl group, hydroxy group and alkoxy group;
hydroxycarbamimidoyl group;
alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group;
- 20 alkylsulfonyl group optionally substituted by a group selected from hydroxy group, alkoxy carbonyl group and mono- or di-alkylcarbamoyl group;
amino group;
mono- or di-alkylamino group optionally substituted by a group
- 25 selected from hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;
alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
mono- or di-alkylureido group optionally substituted by alkoxy group;
- 30 morpholinylcarbonylamino group;

- morpholinyl group optionally substituted by a group selected from oxo group and carboxyl group;
- 5 piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxyalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group, benzyloxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, tetrazolyl group, and dihydrooxadiazolyl group optionally substituted by oxo group;
- 10 piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group optionally substituted by phenyl group, alkoxyalkyl group, oxo group and alkanoyl group;
- pyrrolidinyl group optionally substituted by a group selected from carboxyl group, alkoxyalkyl group, oxo group, and mono- or di-
- 15 alkylamino group;
- pyrrolinyl group optionally substituted by oxo group;
- hexahydrodiazepinyl group optionally substituted by alkanoyl group;
- imidazolidinyl group optionally substituted by oxo group;
- pyridyl group optionally substituted by carboxyl group, hydroxy group,
- 20 alkanoyl group, alkyl group or hydroxyalkyl group (said pyridyl group is optionally further oxidized);
- tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl group;
- dihydrooxadiazolyl group optionally substituted by oxo group;
- 25 dihydroimidazolyl group;
- dihydrooxazolyl group;
- oxazolidinyl group optionally substituted by oxo group;
- tetrahydropyridyl group optionally substituted by benzyl group;
- pyrimidinyl group;
- 30 piperidinyl group optionally substituted by alkyl group or carboxyl

group;

pyrrolidinyloxy group optionally substituted by a group selected from alkyl group, carboxyl group, alkoxycarbonyl group and alkanoyl group; tetrahydropyranyloxy group;

5 tetrahydrofuranyloxy group;

optionally oxidized thianxyloxy group;

morpholinylcarbonyl group;

piperazinylcarbonyl group optionally substituted by a group selected from alkanoyl group and alkyl group;

10 pyrrolidinylcarbonyl group optionally substituted by carboxyl group or alkoxycarbonyl group; and

piperidinylcarbonyl group optionally substituted by carboxyl group or alkoxycarbonyl group;

15 R^6 and R^7 are independently a hydrogen atom, an alkyl group optionally substituted by halogen atom, an alkoxy group optionally substituted by halogen atom, a hydroxy group, a cyano group, or a mono- or d-alkylamino group; or

R^6 and R^7 may combine at the ends to form an alkylenedioxy group;

R^8 is a hydrogen atom;

20 R^{10} is a phenyl or pyridyl group, which phenyl or pyridyl group is optionally substituted by 1 to 4 substituents selected from halogen atom, alkoxycarbonyl group, alkyl group optionally substituted by halogen atom, alkoxy group optionally substituted by halogen atom, hydroxy group, cyano group, amino group, mono- or di-alkylamino group and alkylthio group.

25 8. The compound of claim 7, wherein R^1 is an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group and
30 alkoxycarbonyl group), alkenyl group, halogen atom, cycloalkyl group (said

cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group), piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group), and pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxy carbonyl group, carboxyalkyl group and alkoxy carbonylalkyl group); or a dihydrooxazolyl group optionally substituted by 1 or 2 substituents selected independently from carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group and hydroxyalkyl group; R⁵ is a pyrimidinyl group, a pyridyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an oxazolyl group, a dihydrooxazinyl group, a pyrazolyl group or a dihydropyrazinyl group which group is substituted by 1 to 4 substituents selected from the following groups:

halogen atom;
hydroxy group;
cyano group;
carboxyl group;
alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy group optionally substituted by hydroxy or alkoxy group, alkoxy carbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl

- group optionally substituted by carboxyl or alkoxy-carbonyl group,
piperidinyl group optionally substituted by carboxyl or alkoxy-carbonyl
group, piperazinyl group optionally substituted by alkyl group,
morpholinyl group, alkanoyloxy group and alkylsulfonyl group;
5 alkenyl group optionally substituted by a group selected from cyano
group, hydroxy group and carboxyl group;
alkoxy group optionally substituted by a group selected from halogen
atom, cyano group, hydroxy group, carboxyl group, alkoxy-carbonyl
group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally
10 substituted by hydroxy group, alkoxy group (said alkoxy group is
optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio
group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino
group optionally substituted by carboxyl or alkoxy group, morpholinyl
group, pyrrolidinyl group (said pyrrolidinyl group is optionally
15 substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group
optionally substituted by carboxyl or alkoxy group, optionally oxidized
pyridyl group, dioxolanyl group optionally substituted by alkyl group,
and morpholinyl-carbonyl group;
cycloalkyl group optionally substituted by carboxyl group or
20 alkoxy-carbonyl group;
mono- or di-alkylcarbamoyl group optionally substituted by a group
selected from morpholinyl group, carboxyl group, hydroxy group and
alkoxy group;
hydroxycarbamimidoyl group;
25 alkylthio group optionally substituted by a group selected from
hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group;
amino group;
mono- or di-alkylamino group optionally substituted by a group
selected from hydroxy group, carboxyl group, alkoxy-carbonyl group,
30 alkoxy group, and morpholinyl group;

- alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
mono- or di-alkylureido group optionally substituted by alkoxy group;
morpholinylcarbonylamino group;
- 5 morpholinyl group optionally substituted by oxo group;
piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxyalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group, mono- or di-alkylcarbonyl group, mono- or di-alkylsulfamoyl group
10 and alkylsulfonyl group;
piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group, alkoxyalkyl group, oxo group and alkanoyl group;
- 15 pyrrolidinyl group optionally substituted by a group selected from oxo group, carboxyl group, alkoxyalkyl group and mono- or di-alkylamino group;
hexahydrodiazepinyl group optionally substituted by alkanoyl group;
pyridyl group optionally substituted by hydroxy group, carboxyl group,
20 alkyl group or hydroxyalkyl group (said pyridyl group is optionally further oxidized);
tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl group;
dihydrooxadiazolyl group optionally substituted by oxo group;
- 25 oxazolidinyl group optionally substituted by oxo group;
tetrahydropyridyl group optionally substituted by benzyl group;
pyrimidinyl group;
piperidinyl group optionally substituted by alkyl group or carboxyl group;
- 30 pyrrolidinyl group optionally substituted by a group selected from

alkyl group and alkanoyl group;
tetrahydropyranyloxy group;
tetrahydrofuranyloxy group; and
optionally oxidized thianlyoxy group;

5 R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is optionally substituted by 1 to 4 substituents selected from halogen atom, alkyl group optionally substituted by halogen atom, alkoxy group, hydroxy group, cyano group, amino group and mono- or di-alkylamino group.

9. The compound of claim 1, wherein R¹ is a hydrogen atom; an
10 alkoxy carbonyl group optionally substituted by 1 to 5 substituents selected independently from cyano group, hydroxy group, carboxyl group, alkoxy carbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, carboxyl
15 group, alkoxy carbonyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), alkylthio group, alkylsulfonyl group, alkenyl group, amino group, mono- or di-alkylamino group, tetrazolyl group, carbamoyl group, mono- or di-alkylcarbamoyl group (said mono- or di-alkylcarbamoyl group is optionally substituted by 1 to 3 substituents
20 selected independently from carboxyl group and alkoxy carbonyl group), alkanoylamino group (said alkanoylamino group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxy carbonyl group, hydroxy group and halogen atom), halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3
25 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxy carbonyl group, carboxyalkyl group, alkoxy carbonylalkyl group, carboxyalkoxy group and alkoxy carbonylalkoxy group), phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected
30 independently from hydroxy group, amino group, mono- or di-alkylamino


group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), morpholinyl group optionally substituted by oxo group, piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group), pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, amino group, mono- or di-alkylamino group, halogen atom, oxo group, carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group, carboxyalkoxy group and alkoxycarbonylalkoxy group), and pyrimidinyl group (said pyrimidinyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyalkyl group, alkoxycarbonylalkyl group and carboxyalkoxy group, alkoxycarbonylalkoxy group); dihydrooxazolyl group optionally substituted by 1 to 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, alkyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group; or a mono- or di-alkylcarbonyl group optionally substituted by 1 to 5 substituents selected independently from halogen atom, hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, amino group, mono- or di-alkylamino group, morpholinyl group, pyridyl group, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group) and phenyl group (said phenyl group is optionally substituted by 1 to 3 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, amino group and hydroxy group);

30 R^2 is an alkyl group;

R³ is a hydrogen atom;

R⁴ is an alkylene group;

wherein R⁵ is a group of the formula:



- 5 wherein Ring A is a saturated or unsaturated 5- to 8-membered heterocyclic group containing 1 to 4 heteroatoms selected independently from oxygen, sulfur and nitrogen atoms, and R¹¹ is a group selected from the following groups:
- halogen atom,
- 10 hydroxy group;
- oxo group;
- cyano group;
- carboxyl group;
- sulfo group;
- 15 alkyl group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxy group optionally substituted by hydroxy or alkoxy group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylamino group optionally substituted by alkoxy or carboxyl group, pyrrolidinyl group optionally substituted by carboxyl or alkoxycarbonyl group,
- 20 piperidinyl group optionally substituted by carboxyl or alkoxycarbonyl group, piperazinyl group optionally substituted by alkyl group, morpholinyl group, alkanoyloxy group and alkylsulfonyl group;
- alkenyl group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group,
- 25 benzyloxycarbonyl group and tetrazolyl group;
- alkoxy group optionally substituted by a group selected from halogen atom, cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group optionally

- substituted by hydroxy group, alkoxy group (said alkoxy group is optionally substituted by hydroxy, carboxyl or alkoxy group), alkylthio group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group optionally substituted by carboxyl or alkoxy group, morpholinyl group, pyrrolidinyl group (said pyrrolidinyl group is optionally substituted by carboxyl, alkoxy or oxo group), pyrimidinyl group optionally substituted by carboxyl or alkoxy group, optionally oxidized pyridyl group, dioxolanyl group optionally substituted by alkyl group and morpholinylcarbonyl group;
- 5
- 10 cycloalkyl group optionally substituted by carboxyl group or alkoxycarbonyl group;
alkoxycarbonyl group optionally substituted by phenyl group;
carbamoyl group;
mono- or di-alkylcarbamoyl group optionally substituted by a group
- 15 selected from morpholinyl group, carboxyl group, hydroxy group and alkoxy group;
hydroxycarbamimidoyl group;
alkylthio group optionally substituted by a group selected from hydroxy group, carboxyl group and mono- or di-alkylcarbamoyl group;
- 20 alkylsulfonyl group optionally substituted by a group selected from hydroxy group, alkoxycarbonyl group and mono- or di-alkylcarbamoyl group;
amino group;
mono- or di-alkylamino group optionally substituted by a group
- 25 selected from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group, mono- or di-alkylamino group and morpholinyl group;
alkanoylamino group optionally substituted by a group selected from hydroxy group, alkoxy group, carboxyl group and amino group;
mono- or di-alkylureido group optionally substituted by alkoxy group;
- 30 morpholinylcarbonylamino group;

- morpholinyl group optionally substituted by a group selected from oxo group and carboxyl group;
- 5 piperazinyl group optionally substituted by a group selected from cyano group, alkyl group, hydroxyalkyl group, alkoxyalkyl group, carboxyalkyl group, alkanoyl group, alkoxyalkanoyl group, benzyloxycarbonyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylsulfamoyl group, alkylsulfonyl group, tetrazolyl group, and dihydrooxadiazolyl group optionally substituted by oxo group;
- 10 piperidinyl group optionally substituted by a group selected from carboxyl group, hydroxy group, alkyl group optionally substituted by hydroxy or carboxyl group, alkoxy group optionally substituted by phenyl group, alkoxyalkyl group, oxo group, and alkanoyl group;
- 15 pyrrolidinyl group optionally substituted by a group selected from carboxyl group, alkoxyalkyl group, oxo group, and mono- or di-alkylamino group;
- pyrrolinyl group optionally substituted by oxo group;
- hexahydrodiazepinyl group optionally substituted by alkanoyl group;
- imidazolidinyl group optionally substituted by oxo group;
- 20 pyridyl group optionally substituted by carboxyl group, hydroxy group, alkanoyl group, alkyl group or hydroxyalkyl group (said pyridyl group is optionally further oxidized);
- tetrazolyl group optionally substituted by a group selected from alkyl group and hydroxyalkyl group;
- dihydrooxadiazolyl group optionally substituted by oxo group;
- 25 dihydroimidazolyl group;
- dihydrooxazolyl group;
- oxazolidinyl group optionally substituted by oxo group;
- tetrahydropyridyl group optionally substituted by benzyl group;
- pyrimidinyl group;
- 30 piperidinyl group optionally substituted by alkyl group or carboxyl

- group;
pyrrolidinyloxy group optionally substituted by a group selected from
alkyl group, carboxyl group, alkoxycarbonyl group and alkanoyl group;
tetrahydropyranyloxy group;
5 tetrahydrofuranyloxy group;
optionally oxidized thianyloxy group;
morpholinylcarbonyl group;
piperazinylcarbonyl group optionally substituted by a group selected
from alkanoyl group and alkyl group;
10 pyrrolidinylcarbonyl group optionally substituted by carboxyl group or
alkoxycarbonyl group; and
piperidinylcarbonyl group optionally substituted by carboxyl group or
alkoxycarbonyl group;
- R⁶ and R⁷ are independently a hydrogen atom, an alkyl group optionally
15 substituted by halogen atom, an alkoxy group optionally substituted by
halogen atom, a hydroxy group, a cyano group, or a mono- or d-alkylamino
group; or
R⁶ and R⁷ may combine at the ends to form an alkylenedioxy group;
R⁸ is a hydrogen atom; and
20 R¹⁰ is a phenyl or pyridyl group, which phenyl or pyridyl group is
optionally substituted by 1 to 4 substituents selected from halogen atom,
alkoxycarbonyl group, alkyl group optionally substituted by halogen atom,
alkoxy group optionally substituted by halogen atom, hydroxy group, cyano
group, amino group, mono- or di-alkylamino group and alkylthio group.
- 25 10. The compound of claim 9, wherein Ring A is a pyrimidinyl
group, a pyridyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl
group, a dihydropyrimidinyl group, a pyrazinyl group, a thiazolyl group, an
oxazolyl group, a dihydrooxazinyl group, a pyrazolyl group or a
dihydropyrazinyl group.
- 30 11. The compound of claim 10, wherein Ring A is a pyrimidinyl

group, a tetrazolyl group or a pyridyl group; and R¹¹ is a group selected from the groups:

- 5 alkyl group optionally substituted by a group selected from carboxyl group, hydroxyalkoxy group, mono- or di-alkylamino group optionally substituted by alkoxy group, amino group, mono- or di-alkylcarbamoyl group and morpholinyl group;
- alkenyl group optionally substituted by hydroxy group, carboxyl group or cyano group;
- 10 alkoxy group optionally substituted by a group selected from hydroxy group, carboxyl group, carbamoyl group, alkoxycarbonyl group, mono- or di-alkylcarbamoyl group optionally substituted by hydroxy group, hydroxyalkoxy group, carboxyalkoxy group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group, morpholinyl group, oxopyrrolidinyl group, optionally oxidized pyridyl group and
- 15 morpholinylcarbonyl group;
- carbamoyl group;
- alkylthio group optionally substituted by hydroxy group or mono- or di-alkylcarbamoyl group;
- mono- or di-alkylamino group optionally substituted by hydroxy group,
- 20 carboxyl group or alkoxy group;
- alkanoylamino group optionally substituted by hydroxy group or alkoxy group;
- mono- or di-alkylureido group optionally substituted by alkoxy group; morpholinyl group;
- 25 piperazinyl group optionally substituted by a group selected from alkyl group, hydroxyalkyl group, alkoxycarbonylalkyl group, carboxyalkyl group, alkanoyl group and mono- or di-alkylcarbamoyl group;
- piperidinyl group optionally substituted by a group selected from carboxyl group, alkoxycarbonyl group, hydroxy group, hydroxyalkyl
- 30 group, carboxyalkyl group and oxo group;

- pyrrolidinyl group optionally substituted by a group selected from carboxyl group and mono- or di-alkylamino group;
pyridyl group that is substituted by hydroxyalkyl group or oxidized;
tetrazolyl group optionally substituted by alkyl group or hydroxyalkyl
5 group;
oxodihydrooxadiazolyl group;
pyrimidinyl group;
pyrrolidinyloxy group optionally substituted by alkanoyl group; and
optionally oxidized thianlyloxy group;
- 10 R^6 is a hydrogen atom, an alkyl group optionally substituted by halogen atom, an alkoxy group, a cyano group, or a mono- or di-alkylamino group;
 R^{10} is a phenyl group which is substituted by 1 to 3 substituents selected from halogen atom, alkyl group optionally substituted by halogen atom, alkoxy group and cyano group.
- 15 12. The compound of claim 11, wherein R^1 is an alkoxycarbonyl group optionally substituted by 1 to 5 substituents selected independently from hydroxy group, carboxyl group, alkoxycarbonyl group, alkoxy group (said alkoxy group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group and
20 alkoxycarbonyl group), alkenyl group, halogen atom, cycloalkyl group (said cycloalkyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), phenyl group (said phenyl group is optionally substituted by 1 to 3
25 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group), piperidinyl group (said piperidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group,
30 carboxyalkyl group and alkoxycarbonylalkyl group), and pyrrolidinyl group

(said pyrrolidinyl group is optionally substituted by 1 to 3 substituents selected independently from hydroxy group, halogen atom, carboxyl group, alkoxycarbonyl group, carboxyalkyl group and alkoxycarbonylalkyl group); or a dihydrooxazolyl group optionally substituted by 1 or 2 substituents selected independently from carboxyl group, alkoxycarbonyl group, carboxyalkyl group, alkoxycarbonylalkyl group and hydroxyalkyl group;

R¹¹ is a group selected from the groups:

alkyl group optionally substituted by carboxyl group, alkoxycarbonyl group or hydroxy group,

carboxyalkenyl group;

alkoxy group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkoxycarbonyl group, carbamoyl group, mono- or di-alkylcarbamoyl group, mono- or di-alkylcarbamoyl group substituted by hydroxy group, hydroxyalkoxy group, alkylsulfonyl group, alkylsulfinyl group, mono- or di-alkylamino group and oxopyrrolidinyl group;

mono- or di-alkylamino group optionally substituted by carboxyl group;

alkanoylamino group optionally substituted by hydroxy group or alkoxy group;

morpholinyl group;

piperazinyl group optionally substituted by a group selected from alkyl group, alkanoyl group and mono- or di-alkylcarbamoyl group;

piperidinyl group optionally substituted by carboxyl group, alkoxycarbonyl group, hydroxy group, carboxyalkyl group or hydroxyalkyl group;

pyrrolidinyl group optionally substituted by mono- or di-alkylamino group;

pyridyl group that is substituted by hydroxyalkyl group or oxidized;

tetrazolyl group optionally substituted by hydroxyalkyl group;

pyrimidinyl group;

pyrrolidinyl group optionally substituted by alkyl group or alkanoyl group; and

optionally oxidized thianthryl group; and

- 5 R¹⁰ is a phenyl group which is substituted by 1 to 3 substituents selected from alkyl group optionally substituted by halogen atom, alkoxy group and cyano group.

- 10 13. The compound of claim 12, wherein R¹ is an alkoxycarbonyl group optionally substituted by 1 or 5 substituents selected independently from carboxyl group, alkoxycarbonyl group, halogen atom, hydroxy group and cycloalkyl group;

- 15 R¹¹ is an alkyl group optionally substituted by carboxyl group; a carboxyalkenyl group; an alkoxy group optionally substituted by a group selected from cyano group, hydroxy group, carboxyl group, alkylthio group and alkylsulfonyl group; an mono- or di-alkylamino group optionally substituted by carboxyl group; a hydroxyalkanoylamino group; a morpholinyl group; a piperazinyl group optionally substituted by alkyl group or alkanoyl group; or a piperidinyl group optionally substituted by carboxyl group or hydroxy group;

- 20 R⁶ is an alkyl group optionally substituted by halogen atom, an alkoxy group or a mono- or di-alkylamino group; and

R⁷ is a hydrogen atom.

- 25 14. The compound of claim 13, wherein R¹ is an ethoxycarbonyl group, a hydroxyethoxycarbonyl group, a 2-fluoroethoxycarbonyl group, a 2,2-difluoroethoxycarbonyl group or a 2,2,2-trifluoroethoxycarbonyl group; R² is an ethyl group; R¹⁰ is a phenyl group substituted by 1 to 2 substituents selected from cyano group and trifluoromethyl group; and R⁶ is a methoxy group or a trifluoromethyl group.

- 30 15. The compound of claim 13, wherein R¹ is a carboxy(C₂₋₁₀alkoxy)carbonyl group or an alkoxycarbonyl(C₂₋₁₀alkoxy)carbonyl group;

R² is an ethyl group; R¹⁰ is a phenyl group substituted by 1 to 2 substituents selected from cyano group and trifluoromethyl group; and R⁶ is a methoxy group or a trifluoromethyl group.

16. A compound selected from the following compounds or a pharmaceutically acceptable salt thereof.

- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-hydroxymethylpiperidine-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-methylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-acetylpiperidin-1-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R*,4S*)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(hydroxyacetylamino)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methylsulfonyl-ethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2,3-dihydroxypropoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyvinyl)pyrimidin-2-

- yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-([methyl-(2-carboxyethyl))amino]pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
10 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypiperidin-1-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
15 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
20 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxybutoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
25 (2R,4S)-4-[[5-(2-Carboxyethyl)pyrimidin-2-yl]-[3-cyano-5-trifluoromethylbenzyl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
(2R,4S)-4-[(3-Cyano-5-trifluoromethylbenzyl)-(5-([methyl-(2-carboxyethyl)]-

- amino}pyrimidin-2-yl)}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-{{5-(4-Acetylpiperadin-1-yl)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-6-dimethylamino-2-ethyl-3,4-dihydro-2H-
 5 [1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-{{5-(4-Acetylpiperadin-1-yl)pyrimidin-2-yl}-[3,5-bis(trifluoromethyl)benzyl]}amino-2-ethyl-6-methyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-
 10 2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester;
 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethyl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2,2,2-trifluoroethyl ester;
 15 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypyperidin-1-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid tert-butyl ester;
 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypyperidin-1-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-fluoroethyl ester;
 20 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxypyperidin-1-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 1-methylethyl ester;
 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-1-((R)-4-hydroxymethyl-4,5-dihydrooxazol-2-yl)-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine;
 25 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester; or

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester.

17. A compound selected from the following compounds or a pharmaceutically acceptable salt thereof.

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-

- 2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
5 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
10 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
15 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
20 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
25 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-

- yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
5 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
10 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
15 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-{{[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
20 (2R,4S)-4-{{[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
25 (2R,4S)-4-{{[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-

- 2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{3-Cyano-5-trifluoromethylbenzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
5 (2R,4S)-4-{{3-Cyano-5-trifluoromethylbenzyl}-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
10 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
15 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
20 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyridin-2-yl}}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
25 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(2-methoxyethoxy)pyridin-2-

- yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
5 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyridin-2-yl]amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
10 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
15 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
25 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-

- 2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
5 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
10 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
15 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
20 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
25 (2R,4S)-4-{{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-

- 2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
5 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
10 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
15 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
20 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
25 (2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(3-cyanopropoxy)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;

- yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-dimethylaminopyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
5 (2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
(2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
10 (2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;
(2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;
15 (2R,4S)-4-[[3-Cyano-5-trifluoromethylbenzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;
(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxyethyl ester;
20 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 3-carboxypropyl ester;
25 (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyridin-2-

yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester;


(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{{3,5-Bis(trifluoromethyl)benzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 5-carboxypentyl ester;


(2R,4S)-4-{{3-Cyano-5-trifluoromethylbenzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 4-carboxybutyl ester; or

(2R,4S)-4-{{3-Cyano-5-trifluoromethylbenzyl}-[5-(morpholin-4-yl)pyridin-2-yl}}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methylpropyl ester.

18. A process for preparing a tetrahydronaphthyridine derivative of the formula (I):



wherein the symbols R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R¹⁰ have the same meaning as defined in claim 1, which comprises condensing a compound of the formula (II):




wherein each symbol has the same meaning as defined above with a compound of the formula (III):




- 5 wherein Z^1 is a leaving group and the other symbols have the same meaning as defined above.

19. A compound of the formula (II):




- 10 wherein the symbols R^1 , R^2 , R^3 , R^5 , R^6 , R^7 and R^8 have the same meaning as defined in claim 1, or a salt thereof.

20. A compound of the formula (V):



- 15 wherein the symbols R^1 , R^2 , R^3 , R^6 , R^7 and R^8 have the same meaning as defined in claim 1, or a salt thereof.


21. A diastereomer mixture of the formula (VII-a):




- 20 wherein $R^{15'}$ is an optically active protecting group for amino group and the symbols R^2 , R^3 , R^6 , R^7 and R^8 have the same meaning as defined in claim 1,

or a salt thereof.

22. A process for preparing a diastereomer mixture of the formula (VII-a):



wherein R^{15'} is an optically active protecting group for amino group and the symbols R², R³, R⁶, R⁷ and R⁸ have the same meaning as defined in claim 1, which comprises reacting a compound of the formula (IX):




wherein each symbol has the same meaning as defined above with a compound of the formula (VIII-a):




wherein each symbol has the same meaning as defined above.

15 23. A process for preparing an optically active compound of the formula (VII-b):




wherein the symbols R², R³, R⁶, R⁷ and R⁸ have the same meaning as defined in claim 1, which comprises reacting a compound of the formula


(IX):



wherein each symbol has the same meaning as defined above with a
5 compound of the formula (VIII-a):




wherein R^{15'} is an optically active protecting group for amino group and R³ has the same meaning as defined above, resolving the resulting diastereomer mixture of the formula (VII-a):




wherein each symbol has the same meaning as defined above, and removing the optically active protecting group for amino group.

24. The process of claim 22 or 23, wherein a compound of the formula (XII):



wherein the symbols R², R⁶, R⁷ and R⁸ have the same meaning as defined in claim 1 is used in place of the compound (IX):

20



wherein each symbol has the same meaning as defined above.

25. A pharmaceutical composition, which comprises as an active ingredient a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof.

26. A method for prophylaxis or treatment of arteriosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesteremia, hypertriglyceridemia, familial-hypercholesteremia, cardiovascular diseases, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, restenosis after angioplasty, hypertension, cerebral infarction, cerebral stroke, diabetes, vascular complication of diabetes, thrombotic diseases, obesity or endotoxemia, which comprises administering an effective amount of a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

27. Use of a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, in treatment of patients suffering from arteriosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesteremia, hypertriglyceridemia, familial-hypercholesteremia, cardiovascular diseases, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, restenosis after angioplasty, hypertension, cerebral infarction, cerebral stroke, diabetes, vascular complication of diabetes, thrombotic diseases, obesity or endotoxemia.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 October 2005 (13.10.2005)

PCT

(10) International Publication Number
WO 2005/095395 A3(51) International Patent Classification:
C07D 471/00 (2006.01)(74) Agents: KAWAMIYA, Osamu et al.; AOYAMA &
PARTNERS, IMP Building, 3-7, Shiromi 1-chome,
Chuo-ku, Osaka 5400001 (JP).(21) International Application Number:
PCT/JP2005/006895

(22) International Filing Date: 1 April 2005 (01.04.2005)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
2004-109551 2 April 2004 (02.04.2004) JP(71) Applicant (for all designated States except US): TAN-
ABE SEIYAKU CO., LTD. [JP/JP]; 2-10, Dosho-machi
3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KUBOTA, Hi-
toshi [JP/JP]; c/o TANABE SEIYAKU CO., LTD., 2-10,
Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418505 (JP). NAKAMURA, Yoshinori [JP/JP]; c/o
TANABE SEIYAKU CO., LTD., 2-10, Dosho-machi
3-chome, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).
HIGASHIJIMA, Takanori [JP/JP]; c/o TANABE
SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome,
Chuo-ku, Osaka-shi, Osaka 5418505 (JP). YAMAMOTO,
Yasuo [JP/JP]; c/o TANABE SEIYAKU CO., LTD.,
2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Os-
aka 5418505 (JP). OKA, Kozo [JP/JP]; c/o TANABE
SEIYAKU CO., LTD., 2-10, Dosho-machi 3-chome,
Chuo-ku, Osaka-shi, Osaka 5418505 (JP). IGARASHI,
Shigeki [JP/JP]; c/o TANABE SEIYAKU CO., LTD.,
2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418505 (JP).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
1 June 2006For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN
INHIBITORS

(I)

(57) Abstract: A novel compound of the formula (I): wherein R¹ is
alkoxycarbonyl or the like; R² is alkyl or the like; R³ is hydrogen or the
like; R⁴ is alkylene or the like; R⁵ is optionally substituted heterocyclic
group; R⁶, R⁷, and R⁸ are independently hydrogen; alkyl, alkoxy, or the
like; R⁹ is optionally substituted aromatic ring, or the like; or a pharma-
ceutically acceptable salt thereof, which has an inhibitory activity against
cholesteryl ester transfer protein (CETP).

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/JP2005/006895

A. CLASSIFICATION OF SUBJECT MATTER

C07D471/04 A61K31/4375 A61P3/06
//(C07D471/04,221:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/17166 A (PFIZER PRODUCTS INC.) 30 March 2000 (2000-03-30) cited in the application claims 1-37	1-27
A	WO 00/17164 A (PFIZER PRODUCTS INC.) 30 March 2000 (2000-03-30) cited in the application claims 1-47	1-27
A	WO 00/17165 A (PFIZER PRODUCTS INC.) 30 March 2000 (2000-03-30) cited in the application claims 1-53	1-27
A	EP 0 818 448 A (BAYER AG) 14 January 1998 (1998-01-14) claims 1-11	1-27
-/-		



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 March 2006

Date of mailing of the international search report

31/03/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/JP2005/006895

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 992 496 A (PFIZER PRODUCTS INC.) 12 April 2000 (2000-04-12) claims 1-43 -----	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International

lication No

PCT/JP2005/006895

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0017166	A	30-03-2000	AT 277906 T	15-10-2004
			AU 5439899 A	10-04-2000
			BR 9913842 A	12-06-2001
			CA 2344556 A1	30-03-2000
			DE 69920727 D1	04-11-2004
			DE 69920727 T2	09-03-2006
			EP 1114033 A1	11-07-2001
			ES 2228086 T3	01-04-2005
			JP 3655193 B2	02-06-2005
			JP 2002526477 T	20-08-2002
			MA 26687 A1	20-12-2004
			PT 1114033 T	31-12-2004
WO 0017164	A	30-03-2000	AT 297898 T	15-07-2005
			AU 752566 B2	19-09-2002
			AU 5440199 A	10-04-2000
			BG 105428 A	31-01-2002
			BR 9913810 A	19-06-2001
			CA 2344350 A1	30-03-2000
			CN 1318058 A	17-10-2001
			CZ 20010955 A3	12-12-2001
			DE 69925845 D1	21-07-2005
			DK 1114031 T3	12-09-2005
			EA 4674 B1	24-06-2004
			EE 200100166 A	17-06-2002
			EP 1114031 A1	11-07-2001
			ES 2243069 T3	16-11-2005
			HR 20010201 A1	30-04-2002
			HU 0103506 A2	28-01-2002
			ID 28026 A	03-05-2001
			JP 3626685 B2	09-03-2005
			JP 2002526475 T	20-08-2002
			JP 2004339239 A	02-12-2004
			MA 26688 A1	20-12-2004
			NO 20011350 A	09-05-2001
			NZ 509840 A	26-11-2002
			OA 11650 A	07-12-2004
			PL 347099 A1	25-03-2002
			PT 1114031 T	30-09-2005
			SK 3542001 A3	04-06-2002
			TR 200100768 T2	23-07-2001
			UA 68390 C2	17-09-2001
WO 0017165	A	30-03-2000	AT 268324 T	15-06-2004
			AU 747715 B2	23-05-2002
			AU 5440399 A	10-04-2000
			BG 105429 A	31-12-2001
			BR 9913855 A	24-07-2001
			CA 2344248 A1	30-03-2000
			CN 1318057 A	17-10-2001
			CN 1515259 A	28-07-2004
			CZ 20010954 A3	12-12-2001
			DE 69917790 D1	08-07-2004
			DE 69917790 T2	09-06-2005
			DK 1114032 T3	16-08-2004
			EA 5761 B1	30-06-2005
			EE 200100167 A	17-06-2002
			EP 1114032 A1	11-07-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2005/006895

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0017165	A		ES 2221420 T3	16-12-2004
			GC 0000108 A	29-06-2005
			HR 20010200 A1	30-04-2002
			HU 0103512 A2	28-02-2002
			ID 27838 A	26-04-2001
			JP 3561474 B2	02-09-2004
			JP 2002526476 T	20-08-2002
			MA 26689 A1	20-12-2004
			NO 20011349 A	14-05-2001
			NZ 509837 A	26-11-2002
			OA 11651 A	07-12-2004
			PL 346830 A1	25-02-2002
			PT 1114032 T	30-09-2004
			SK 3532001 A3	03-12-2001
			TR 200100780 T2	23-07-2001
			TW 502022 B	11-09-2002
			ZA 200101745 A	02-05-2002
EP 0818448	A	14-01-1998	AT 254106 T	15-11-2003
			AU 728136 B2	04-01-2001
			AU 2845197 A	15-01-1998
			BG 63691 B1	30-09-2002
			BG 101747 A	30-04-1998
			BG 63692 B2	30-09-2002
			BG 63661 B2	30-08-2002
			BR 9703884 A	01-09-1998
			CA 2209640 A1	08-01-1998
			CN 1175574 A	11-03-1998
			CZ 9702143 A3	14-01-1998
			DK 818448 T3	22-03-2004
			DZ 2261 A1	18-12-2002
			EE 9700145 A	16-02-1998
			ES 2210417 T3	01-07-2004
			HR 970330 A1	30-04-1998
			HU 9701169 A2	28-06-1999
			ID 20376 A	03-12-1998
			IL 121236 A	20-05-2001
			JP 10067746 A	10-03-1998
			MA 24262 A1	01-04-1998
			NO 973145 A	09-01-1998
			NZ 328261 A	29-06-1999
			PL 320952 A1	19-01-1998
			PT 818448 T	30-04-2004
			RU 2194698 C2	20-12-2002
			SK 92797 A3	14-01-1998
			TR 9700585 A2	21-01-1998
			TW 575566 B	11-02-2004
			US 6069148 A	30-05-2000
EP 0992496	A	12-04-2000	AT 301640 T	15-08-2005
			BR 9904162 A	12-09-2000
			CA 2282112 A1	17-03-2000
			DE 69926582 D1	15-09-2005
			ES 2245817 T3	16-01-2006
			JP 3469829 B2	25-11-2003
			JP 2000095764 A	04-04-2000